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Abstract 
Oligodendrocytes produce and wrap an insulating, fatty substance called myelin around axons 
to increase the conduction velocity of action potentials along these axons and to provide them 
with critical metabolic support.  Highly myelinated white matter regions are amongst the first 
to be damaged in Alzheimer’s disease (AD), and early oligodendrocyte damage has been 
detected in transgenic mice carrying human genetic variants associated with the development 
of AD. In diseases such as multiple sclerosis, immature brain cells called oligodendrocyte 
progenitor cells (OPCs) proliferate and differentiate into myelinating oligodendrocytes in an 
attempt to replace oligodendrocytes lost to the disease, restore action potential conduction 
speed and protect neurons from further damage.  However, OPC fate in the early stages of AD-
like pathology is unknown. 
In this thesis, I have shown that the cells of the oligodendrocyte lineage respond differently to 
hyperphosphorylated microtubule-associated protein tau (tau) (Chapter 3) and amyloidosis 
(Chapter 4), two major pathological features of AD, respectively recapitulated in transgenic 
mice by the overexpression in neurons of a human genetic variant of microtubule-associated 
protein tau (MAPT) or the amyloid precursor protein (APP).  Overexpression of MAPT in 
neurons indirectly increased new oligodendrocyte addition throughout the brain; however, this 
was not associated with a change in total oligodendrocyte number, proportion of myelinated 
axons and myelin thickness in MAPT mice compared to WT (Chapter 3).  The OPC response 
to glutamate and GABA was unchanged in pre-symptomatic MAPT mice; however, OPC 
responded more robustly to GABA in early amyloid pathology.  By overexpressing APP in 
neurons and oligodendrocytes throughout life, developmental myelin thickness was increased, 
but amyloid plaque formation was also coincident with an increase in oligodendrogenesis 
between 5 and 6 months of age in APP mice (Chapter 4).  Together, this thesis suggests that 
xxi 
oligodendrocyte turnover is an early feature of both tau and amyloid pathology, while myelin 
remodelling only occurs in amyloid pathology, which may result from neurotransmitter or 
excitatory-inhibitory signalling imbalance within the neuronal network.  
My data suggest that OPCs and oligodendrocytes are affected by both tauopathy and 
amyloidosis, which are critical aspects of pathology in people diagnosed with AD.  More 
specifically, my data suggest that oligodendrocytes are particularly susceptible to undergo cell 
death in response to these pathological insults.  The lost oligodendrocytes are replaced by OPCs 
early on, suggesting that early interventions that promote oligodendrocyte survival and 
oligodendrogenesis could be very beneficial for preserving neural circuit function in people 
with AD, and slowing neurodegeneration in other tauopathies.
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Chapter 1: Introduction 
The central nervous system (CNS) includes the brain, spinal cord and optic nerve; and is 
responsible for cognition and executive function.  The CNS is composed of neurons, which are 
the electrically active cells critical for neurotransmission (reviewed by Yuste, 2015); vascular 
cells, which regulate blood flow (reviewed by Mazurek et al., 2017); and three major types of 
glial cells - microglia, astrocytes and oligodendrocytes.  Microglia are critical for maintaining 
brain homeostasis through their role in clearing cellular debris (Ayata et al., 2018; Villani et 
al., 2019) and pruning synapses (Paolicelli et al., 2011).  By contrast, astrocytes ensure brain 
homeostasis through neurotransmitters reuptake (Voutsinos-Porche et al., 2003; Cho et al., 
2018), delivery of nutrients from blood-vessels to the electrically conducting parts of neurons 
known as axons (García-Cáceres et al., 2016) and maintenance of ion balance at the synapse 
(Sibille et al., 2015).  The third glial cell type, the oligodendrocytes, create and wrap a lipid 
and protein rich substance known as myelin around axons, which facilitates their rapid saltatory 
conduction of action potentials (reviewed by Hughes and Appel, 2016).   Small myelinic 
channels in the myelin sheath also allow oligodendrocytes to provide critical metabolic support 
to axons (Fünfschilling et al., 2012; Lee et al., 2012; Meyer et al., 2018).  Each glial cell type 
is critical for CNS function and the dysregulation or loss of these cells has been shown to cause 
or exacerbate a number of pathological conditions.  
 
Oligodendrocyte death and the associated myelin loss, known as demyelination, are key 
pathological feature of multiple sclerosis (Traka et al., 2015; Way et al., 2015), and can also 
be observed in various types of dementia, including frontotemporal dementia (Kovacs et al., 
2008; Zhang et al., 2009) and Alzheimer’s disease (AD: Zhang et al., 2009; Gagyi et al., 2012).  
This thesis will explore the impact that the expression of two human pathological proteins, that 
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are known to result in frontotemporal dementia or AD, have on the behaviour of 
oligodendrocytes and their precursor cells, the oligodendrocyte progenitor cells (OPCs). 
 
1.1. Developmental oligodendrogenesis 
OPCs also known as NG2 (neural / glial antigen 2) glia or polydendrocytes are immature 
precursor cells that give rise to mature myelinating oligodendrocytes in the developing (Zhu et 
al., 2008, 2011) and mature (Dimou et al., 2008; Rivers et al., 2008; Kang et al., 2010; Zhu et 
al., 2011; Young et al., 2013) CNS.  OPC can be identified in situ by their expression of the 
chondroitin sulphate proteoglycan NG2 (Nishiyama et al., 1996), the mitogenic receptor 
platelet-derived growth factor receptor a (PDGFRa; Pringle et al., 1992) and the transcription 
factor OLIG2 (Ligon et al., 2004, 2006).  During mouse development OPCs are produced from 
neural stem cells located in the ventricular zone of the brain (Kessaris et al., 2006) and spinal 
cord (Fu et al., 2002; Masahira et al., 2006).  In the brain, OPCs are generated in three waves: 
the first involves OPC production from neural stem cells located in the medial ganglionic 
eminence at embryonic day 12.5; the second comprises OPC production from the lateral and 
caudal ganglionic eminence at embryonic day 15.5, and the third wave of OPC generation 
occurs after birth, with OPCs being produced from neural stem cells in the ventricular zone of 
the cortex (Kessaris et al., 2006).   
 
Once formed, OPC undergoes symmetric or asymmetric division resulting in two OPCs or an 
OPC and a differentiating oligodendrocyte (Sugiarto et al., 2011; Zhu et al., 2011; Hill et al., 
2014; Boda et al., 2015), or alternatively directly differentiates to produce an oligodendrocyte.  
In rodents, OPCs start to differentiate into mature myelinating oligodendrocytes after birth with 
the peak period of oligodendrogenesis observed between postnatal day (P)7 and P21 in the 
optic nerve (Barres et al., 1992).  OPC production, differentiation and oligodendrocyte 
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maturation in the human CNS follow a similar pattern, with OPCs being observed from 9 weeks 
of gestation; however, they commence differentiation prior to birth (Back et al., 2001; 
Jakovcevski and Zecevic, 2005), with the first myelin sheaths being produced by 
oligodendrocytes at approximately 18 weeks of gestation (Jakovcevski and Zecevic, 2005; 
Jakovcevski et al., 2007, 2009).   
 
OPC differentiation is associated with significant changes in gene transcription (Copray et al., 
2006; Maire et al., 2010; Hornig et al., 2013; Zhu et al., 2014; Figure 1.1).  NG2 and PDGFRa 
expression are downregulated (Zhou et al., 2000, 2001; Lu et al., 2002; Zhou and Anderson, 
2002; Jakovcevski and Zecevic, 2005) as an OPC becomes a premyelinating oligodendrocyte, 
which can be identified by the expression of ectonucleotide pyrophosphatase 
phosphodiesterase 6 (ENPP6; Zhang et al., 2014; Xiao et al., 2016), breast carcinoma amplified 
sequence 1 (BCAS1; Fard et al., 2017) and the transcription factor critical for oligodendrocyte 
maturation, myelin regulatory factor (MyRF; Cahoy et al., 2008; Emery et al., 2009; Bujalka 
et al., 2013; Hornig et al., 2013).  MyRF expression in premyelinating oligodendrocytes 
triggers the expression of myelin proteins leading to their maturation into myelinating 
oligodendrocytes (Emery et al., 2009). 
 
In the developing CNS, cell death allows the removal of unnecessary oligodendrocytes (Barres 
et al., 1992; Trapp et al., 1997).  In the rat optic nerve, cell death peaks in the first 10 days of 
postnatal life with 0.25% of all cells dying, but decreases drastically by P45 (Barres et al., 
1992).  Between P4 and P12, ~15% of all propidium iodide-labelled cells with pyknotic nuclei 
co-labelled with the oligodendrocyte-specific RIP antigen (Berger and Frotscher, 1994; Butt et 
al., 1995; Watanabe et al., 2006), suggesting that a substantial number of oligodendrocytes die 







Figure 1.1. Schematic of OPC differentiation 
OPC can be identified by their expression of the mitogenic receptor PDGFRa and the proteoglycan NG2.  As 
they differentiate into premyelinating oligodendrocytes, the expression of these markers is downregulated, and 
expression of BCAS1, ENPP6, ASPA, MyRF, PLP, MBP and CNP are induced.  As premyelinating 
oligodendrocytes mature into myelinating oligodendrocytes, expression of BCAS1 and ENPP6 is lost, and 
expression of MOG is induced.  All the cells of the oligodendrocyte lineage can be identified by their expression 




rapidly during cell death, it is unlikely to allow the detection of oligodendrocytes in late stages 
of programmed cell death.  To address this, hybridoma cells that secreted antibodies against an 
extracellular oligodendrocyte antigen (galactocerebroside) were injected into the subarachnoid 
space of P2 rats.  This approach allowed the comprehensive and long-lived labelling of these 
cells and revealed that ~91% of cells that were dying in the P5 rat optic nerve were 
oligodendrocytes (Barres et al., 1992).  Furthermore, injection of bromodeoxyuridine (BrdU) 
in the optic nerve at P15 revealed that oligodendrocytes die within 2 to 3 days after being 
generated (Barres et al., 1992).  In the developing rat cerebral cortex, ~20% of premyelinating 
oligodendrocytes undergo cell death between P7 and P21; and by P28 it increases to ~37% 
(Trapp et al., 1997) as premyelinating oligodendrocytes that are not necessary for myelination 
degenerate during development (Barres et al., 1992; Trapp et al., 1997).  However, the majority 
of premyelinating oligodendrocytes undergo further transcriptional and morphological changes 
to become mature myelinating oligodendrocytes (Fitzner et al., 2006; Emery et al., 2009). 
 
As oligodendrocytes differentiate into mature myelinating oligodendrocytes, they extend many 
new cellular processes (Fitzner et al., 2006).  This process is supported by alterations to the 
cytoskeleton (Wilson and Brophy, 1989).  Process outgrowth requires the transport of mRNAs 
that code for the synthesis of myelin-specific proteins such as myelin basic protein (MBP), to 
the cellular extensions (Ainger et al., 1993, 1997; Carson et al., 1997; Smith, 2004).  MBP 
mRNA translocation in oligodendrocytes depends on intact microtubules and kinesins (Carson 
et al., 1997), which require expression of microtubule-associated proteins such as microtubule-
associated protein 2 and microtubule-associated protein tau (tau) to stabilize and organize the 
microtubule network (Al-Bassam et al., 2002; Kadavath et al., 2015; Shigematsu et al., 2018).  
Microtubule-associated protein 2 and tau are expressed by oligodendrocytes in vitro (Müller et 
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al., 1997; Richter-Landsberg and Gorath, 1999) and facilitate oligodendrocyte process 
outgrowth as well as the formation and maintenance of myelin sheaths.   
 
1.2. Myelination 
During the early stages of myelin formation also called myelination or myelinogenesis, 
oligodendrocytes produce a cholesterol-rich membrane (Saher et al., 2005) looped around 
axons that progressively forms a compact multilamellar spiral structure (Aggarwal et al., 2013; 
Snaidero et al., 2014).  Each oligodendrocyte ensheathes multiple selected axon segments 
(Matthews and Duncan, 1971; Chong et al., 2012).  The ensheathment process occurs over a 
brief time window.  For example, ensheathment is completed within 12-18 hours in rat cortical 
cultures (Downes and Mullins, 2014), while oligodendrocytes produce new myelin internodes 
during a period of 5 hours in zebrafish (Czopka et al., 2013).  In zebrafish, a small proportion 
of the myelin sheaths is subsequently rapidly retracted over the following 2 days after which 
oligodendrocyte morphology and myelin sheath number remain stable. 
 
The myelin sheath is composed of various lipids and proteins (Figure 1.2a).  By transmission 
electron microscopy (TEM), the myelin sheath appears to have alternative major dense lines, 
or dark and light layers (reviewed by Simons and Nave, 2016).  Myelin is 40% water and its 
dry mass includes 70% lipid and 30% protein (O’Brien and Sampson, 1965), which form the 
different dark and light layers observed using TEM (Figure 1.2b).  Myelin contains 
cholesterol, phospholipids and glycolipids, and is particularly rich in glycosphingolipids, 
including galactocerebrosides (Raff et al., 1978; Zalc et al., 1981).  MBP and proteolipid 
protein (PLP) represent 30% and 50% of myelin proteins respectively.  Other proteins, such as 







Figure 1.2. Schematic of myelin structure  
a) Myelin is composed of various lipids and proteins including MBP, PLP, CNP, MOG and MAG.  These proteins 
regulate myelin formation, compaction and maintenance.  b) As myelin sheaths are wrapped around the axon, 





and myelin oligodendrocyte glycoprotein (MOG) are also present (Scolding et al., 1989; Yin 
et al., 1998; Marques et al., 2016; Snaidero et al., 2017). 
 
Proteins within the myelin membrane regulate myelin sheath compaction and stability, and the 
appropriate compaction of myelin is required for the fast transmission of action potentials as 
well as the ability of oligodendrocytes to offer long-term metabolic support to axons (Gutiérrez 
et al., 1995; Griffiths et al., 1998; Lappe-Siefke et al., 2003).  To provide an example, MBP is 
required for the compaction and maintenance of the myelin sheath (Allinquant et al., 1991; 
Weil et al., 2016), with the MBP gene deleted shiverer mice showing myelin decompaction 
(Allinquant et al., 1991), and MBP loss causing myelin breakdown and ultimately axonal 
degeneration (Weil et al., 2016).  The ratio of CNP to MBP protein is also important, as it 
determines the level of myelin compaction (Snaidero et al., 2017), with CNP counteracting the 
MBP-driven myelin compaction (Snaidero et al., 2017) and allowing oligodendrocyte process 
outgrowth (Lee et al., 2005) and the formation of the axo-myelinic channels necessary for 
axonal support (Lappe-Siefke et al., 2003).  Consequently, mice overexpressing CNP have 
impaired MBP accumulation and reduced myelin compaction (Gravel et al., 1996; Yin et al., 
1997).  PLP is largely required for myelin maintenance, as Plp-deficient mice develop myelin 
decompaction in the optic nerve (Boison and Stoffel, 1994; Klugmann et al., 1997; Rosenbluth 
et al., 2006), which is ultimately associated with axonal mitochondrial dysfunction and axon 
degeneration (Yin et al., 2016a).  Premature oligodendrocyte death observed from P4 in the 
spinal cord, P12 in the optic nerve and P16 in the corpus callosum of jimpy mice expressing a 
plp mutation has been associated with gross myelin deficit observed in these mice (Knapp et 
al., 1986).  Similarly, within 6 months of gene deletion, tamoxifen-inducible Plp-deficient mice 
also show myelin disassembly and outfoldings of the sheath, as well as axonal sprouting and 
spheroid formation in the optic nerve (Lüders et al., 2019).   
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Once generated, oligodendrocytes and their myelin internodes are remarkably stable 
throughout life (Tripathi et al., 2017; Auer et al., 2018; Hill et al., 2018; Hughes et al., 2018).  
For example, in the mouse corpus callosum, ~90% of developmentally born oligodendrocytes 
survive for over 8 months, compared with ~70% in the motor cortex, and ~60% in the spinal 
cord and optic nerve (Tripathi et al., 2017).  While the oligodendrocytes themselves largely 
survived long-term, a subset of myelin internodes was found to extend or retract (Auer et al., 
2018; Hill et al., 2018), indicating that mature myelinating oligodendrocytes may retain some 
level of plasticity.  Indeed the level of myelin plasticity observed in the adult CNS is quite 
significant, as in addition to plastic changes made by existing mature oligodendrocytes, it has 
been demonstrated that new oligodendrocytes are added to the brain of adult rodents (Rivers 
et al., 2008; Young et al., 2013; Hill et al., 2018; Hughes et al., 2018) and humans (Yeung et 
al., 2014) throughout life.   
 
1.3. Oligodendrogenesis occurs in the healthy adult brain 
Following developmental oligodendrogenesis, OPCs are maintained in the adult CNS (Wren 
et al., 1992).  In the rodent brain, OPCs represent 5-8% of all cells (Dawson et al., 2003; Dimou 
et al., 2008; Rivers et al., 2008) and the population is maintained in the brain parenchyma 
through a process of self-renewal (Wren et al., 1992; Menn et al., 2006); however, a small 
number of new OPCs are generated from stem cells in the subventricular zone (Nait-Oumesmar 
et al., 1999; Picard-Riera et al., 2002; Menn et al., 2006).  Like their developmental 
counterparts, adult OPCs express the chondroitin sulphate proteoglycan NG2, the mitogenic 
receptor PDGFRα and the O4 glycolipid antigen, and while they proliferate less frequently, 
and differentiate more slowly (Wolswijk et al., 1989, 1990; Wren et al., 1992; Psachoulia et 
al., 2009), they continue to generate new oligodendrocytes throughout life.  Of the 
premyelinating oligodendrocytes produced in the mouse cortex between ~8-14 months of age, 
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Hughes et al. (2018) demonstrated that only ~22% survived to form mature myelinating 
oligodendrocytes.  These data suggest that more cells are born than are required for 
oligodendrocyte addition.  However, as adult parenchymal OPCs increasingly express 
senescence markers (Kujuro et al., 2010) and show reduced proliferation with increasing age 
(Lasiene et al., 2009; Young et al., 2013), the steady supply of immature premyelinating 
oligodendrocytes is diminished with aging. 
 
1.4. Oligodendrocyte loss with aging and injury 
White and grey matter volumes reduce with aging in human (Giorgio et al., 2010; Gogniat et 
al., 2018), and rhesus monkey brain (Wisco et al., 2008), and this pattern of tissue loss is also 
seen in senescence accelerated mice (Tanaka et al., 2005).  Senescence accelerated mice 
experience oligodendrocyte loss from the hippocampus, but have normal numbers of 
oligodendrocytes in the cerebral cortex and optic nerve at 10 months of age (Tanaka et al., 
2005).  With normal aging, mice experience cortical oligodendrocyte loss from approximately 
2 years of age (Hill et al., 2018).  In aging, increased oxidative stress (Dröge and Schipper, 
2007), neuroinflammation (Mecha et al., 2012) and changes in cytokine production (Chen et 
al., 2008) may stress oligodendrocytes, which have a high metabolic demand, and this may 
render them susceptible to cell death.  However, oligodendrocytes can also switch their energy 
consumption in response to nutrient deprivation to prioritise cell survival (Rone et al., 2016).  
This ability may explain discrepancy between the decreased oligodendrocyte density in mice 
and increased oligodendrocyte population in rhesus monkeys (Peters, 2004) but relatively 
stable oligodendrocyte population in humans during aging (Yeung et al., 2014).  Indeed to 
promote their survival following metabolic stress, human oligodendrocytes have the ability to 
reduce glycolytic ATP production leading to myelin process withdrawal and demyelination 




Demyelination is a process inducing the degeneration and loss of myelin sheaths, and is a key 
pathological feature of multiple sclerosis (Haider et al., 2016; Schirmer et al., 2019).  Multiple 
sclerosis is an autoimmune disease in which peripheral immune cells invade the CNS and cause 
myelin loss from discrete regions referred to as lesions.  Lesions develop in the brain, spinal 
cord and optic nerve, and lead to motor and cognitive impairment (Manrique-Hoyos et al., 
2012; Hulst et al., 2013; Sbardella et al., 2013).  People are generally diagnosed with multiple 
sclerosis between 20 and 45 years of age and the disease affects three times as many women 
as men (Evans et al., 2013).  A variety of immunomodulatory drugs can be effective reducing 
immune cell infiltration of the CNS (reviewed by Goldenberg, 2012); however, no treatment 
is currently available to prevent oligodendrocyte death and demyelination or promote 
oligodendrogenesis and remyelination.  
 
1.5. Remyelination is mediated by oligodendrocyte addition to the brain 
Remyelination is the process by which OPCs form new oligodendrocytes that elaborate new 
myelin sheaths on previously demyelinated axons (Franklin et al., 1997; Gensert and Goldman, 
1997; Figure 1.3).  Parenchymal OPCs and OPCs newly formed in the subventricular zone of 
the adult mouse brain successfully produce new oligodendrocytes involved in the spontaneous 
remyelination process following demyelination (Nait-Oumesmar et al., 1999; Menn et al., 
2006; Serwanski et al., 2018).  OPCs from the subventricular zone have been shown to 
remyelinate more efficiently in the short-term, while parenchymal OPCs have been shown to 
produce long-term repair following cuprizone-induced demyelination (Brousse et al., 2015).  
New oligodendrocytes may be added to a lesion site following demyelination through 






Figure 1.3. Schematic of remyelination by new oligodendrocyte addition 
When an oligodendrocyte dies (grey), an OPC or premyelinating oligodendrocyte (green) can contact the 
demyelinated axon and differentiate into a new mature, myelinating oligodendrocyte and wrap new myelin sheaths 
around the axon. Figure created with Biorender. 
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proliferate and differentiate into immature and mature myelinating oligodendrocytes (Xing et 
al., 2014).  Following 4 weeks of cuprizone-induced demyelination in mice, OPC number 
tripled in the corpus callosum, the oligodendrocyte population was replaced within 1 week of 
recovery, and remyelination was completed within 6 weeks (Baxi et al., 2017).  While OPCs 
can differentiate into oligodendrocytes or astrocytes in vitro (Raff et al., 1983) and in vivo (Zhu 
et al., 2007), they preferentially differentiate into oligodendrocytes following induced 
demyelination in the corpus callosum (Nait-Oumesmar et al., 1999) and spinal cord (Kang et 
al., 2010; Tripathi et al., 2010) of transgenic mice.   
 
The myelin formed during remyelination is thinner and shorter than myelin formed during 
development but can still protect axons (Duncan et al., 2017).  Axonal conduction is improved 
by new myelin internode addition as it restores saltatory conduction; however, axonal 
conduction is not as rapid following remyelination as it was prior to demyelination (Brill et al., 
1977; Blakemore and Murray, 1981).  Using TEM, remyelinated axons can be distinguished 
from developmentally myelinated axons (Gledhill and McDonald, 1977; Prineas and Connell, 
1979; Blakemore and Murray, 1981) with the exception of smaller diameter axons (Stidworthy 
et al., 2003).  However, Powers et al. (2013) showed that 6 months after contusion-induced 
partial spinal cord demyelination, remyelinated and developmentally myelinated axons are 
indistinguishable with the exception of the largest diameter axons.   
 
In advanced demyelinating diseases, oligodendrocytes establish contact with axons but fail to 
myelinate, which result in axonal dystrophy, swelling and degeneration (Chang et al., 2002).  
OPCs and premyelinating oligodendrocytes have been identified in demyelinated regions 
(Boyd et al., 2013; Fard et al., 2017) when mature oligodendrocytes are rare (Chang et al., 
2002; Kuhlmann et al., 2008).  For successful remyelination, OPC proliferation, 
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oligodendrocyte differentiation and survival must be promoted.  In the past decade, various 
factors have been identified that can enhance remyelination in vitro and in vivo including the 
neuregulin, neurotrophin-3 and the brain-derived neurotrophic factor, which promote OPC 
proliferation, differentiation and remyelination (Vondran et al., 2011; Lundgaard et al., 2013; 
Wong et al., 2013; McTigue et al., 2018). 
 
Myelin loss is observed in a number of conditions that are not classically thought of as 
demyelinating diseases.  For example, myelin loss has been detected in multiple system atrophy 
(Wakabayashi et al., 1998), amyotrophic lateral sclerosis (Philips et al., 2013), traumatic brain 
injury (Flygt et al., 2013, 2016), perinatal white matter injury (Back and Rosenberg, 2014), 
neuropsychiatric diseases (Tkachev et al., 2003) and other neurodegenerative disorders 
including frontotemporal dementia (Zhang et al., 2009) and AD (Bartzokis et al., 2004; Zhan 
et al., 2014; Dean et al., 2017).  However, the extent of oligodendrocyte loss and replacement 
has been poorly characterised in many of these conditions. 
 
1.6. Alzheimer’s disease 
AD is a neurodegenerative disease and the most common form of dementia.  It is characterized 
by significant brain atrophy (Jack et al., 2010), memory loss and executive function decline 
(Garcia-Alvarez et al., 2019).  Personality and behavioural changes such as enhanced paranoia, 
aggression, delusions, hallucinations, apathy, elevated fear and sleep disturbances are often 
observed in AD patients (McKhann et al., 1984).  Clinically, AD can be partially diagnosed 
using multiple tests and the medical history of each patient but the diagnosis always has to be 
confirmed post-mortem by brain tissue analysis with assessment of amyloid beta (Ab) and tau 
biomarkers in the cerebrospinal fluid (Andreasen et al., 2001).  The formation of amyloid 
plaques (amyloid pathology, accumulated Ab) and neurofibrillary tangles (tau pathology, 
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aggregated tau) were first described in 1906 by German psychiatrist and neurologist Alois 
Alzheimer (translation of original paper by Stelzmann et al., 1995; Graeber and Mehraein, 
1999); and are now known as the main pathological features of AD.  However, more than a 
century after this discovery, the underlying cause of AD in the majority of patients remains 
unclear (reviewed by Selkoe, 2001). 
 
AD patients are generally classified as having familial or sporadic AD depending on the 
presence or absence of an inherited genetic mutation known to precipitate the disease (Haass 
et al., 1995; Lemere et al., 1996; Cruchaga et al., 2012; Jin et al., 2012; Hatami et al., 2017).  
Familial AD has been the main form studied in the past decades while sporadic AD actually 
represents about 99% of all AD cases (Goedert and Spillantini, 2006).  It is not possible to 
produce faithful mouse models of sporadic AD without knowing the precise cause of this 
disease in humans; however, some mouse models have been developed that produce age-
related deficits in memory, that are being used in this context.  For example, high-cholesterol 
diet models were generated to investigate lipid mechanism disorders associated with AD, while 
senescence-accelerated models were developed to define aging implication on AD progression 
(reviewed by Zhang et al., 2020).  None of these models are a true model of sporadic AD, but 
allow instead specific investigation of defective mechanisms observed in human sporadic AD 
cases.  Most research studies instead use mouse models of familial AD, which cannot be used 
to study the cause of sporadic AD, but can be used to gain insight into the molecular and cellular 
changes that are common to both familial and sporadic forms of AD.  It has been established 
that the pathological phenotype produced by both forms of AD is very similar and can often be 
mistaken if the age of the patient is unknown by the neuropathologist studying the case 
(McKhann et al., 1984).  The vast majority of genetic mutations known to cause familial AD 
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are found within the amyloid precursor protein (APP) gene, or genes coding for proteins 
known to alter APP expression and activity (Blauwendraat et al., 2019; Giau et al., 2019). 
 
1.6.1. Amyloid pathology 
Amyloid pathology is mainly characterized by the extracellular aggregation of Ab peptides 
forming amyloid plaques also called senile plaques, which disrupt synapses and cause neuronal 
loss (reviewed by Selkoe and Hardy, 2016; Kashyap et al., 2019).  The Ab peptides result from 
the cleavage of the single transmembrane APP by beta secretase and gamma secretase (Kang 
et al., 1987; Vassar et al., 1999; Takasugi et al., 2003).  The main peptides obtained from this 
cleavage are the Ab40 and Ab42 oligomers (Citron et al., 1996; Qiang et al., 2017).  Ab42 is 
more likely to aggregate and form amyloid plaques while Ab40 is the main form of circulating 
Ab in the plasma, cerebrospinal fluid and brain interstitial fluid (Roher et al., 2009). 
 
The primary physiological function of APP is unclear; however, many roles have been 
proposed, including the facilitation of intracellular and extracellular signalling, gene regulation 
and activity as a trophic factor (reviewed by Dawkins and Small, 2014).  Interestingly, APP 
levels are elevated at sites of axonal damage and in dystrophic neurites around amyloid plaques 
suggesting that physiological APP might participate in synaptic repair and homeostasis (Cras 
et al., 1991; Joachim et al., 1991; Yasuhara et al., 1994).  However, mutations in the APP gene 
can affect the ratio of Ab40/Ab42 and increase the production of Ab42 as well as its aggregation 
in the extracellular milieu in AD (Levy et al., 1990; Citron et al., 1992; Haass et al., 1995; 
Cheng et al., 2004).  The APP gene is located on chromosome 21 and patients with Down 
syndrome (trisomy 21) have an extra copy of the APP gene, which causes an increased risk of 
developing AD (Potter et al., 2016).  Goate et al. (1991) identified the first mutation of the APP 
gene involved in AD as a missense mutation in codon 717 leading to the replacement of a 
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valine by an isoleucine (Val-Ile), this mutation is now known as the London mutation (Goate 
et al., 1991).  At present, only one mutation of the APP gene has been identified as being 
protective against the development of AD (Hashimoto and Matsuoka, 2014) despite the 
identification of numerous pathological mutations in APP and its associated regulators. 
 
Presenilins are transmembrane proteins involved in the cleavage of APP and genetic mutations 
affecting the function of these proteins can impact the ratio of Ab40/Ab42 (Jankowsky et al., 
2004).  Presenilins 1 (PSEN1) and  2 (PSEN2) are subunits of the protease gamma secretase 
and mutations of both PSEN1 and PSEN2 have been associated with an accelerated AD 
phenotype development (Steiner et al., 1999; McMillan et al., 2000; Lou et al., 2017; Giau et 
al., 2019).  Notably, Scheuner et al. (1996) showed that mutations of the PSEN1 gene (on 
chromosome 14) and PSEN2 gene (on chromosome 1) led to the increased cleavage of APP to 
produce more Ab42 and less Ab40 in human plasma, consequently leading to increased amyloid 
plaque formation in the brain.  Jankowsky et al. (2004) showed that decreased Ab40/Ab42 ratio 
following Ab42 increase, and subsequent accelerated amyloid pathology were associated with 
PSEN1 overexpression rather than PSEN1 loss of function. 
 
Various AD associated mutations detected in the APP, PSEN1 and PSEN2 genes have been 
expressed in transgenic mice to study AD progression (reviewed by Elder et al., 2010).  These 
mutations mostly induce an amino acid substitution, which is called a missense mutation.  
Commonly studied APP mutations include the mutant human APP Swedish (K670N, M671L; 
Mullan et al., 1992), Indiana (V717F; Murrell et al., 1991), London (V717I, Goate et al., 1991) 
and Florida (I716V; Eckman et al., 1997) AD mutations.  In addition, common PSEN1 
mutations used include M146L, L286V, L166P and deltaE9; and finally, the main PSEN2 
mutation used is N141I.  By transgenically expressing these pathological mutations, it has been 
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possible to study disease progression and evaluate the effect of Ab production and plaque 
formation on neuronal survival, gliosis, synaptic function and cognitive impairment.   
 
Some of the most commonly used mouse models of amyloid pathology include the J20 (APP 
Swedish and APP Indiana mutations; Mucke et al., 2000), APP/PS1 (APP Swedish, PSEN1 
L166P; Radde et al., 2006), and 5xFAD (APP Swedish, APP Florida, APP London, PSEN1 
M146L and PSEN1 L286V mutations; Oakley et al., 2006) mouse lines.  All these models 
present with different pathological time courses and are influenced by the mutations but also 
the genetic background of the mouse line.  The J20 mouse line expressing a three point 
mutation in the APP gene exhibits cognitive impairment at approximately 4 months of age in 
the radial arm maze (Wright et al., 2013), and which is severe enough to be detected in the 
Morris water maze at 6-7 months of age (Palop et al., 2003).  The cognitive phenotype appears 
prior to amyloid plaque formation (Hong et al., 2016) and reactive gliosis (Wright et al., 2013), 
which are detected from 5-6 months of age.  By contrast the APP/PS1 mice exhibit amyloid 
plaque and gliosis at approximately 1 month of age (Radde et al., 2006), synaptic loss from 2 
months of age (Bittner et al., 2012), and cognitive impairment from 7 months of age in the 
Morris water maze (Serneels et al., 2009).  On a hybrid background (C57BL/6 x SJL), 5xFAD 
mice develop amyloid plaques and gliosis at 2 months of age (Oakley et al., 2006), synaptic 
deficits from 4 months of age and spatial working memory impairment by 4-5 months of age 
in the Y maze, prior to neuronal loss (Oakley et al., 2006; Devi and Ohno, 2010).  On a 
C57BL/6 background,  5xFAD mice still develop amyloid plaques (Richard et al., 2015) and 
gliosis  (Giannoni et al., 2016) at 2 months of age, yet synaptic deficits (Buskila et al., 2013) 
are also observed at 2 months of age, followed by synapse loss (Crowe and Ellis-Davies, 2014) 
and working memory impairment in the cross-maze at 6 months of age and neuronal loss at 12 
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months of age (Jawhar et al., 2012).  Transgenic mice have become precious tools to understand 
AD development and the progression of the amyloid but also the tau pathology. 
 
1.6.2. Tau pathology 
In the healthy brain, tau proteins promote microtubule network integrity (Weingarten et al., 
1975; Qiang et al., 2018).  There are six isoforms of tau, which are encoded by the microtubule-
associated protein tau (MAPT) gene located on chromosome 17 (Neve et al., 1986; Goedert et 
al., 1989).  These six isoforms are divided in two main groups: those with 3 (3R-tau) or 4 (4R-
tau) microtubule binding repeats (Goode et al., 2000; reviewed by Venkatramani and Panda, 
2019).  Tau isoform composition determines the effectiveness of microtubule assembly; 4R-
tau strongly stabilises microtubules and effectively prevents disassembly compared to 3R-tau 
repeats (Panda et al., 2003).  In frontotemporal dementia with parkinsonism-17, MAPT 
mutations shift the 3R:4R ratio, promoting microtubule disassembly (D’Souza et al., 1999).  
The phosphorylation of tau regulates microtubule assembly (Utton et al., 1997) and tau 
hyperphosphorylation leads to microtubule disassembly (Alonso et al., 1994) and the formation 
of neurofibrillary tangles inside neurons (Grundke-Iqbal et al., 1986; Alonso et al., 1996, 
2001), which is a pathological characteristic of tauopathies.  
 
In AD, tau can be found in the brain as toxic oligomers that accumulate into neurofibrillary 
tangles, which are less toxic (D’Orange et al., 2018).  Elevated tau and phosphorylated tau 
levels have been reported in the cerebrospinal fluid of AD patients and those with other 
tauopathies (Arai et al., 1995, 1997).  Khatoon et al. (1992) reported that total tau was four to 
eight-fold higher in the brain of AD patients relative to age-matched controls due to a 
significant increase in hyperphosphorylated tau.  Köpke et al. (1993) reported that 40% of tau 
found in the AD brain was hyperphosphorylated oligomeric tau, which is highly toxic in vitro 
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(Gómez-Ramos et al., 2006).  The oligomeric toxic form of tau can be removed from the 
cerebrospinal fluid by promoting protein aggregation into neurofibrillary tangles, which 
promotes neuronal survival (D’Orange et al., 2018).  Phosphorylation of tau at phosphorylation 
sites Ser262 and Ser214, required for tau detachment from microtubules, protects against its 
aggregation (Schneider et al., 1999).  It has been suggested that neurofibrillary tangles observed 
in neurons are formed to be cleared but this process would be overwhelmed at some stages, 
notably due to tau slower turnover rate following acetylation (Noack et al., 2014).  Tau 
aggregates are mainly found in neurons; however, tau inclusions can also be found in astrocytes 
and oligodendrocytes (Hashimoto et al., 2003; Lin et al., 2003a; Ren et al., 2014).  Clearance 
of abnormal tau aggregates can occur via two main pathways: the ubiquitin-proteasome and 
the autophagy-lysosomal pathways (Krishnamurthy et al., 2011; Leyk et al., 2015; Guo et al., 
2016).  However, phosphorylation and acetylation can lead to the malfunction of these two 
pathways (reviewed by Richter-Landsberg, 2016).   
 
Mutations of the MAPT gene have been discovered and linked to various neurodegenerative 
diseases with AD-like phenotypes; yet, while MAPT genetic risk variants have been described 
in AD (Myers et al., 2005; Laws et al., 2007; Jin et al., 2012; Allen et al., 2014), no mutations 
have been associated with AD pathology (reviewed by Cacace et al., 2016; Blauwendraat et 
al., 2019).  Mutations that induce the hyperphosphorylation of tau have been identified in 
patients with frontotemporal dementia (Bugiani et al., 1999), frontotemporal dementia 
parkinsonism linked to chromosome 17 (Hutton et al., 1998), corticobasal degeneration and 
multiple system atrophy (Spillantini et al., 1998).   
 
The overexpression of missense mutations such as MAPT*P301S (Yoshiyama et al., 2007) or 
MAPT*P301L (Lewis et al., 2000) in transgenic mice have been used to study tau pathology 
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progression.  PS19 transgenic mice overexpress the MAPT*P301S mutation in neurons under 
the control of the prion protein promoter, and exhibit early gliosis and synapse loss at 3 months 
of age followed by cognitive impairment by 6 months of age in the Morris water maze 
(Takeuchi et al., 2011) coincident with the formation of neurofibrillary tangles prior to neuron 
loss (Yoshiyama et al., 2007).  The JNPL3 transgenic mice overexpress MAPT*P301L in 
neurons under the control of the prion protein promoter, and develop neurofibrillary tangles by 
4.5 months, while gliosis and neuronal loss have not been observed prior to 10 months of age 
(Lewis et al., 2000).  When this variant is overexpressed in CamKIIa+ neurons, spatial memory 
impairment (Ramsden et al., 2005; Santacruz et al., 2005) and gliosis (Helboe et al., 2017) are 
observed from 2.5 months of age followed by neurofibrillary tangle formation at 4 months of 
age and subsequent neuron loss (Ramsden et al., 2005; Santacruz et al., 2005).  Surprisingly, 
deletion of the endogenous Mapt in transgenic mice either resulted in motor deficits (Ikegami 
et al., 2000; Lei et al., 2012; Morris et al., 2013), or produced no overt motor and cognitive 
deficits (Van Hummel et al., 2016; Tan et al., 2018). 
 
1.7. Progressive white and grey matter loss lead to cognitive deficit in 
Alzheimer’s disease 
In addition to the two main pathological features, the amyloid and tau pathology, AD is 
characterised by white and grey matter diminution (Defrancesco et al., 2014).  White and grey 
matter loss occur in aging as observed using magnetic resonance imaging (Ge et al., 2002); 
however, brain atrophy is more severe in AD and mostly prevalent in frontal and temporal 
lobes (Van Der Flier et al., 2002) leading to memory impairment (Di Paola et al., 2007; Irish 
et al., 2014; Rémy et al., 2015).  Using magnetic resonance imaging, it was demonstrated that 
first brain areas affected in AD are the entorhinal cortex and the hippocampus (Du et al., 2001; 
Pennanen et al., 2004), which are two key regions involved in learning and memory (Hyman 
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et al., 1984).  Like grey matter, degenerated white matter was observed in the parietal, frontal 
and temporal lobes of people diagnosed with AD using both diffusion tensor (Zhang et al., 
2009) and T1-weighted (Baron et al., 2001) magnetic resonance imaging, and occurs in early 
AD suggesting it may participate in pathology development (reviewed by Nasrabady et al., 
2018). 
 
White matter damage is found in many brain regions in AD starting in regions defined as late-
myelinating (Stricker et al., 2009; Gao et al., 2011; Benitez et al., 2014) in accordance with the 
retrogenesis model (Reisberg et al., 1999; Brickman et al., 2012).  Loss of white matter occurs 
in the parietal, frontal and temporal regions and affects the corpus callosum tracts (Hampel et 
al., 1998; Dean et al., 2017), uncinate fasciculus tracts and cingulum tracts in AD patients 
(Rose et al., 2000; Zhang et al., 2009).  Using diffusion tensor imaging, Stricker et al. (2009) 
showed white matter loss was more pronounced in late-myelinating fibre tracts including the 
inferior and the superior longitudinal fasciculi fibre pathways compared to early myelinating-
tracts.  Additionally, Benitez et al. (2014) characterized white matter tract metrics using 
diffusional kurtosis imaging and showed a correlation between the decrease in late-myelinating 
tracts integrity (superior and inferior longitudinal fasciculi) and patient semantic verbal fluency 
decline, a cognitive function affected in AD (Benitez et al., 2014).  Moreover, early disruption 
of fronto-hippocampal white matter connectivity initiates episodic memory impairment in 
people diagnosed with AD (Rémy et al., 2015).   
 
White matter degeneration is associated with myelin alterations and oligodendrocyte loss in 
late AD (Ihara et al., 2010; Nielsen et al., 2014; Ota et al., 2019), and oligodendrocytes are 
particularly absent in amyloid plaque vicinity in post-mortem AD brain tissue (Mitew et al., 
2010).  AD-related myelin decrease correlates with increased phosphorylated tau and amyloid 
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levels in late myelinating regions Notably, cholesterol and myelin protein levels, including 
CNP, MBP and PLP, are reduced in the white matter of people with AD, analysed post-mortem 
(Roher et al., 2002).  Additionally, oligodendrocytes have shrunken nuclei (Gagyi et al., 2012), 
and increased DNA damage has been associated with increased oligodendrocyte death (Tse et 
al., 2018). 
 
White matter loss is also observed in transgenic mouse models of AD (reviewed in Table 1.1); 
and is associated with cognitive impairment.  Myelin pathology in transgenic mouse models of 
AD includes the focal loss of myelin from the vicinity of amyloid plaques (Mitew et al., 2010), 
the development of myelin aberrations such as myelin outfoldings (Behrendt et al., 2013), the 
abnormal expression of MBP in the nuclei of oligodendrocytes (Desai et al., 2011), and 
decreased MBP expression (Desai et al., 2010).  White matter pathology often develops prior 
to the onset of cognitive deficits in AD transgenic mouse models (see Table 1.1), and the 
progressive loss of oligodendrocytes and myelin seem to precipitate learning and memory 
impairment. 
 
1.8. Oligodendrocytes contribute to learning and memory 
Cognitive changes in AD have been largely attributed to synaptic deficits and neuronal loss; 
however, it may also be exacerbated by changes in oligodendrogenesis and myelin levels 
(reviewed by Bartzokis, 2011).  Social isolation during rodent development reduces myelin 
levels and impairs working memory (Makinodan et al., 2012; Yang et al., 2017).  Similarly, 
induced-oligodendrocyte loss and demyelination in the rat hippocampus (Xu et al., 2017) or 
mouse prefrontal cortex (Xu et al., 2010) impairs working memory; but preventing cuprizone-




Table 1.1. Overview of myelin and oligodendrocyte pathology in commonly used transgenic mouse models of AD.  




- Myelin aberrations 
- Myelin loss in amyloid plaque core 
- Increased OPC proliferation and differentiation 
à age: 6 months, brain region: cortical grey and white matter 
 
- Spatial learning and memory deficit in 
Morris water maze at 7 months of age 
Behrendt et al., 2013 





- Decreased g-ratio and internode length 
- Increased MBP, NG2 and CNPase relative density 
à age:2 months, brain region: hippocampus 
 
- Downregulation of MBP mRNA (from 3 months, more 
advanced at 6 months) 
- Increase in NG2+ cells 
à age: 6 months, brain region: temporal lobe 
 
- Spatial learning deficit in Morris water 
maze at 12 months of age 
 
 
Wu et al., 2017 
Dong et al., 2018 






- Decreased myelin levels in amyloid plaque vicinity 
à age: 13 months 
- Spatial learning normal at 5-7 months but 
deteriorates by 15-17 months in water maze 
and radial arm maze 
 
Mitew et al., 2010 
Arendash et al., 2001  
 
Tg2576 APPK670N,M671L - Decreased myelin levels in amyloid plaque vicinity 
à age: 13 months 
- Impaired spatial learning and working 
memory develops between 6 to 12 months of 
age 
 
NB: Mice subject to blindness 
 
Mitew et al., 2010 




- Myelin abnormalities 
à age: 2 and 6 months, brain region: hippocampus and entorhinal 
cortex 
 
- Decreased myelin level 
- Decreased number of myelinated processes  
- Increased CC1+ oligodendrocytes 
- No change in OLIG2+ cells 
à age: 6 months, brain region: hippocampus (CA1) 
 
- Aberrant expression of MBP within oligodendrocyte nuclei – 
mature oligodendrocytes are non-myelinating. 
à age: 9 months, brain region: entorhinal cortex 
 
- Memory retention deficit from 4 months of 
age in Morris water maze 
 
- Spatial learning deficit from 6 months of 
age in Morris water maze 
 
Desai et al., 2009 
Desai et al., 2010 
Desai et al., 2011 




Table 1.1. Overview of myelin and oligodendrocyte pathology in commonly used transgenic mouse models of AD. (continued)
Mouse Mutations Myelin and oligodendrocyte pathology Cognition References 






- Myelin aberrations 
- Increased g-ratio due to decreased myelin thickness, and 
progressive decrease of axon calibre with age 
à age: 1, 2, 3 and 5 months, brain region: prelimbic area, 
retrosplenial granular cortex, CA1, entorhinal cortex 
- Spatial learning deficit in Morris Water 
Maze from 1 month of age 
 
- Motor deficits from 12 months of age 
(females) 
Gu et al., 2018 
Chu et al., 2017 
Tang et al., 2016 




Not reported - Increased hyperactivity in open field test, 
Y-maze and elevated plus maze at 6-7 
months of age 
 
- Decreased anxiety-like behaviour in 
elevated plus maze at 6,7 and 10 months of 
age 
 
- Spatial memory retention deficit in Barnes 
Maze and Morris Water Maze from 6 
months of age 
 
- Spatial learning deficit at 10 months of age 
 
Takeuchi et al., 2011 
Dumont et al., 2011 






Not reported - Hyperactivity from 2 months of age 
reported in multiple tests (e.g. open field, 
elevated plus maze) 
 
- Decreased anxiety-like behaviour in 
elevated plus maze from 2 months of age 
 
- Spatial learning and memory deficit 
observed in radial arm maze from 4 months 
of age, in Morris water maze from 3-4 
months of age, in Barnes Maze from 5 
months of age 
 
Wright et al., 2013 
Cheng et al., 2007 
Harris et al., 2010 
Cissé et al., 2011 
Murakami et al., 2011 
Sanchez et al., 2012 
Dubal et al., 2015 
Nunes et al., 2015 
Mably et al., 2015 
Mesquita et al., 2015 
Fujikawa et al., 2017 




white matter ultrastructure changes have been reported in humans following complex-motor 
skill training (Scholz et al., 2009; Sampaio-Baptista et al., 2013), and recent evidences 
demonstrate that new oligodendrocyte addition and myelination are required throughout life 
for motor-skill learning (Mckenzie et al., 2014; Xiao et al., 2016). 
 
Learning is the ability to acquire, modify or reinforce new knowledge, behaviours and skills.  
It can be active or passive, associative or non-associative, and involves the acquisition of pure 
data or the formation of an association between, for example, a place and an emotion (reviewed 
by Milner et al., 1998).  Learning stimulates short and long-term memory creation.  Short-term 
memory includes sensory and working memory (Cowan, 2009).  Long-term memory is 
characterized as either declarative/explicit and includes the recollection of facts (semantic 
memory) and events (episodic-like or spatial memory) (Squire and Zola, 1996), or as non-
declarative/implicit and includes the recollection of learned skills (procedural memory) and 
reflexes to an event (classical conditioning) (Milner et al., 1998).  Learning and memory 
processes are associated with measurable changes in brain microstructure. 
 
Learning is associated with ultrastructural changes in grey and white matter regions of the CNS 
in humans (Gaser and Schlaug, 2003; Scholz et al., 2009; Jiang et al., 2016) and rodents 
(Sampaio-Baptista et al., 2013; Mckenzie et al., 2014).  Changes in white matter architecture 
were also described in the healthy human brain in the intraparietal sulcus following juggling 
training (Scholz et al., 2009).  Healthy aged individuals trained in a single (reasoning) or multi-
domain cognitive training (reasoning, memory, visual and motor) twice per week for 12 weeks 
experienced cortical thickness changes in correlation with the type of cognitive task performed 
(Jiang et al., 2016).  For example, improvement in immediate memory was correlated with an 
increase in cortical thickness in the entorhinal cortex following single-domain cognitive 
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training.  Correspondingly, brain structure differences were observed between musicians, non-
professional musicians and non-musician controls proving that experience and training can 
modify the brain structure in a training dependent-manner as grey matter volume correlates 
with training intensity (Gaser and Schlaug, 2003).  Motor-dependent training tasks showed that 
learning is associated with alteration in white and grey matter regions including but not limited 
to corpus callosum, primary motor and somatosensory cortex, which could either be associated 
with myelin, neuronal changes or both.  By performing transgenic lineage tracing of OPCs and 
delivery of 5-ethynyl-2’-deoxyuridine (EdU), Mckenzie et al. (2014) showed that motor skill 
training stimulates OPC proliferation and increases the number of new oligodendrocytes added 
to the adult mouse brain.  Furthermore, rats trained to perform a skilled reaching task 
demonstrated an increase in myelination in the cingulum, external capsule and corpus callosum 
subjacent to the sensorimotor cortex contralateral to the trained limb relative to control groups 
including unskilled reaching and caged controls (Sampaio-Baptista et al., 2013).  Adult 
oligodendrogenesis and myelination are required for learning and memory acquisition, and in 
turn neuronal activity changes occurring during learning regulate new oligodendrocyte 
addition and myelination; however, neuronal activity is altered in AD. 
 
1.9. Neuronal activity changes in Alzheimer’s disease 
Neuronal activity is impeded in AD by neurotransmitters or excitatory-inhibitory signalling 
imbalance leading to Aβ-induced neuronal hyperactivity followed by neuron loss.  Glutamate 
accumulates in the synaptic cleft as transporters fail its reuptake (Masliah et al., 1996; Scott et 
al., 2002; Potier et al., 2010), particularly in close vicinity of amyloid plaques (Hefendehl et 
al., 2016), which overexcite the neuronal network in early AD.  Glutamate-induced 
overactivation becomes toxic and progressively induces synaptic deficits and neuron death in 
late AD (reviewed by Ong et al., 2013).  As a consequence of excitatory-inhibitory signalling 
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imbalance, theta oscillations are boosted in early AD (Montez et al., 2009), while their decrease 
in late AD correlates with cognitive deficit reported by mini-mental state examination (Engels 
et al., 2016).  Alterations of neural oscillations associated with amyloid plaque burden (Mander 
et al., 2015) lead to cognitive deficit (Verret et al., 2012; Bender et al., 2016) and increase the 
risk of epileptic seizures associated with abnormal neuronal activity in people diagnosed with 
AD (Amatniek et al., 2006; reviewed by Kitchigina, 2018).  Nonetheless, rescuing gamma-
aminobutyric acid (GABA) levels in cell cultures (Velasco and Tapia, 2002) and enhancing 
GABAA receptors activity in rodents (Paula-Lima et al., 2005; Brito-Moreira et al., 2011) can 
protect against glutamate-induced neuron damage. 
 
Abnormal neuronal network connectivity and disproportion of excitatory-inhibitory signalling 
(Palop et al., 2007; Busche et al., 2008, 2012; Sun et al., 2009; Verret et al., 2012; Van Groen 
et al., 2014) alter neuron status to hypoactive or hyperactive based on amyloid plaque vicinity 
in AD transgenic mice (Busche et al., 2008), resulting in epileptic-seizures and behavioural 
abnormalities (Palop et al., 2007; Sanchez et al., 2012; Verret et al., 2012).  Neuronal 
hyperactivity has been associated with progressive amyloid accumulation in the brain (Busche 
et al., 2012; Lerdkrai et al., 2018) starting with early hippocampal hyperactivity following 
soluble Aβ accumulation (Busche et al., 2012), while neuronal hypoactivity occurs only after 
amyloid plaque formation (Busche et al., 2012).  By contrast, human MAPT overexpression in 
transgenic mice leads to an increase in hypoactive or silent neurons (Busche et al., 2008), and 
MAPT overexpression overlooks amyloid-induced hyperactivity in mice recapitulating both 
the amyloid and tau pathology leading to an increase in silent neuron population following 
soluble tau accumulation (Busche et al., 2019).  This suggests an early Aβ-induced 
overexcitation of neuronal activity followed by the loss of neuronal function as observed in 




Soluble Aβ accumulation triggers the loss of white matter integrity in the fimbria/fornix and 
perforant pathways (Van Groen et al., 2014) highly involved in memory processing (Amaral 
et al., 2014, 2018).  Amyloidosis induces astrocytic glutamate release, associated with early 
neuronal hyperactivity and neuronal hypoactivity in advanced AD (reviewed by Findley et al., 
2019), and reduces synaptic density (Talantova et al., 2013).  Glutamate promotes tau 
phosphorylation (Sindou et al., 1994) and tau accumulation reduces dendritic length and 
synapse number (Yin et al., 2016b) leading to neuron hypoactivity and loss.  Neuronal activity 
is regulated by APP and tau accumulation, and can in turn regulate amyloid burden (Bero et 
al., 2011; Zhen et al., 2017) and extracellular tau level released in mice (Yamada et al., 2014) 
consequently worsening AD pathology.  However, as early AD pathology is associated with 
an increase in neuronal activity, this could result in an increased rate of oligodendrocyte 
addition to the brain. 
 
1.10. Neuronal activity promotes new oligodendrocyte addition 
Oligodendrocyte addition and adaptive myelination are promoted by neuronal activity.  
Optogenetic stimulation of layer V projection neurons in the premotor cortex of awake and 
behaving Thy1::ChR2 mice rapidly enhanced OPC proliferation.  Within 4 weeks post-
stimulation oligodendrogenesis and myelin thickness were boosted in the premotor cortex and 
corpus callosum, which was associated with motor performance improvement in the CatWalk 
gait test relative to controls (Gibson et al., 2014).  Similarly, pharmacological increase of 
neuronal activity of some somatosensory axons using h3MDq-DREADD (designer receptor 
exclusively activated by a designer drug) and clozapine-N-oxide injection in the somatosensory 
cortex of Pdgfrα-CreERT2::Tau-mGFP mice led to an increase in PDGFRα+ OPC density, 
PDGFRα+ EdU+ proliferating OPCs, aspartoacylase (ASPA)+ EdU+ newly added 
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oligodendrocytes and an increase in the proportion of green fluorescent protein (GFP)+ 
myelinated axons in the corpus callosum (Mitew et al., 2018).  While electrically active axons 
are preferentially myelinated, a decrease of neuronal activity does not result in oligodendrocyte 
and myelin degeneration but in myelination adjustment.  Overexpression of Kir2.1 to reduce 
neuron excitability in mice did not alter OPC density, proliferation and differentiation but the 
number of GFP+ myelinated axons was decreased in the corpus callosum (Mitew et al., 2018).  
Neuronal activity regulates myelination, and myelination regulates neural synchronicity.  
Overexpression of PLP in PLP-tg mice (Kagawa et al., 1994) result in motor learning 
impairment, reduced oligodendrogenesis and MBP mRNA expression relative to controls 
following motor training (Kato et al., 2019).  Decreased task-related and spontaneous Ca2+ 
transients were observed in PLP-tg mice compared to controls during motor learning 
suggesting an incapacity of myelin to regulate excitatory signalling as parvalbumin-positive 
inhibitory interneurons functioned normally (Kato et al., 2019).  Optogenetic stimulation of 
thalamic cell bodies in PLP-tg mice, 3 weeks post-injection with AAV2/1-Syn-ChR2 (H134R)-
EYFP into the thalamus, increased spike latency, spike volley duration and number of spikes; 
and rescued motor learning during the pull lever task indicating a potential compensation for 
thalamic activity by input adjustment (Kato et al., 2019).  New oligodendrocyte addition and 
myelination are enhanced by neuronal activity and in turn myelination regulates neural 
synchronicity required for learning and memory acquisition but the continuous role of 
oligodendrogenesis in memory maintenance in the healthy CNS and in pathological conditions 
is unknown.   
 
1.11. Amyloidosis affects the cells of the oligodendrocyte lineage 
Human studies suggest that amyloid alters mature oligodendrocyte morphology (Roher et al., 
2002), and in vitro evidences found that Ab peptides are toxic for oligodendrocytes (Xu et al., 
31 
 
2001; Horiuchi et al., 2012).  Xu et al. (2001) indicated that Ab40 as well as its truncated 
fragment Ab25-35 led to oligodendrocyte death in cultures obtained from the cortex of P1-2 rats.  
Horiuchi et al. (2012) later showed that Ab1-42 oligomers are cytotoxic for mature myelinating 
oligodendrocytes and inhibit myelin sheaths formation in vitro.  Ab-induced oligodendrocyte 
dysfunction was reported to be increased by PSEN1 mutation, using the 3xTg transgenic mouse 
line (Desai et al., 2011).  Desai et al. (2011) showed that MBP distribution was impaired in 
mature myelinating oligodendrocytes, which consequently were not able to produce myelin 
sheaths.  Increase in MBP degradation and formation of myelin vesicles was observed in the 
periventricular white matter of AD patients using immunohistochemical staining of AD brain 
tissue post-mortem (Zhan et al., 2014), and degraded MBP was found to colocalize with Ab1-
42 peptides in the core of amyloid plaques (Zhan et al., 2015).   
 
The main myelin protein MBP binds to Ab peptides and inhibits Ab fibrils formation (Hoos et 
al., 2009; Liao et al., 2009; Ou-Yang et al., 2015).  Using cell culture, Liao et al. (2009) 
demonstrated that purified human MBP and recombinant human MBP could bind and degrade 
Aβ40 and Aβ42 peptides in vitro.  In addition, using a mouse line expressing the APP Swedish 
mutation (Tg2576), they reported that MBP could degrade assembled fibrillar Aβ in situ.  These 
data are consistent with results reported by Hoos et al. (2009) showing that MBP could interact 
with Aβ peptides and inhibit Aβ fibril formation in vitro.  The N-terminal domain of MBP and 
particularly four residues (K54, R55, G56, and K59) found between residues 54 and 64 of 
MBP1-64 (Kotarba et al., 2013) mediates Ab fibrillar aggregation inhibition (Liao et al., 2010).  
Transgenic mice Tg-MBP1-EGFP overexpressing MBP1-64 in neurons via the Thy1.2 promoter 
crossed with 5xFAD mice (Oakley et al., 2006) presented a decrease in insoluble Ab and 
fibrillar amyloid following a decrease in the size of amyloid plaques rather than a decrease in 




Ab directly interacts with OPCs (NG2 cells) and can affect their morphology. Human NG2 
cells exposed to Ab oligomer or fibril enriched preparation in vitro experienced morphological 
changes and fibrillar Ab1-42 decreased NG2 concentrations (Nielsen et al., 2013).  AD patients 
presented lower cerebrospinal fluid NG2 levels compared to controls that was correlated to 
AD-related biomarkers including Ab, consequently a prolonged exposure to Ab might actually 
be toxic for OPCs (Nielsen et al., 2013).  While decrease in NG2 levels were observed in 
diagnosed AD patients with advanced AD stages, the ratio of NG2 cells in the temporal lobe 
was increased in concomitance with early loss of myelin in the corpus callosum at 6 months of 
age in APPSwe/PSEN1dE9 mice (Dong et al., 2018).  NG2 cell clusters around amyloid 
plaques were observed between 6 and 15 months of age in APPSwe/PSEN1dE9 mice and NG2 
cells cleared Ab42 peptides in OPC cultures derived from Sprague-Dawley rats at P1-2; and Ab 
clearance by NG2 cells occurred via endocytosis and autophagy (Li et al., 2013).  Processes by 
which OPCs can promote homeostasis and remyelination and consequently delay 
neurodegeneration are still unclear.  However, the increase in OPC ratio following 
demyelination suggests that OPCs could promote repair in AD as observed in multiple sclerosis 
(Keirstead et al., 1998; Chang et al., 2000; Girolamo et al., 2010). 
 
Oligodendrocyte and myelin alterations can be rescued in amyloid-like pathology.  In APP/PS1 
mouse model, an increase in total OLIG2+ oligodendrocyte population and the proportion of 
proliferating OLIG2+ cells were observed at 6 and 11 months of age in APP/PS1 mice 
compared to controls (Behrendt et al., 2013).  The increase in OLIG2+ cells corresponded to a 
significant increase in proliferating NG2+ BrdU+ OPCs and GSTπ+ BrdU+ newly differentiated 
oligodendrocytes in cortical grey and white matter at 6 months of age.  The increase in OPC 
proliferation and differentiation was associated with myelin aberration repair between 6 and 9 
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months of age, which was observed by Gallyas impregnation and MAG immunostaining 
(Behrendt et al., 2013).  APP/PS1 mice showed focal myelin loss around amyloid plaques, 
which was previously reported by Mitew et al. (2010) in APPSwe/PSEN1M146L mice and AD 
brain tissue post-mortem.  The amyloid pathology seems to initially increase oligodendrocyte 
addition in rodents; however, a similar effect was not observed in humans.  Nielsen et al. (2013) 
observed a decrease in NG2 immunoreactivity in the molecular layer of the hippocampus in 
post-mortem brain specimens from clinically diagnosed and post-mortem verified AD patients 
compared to non-demented controls (Nielsen et al., 2013).  These findings were in accordance 
with the reported decreased OLIG2+ oligodendrocyte population in grey and white matter of 
the sensory motor cortex, superior temporal gyrus and the mid frontal gyrus in AD brain tissue 
post-mortem (Behrendt et al., 2013).  As brain tissue samples used in human studies were 
obtained from mild to severe AD patients, the decrease in oligodendrocytes may only 
correspond to advanced stages of the disease, consequently the fate of the cells of the 
oligodendrocyte lineage in early AD remains unclear and further investigations are required. 
 
1.12. Tau alterations disturb the cells of the oligodendrocyte lineage 
Tau modifications alter oligodendrocyte differentiation and process outgrowth.  Seiberlich et 
al., (2015) showed that oligodendrocytes lacking tau following siRNA knockdown of MAPT 
in vitro remained in a progenitor state rather than differentiate due to a lack of MBP transport 
from the soma to the processes, which resulted in shorter processes and an incapacity to form 
appropriate contact with neurons to differentiate into oligodendrocytes and form myelin 
internodes.  A transient tau dephosphorylation in oligodendrocytes following hydrogen 
peroxide exposure resulted in a loss of oligodendrocyte cellular processes in OPC cultures 
prepared from primary mixed glial cultures established from rat neonate brains (LoPresti and 
Konat, 2001).  Tau expression and phosphorylation modulate oligodendrocyte differentiation, 
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process outgrowth and myelination; yet, the fate of oligodendrocytes in presence of 
hyperphosphorylated tau remains unknown. 
 
Overexpression of human MAPT in transgenic mouse models leads to oligodendrocyte and 
myelin loss associated with cognitive and motor impairment.  In transgenic mice 
overexpressing Prnp-MAPT*P301L mutation, motor impairment was associated with 
increased tau levels and dying TUNEL+ and Caspase3+ cells in females and males compared 
to non-transgenic controls (Zehr et al., 2004).  Oligodendrocytes were found to be apoptotic 
while neurons and astrocytes did not colocalized with TUNEL+ and Caspase3+ cells (Zehr et 
al., 2004).  Overexpression of a MAPT*P301L mutation driven in oligodendrocytes by the CNP 
promoter in transgenic mice engendered impaired axonal transport prior to myelin and axon 
degeneration and the appearance of Thioflavin-S+ tau inclusions in oligodendrocytes, 
oligodendrocyte death and motor impairment (Higuchi et al., 2005).  Overexpression of the 
three 3R human isoforms via overexpression of MAPT*P301L mutation, associated with 
frontotemporal dementia parkinsonism linked to the chromosome 17, expressed in neurons, 
astrocytes and oligodendrocytes under the control of the mouse α-tubulin promoter resulted in 
tau inclusions in oligodendrocytes and astrocytes by 6 months of age, myelin and glial 
degeneration and motor deficits by 24-25 months of age.  Significant age-related loss of 
oligodendrocytes in the basal ganglia, cerebellum and brain stem; and loss of myelin associated 
with neuronal loss in the spinal cord were found between 1 and 24 months of age in these mice 
(Higuchi et al., 2002).  The conditional overexpression of MAPT*P301L in CamKIIa+ neurons 
resulted in myelin thinning of myelinated axons from the perforant pathway, a widespread 
myelin damage of myelinated axons from the ammonic path in the para-ventricular alveus near 
the Cornu Ammonis field 2 (CA2) region of the hippocampus; and myelin remodelling in the 
optic nerve with no signs of demyelination but associated with a transient decrease in neuronal 
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excitability at 1 month post induction, which recovered by 6 months post-induction (Jackson 
et al., 2018).  Brain regions can react differently to MAPT overexpression and some areas may 
be prone to oligodendrocyte and myelin replacement in tauopathy. 
 
MAPT overexpression may enhance OPC differentiation.  Following focal lysolecithin-induced 
demyelination of the spinal cord ventral funiculus of 2-months old Thy1.2-MAPTP301S mice, 
OPC density (Sox2+ / OLIG2+ cells per mm2) is maintained within the lesion (Ossola et al., 
2016).  However, mature oligodendrocyte density (Adenomatous polyposis coli (APC)+ / 
OLIG2+ cells per mm2; and PLP+ cells per mm2) and expression of MBP was increased in 
Thy1.2-MAPTP301S mice relative to controls within the lesioned area.  A three-fold increase in 
mature oligodendrocyte density (MBP+ / OLIG2+ cells per mm2) was additionally observed in 
OPC cultures from P10-12 Thy1.2-MAPTP301S mice compared to controls suggesting that OPC 
enhanced ability to proliferate and differentiate was acquired from microenvironment priming 
as OPCs did not directly expressed the MAPT mutation but yet retained their enhanced ability 
in vitro.  Nevertheless, in accordance with previous findings, the interaction of tau with the 
cells of the oligodendrocyte lineage is evident.  However, OPC response to MAPT 




1.13. Hypothesis & Aims 
OPCs generate new oligodendrocytes throughout life in the healthy brain, and can increase 
oligodendrocyte production in response to demyelination to promote myelin replacement and 
maintain neuronal activity.  Myelin loss is observed in late AD, but whether OPCs have the 
ability to increase new oligodendrocyte addition to replace oligodendrocytes and myelin early 
in AD is unclear.  A recent study showed that OPCs produced larger numbers of new 
oligodendrocytes in response to a focal, demyelination injury in the spinal cord of transgenic 
mice that overexpress a dementia-associated pathogenic variant of human MAPT (Ossola et al., 
2016); and that new oligodendrocyte addition can also be enhanced by the overexpression of 
human pathogenic versions of APP and PSEN1 (Behrendt et al., 2013).  However, it is not 
known whether the overexpression of pathogenic MAPT or APP is sufficient to affect cells of 
the oligodendrocyte lineage early in AD development.  I hypothesise that the overexpression 
of pathological human MAPT and APP, primarily in neurons, will be sufficient to induce 
oligodendrocyte damage and that this will result in elevated oligodendrogenesis. 
 
I will evaluate this hypothesis, by achieving the following aims: 
 
Aim 1: To determine whether the overexpression of MAPT has a pathological effect on 
cells of the oligodendrocyte lineage 
I will assess cognitive performances of Prnp-MAPTP301S transgenic mice, that primarily 
overexpress hyperphosphorylated human tau in neurons in the CNS, by performing a series of 
behavioural assessments to ensure that these mice do not experience significant memory 
impairment prior to 6 months of age, in order to define the pre-symptomatic period.  I will then 
use Cre-lox lineage tracing technology to label OPCs and follow their fate over time, 
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quantifying oligodendrogenesis in the hippocampus, entorhinal cortex and fimbria of control 
and Prnp-MAPTP301S transgenic mice.  I will use histological approaches and transmission 
electron microscopy to determine the impact of any change in oligodendrogenesis on 
myelination in the hippocampus. 
 
Aim 2: To determine whether the overexpression of a human AD-associated variant of 
APP has a pathological effect on cells of the oligodendrocyte lineage 
I will determine the pre-symptomatic period of PDGFb-APPSw,Ind mice, overexpressing human 
APP Swedish and Indiana mutations in neurons and oligodendrocytes, using a battery of 
behavioural assessments.  I will assess PDGFRα+ OPC density in the hippocampus, entorhinal 
cortex and fimbria of PDGFb-APPSw,Ind transgenic mice and WT littermates over time, using 
immunohistochemistry.  I will compare the electrophysiological properties of OPCs in control, 
Prnp-MAPTP301S and PDGFb-APPSw,Ind mice, in order to determine whether amyloid pathology 
influences the membrane properties of these cells or their ability to respond to neurotransmitter 
signalling.  I will use transmission electron microscopy to determine if myelin thickness is 
altered in the hippocampus of PDGFb-APPSw,Ind mice during the pre-symptomatic period. 
Using Cre-lox lineage tracing technology and histological approaches, I will quantify 
oligodendrogenesis in control and PDGFb-APPSw,Ind mice, and determine whether amyloid 
pathology impacts the total number of oligodendrocytes. 
 
This research will provide critical insight into the impact that AD pathology has on cells of the 
oligodendrocyte lineage.  I will particularly study the impact that AD pathology has on these 
cells prior to the onset of behavioural symptoms in order to understand some of the earliest 
cellular changes that underpin neurodegeneration, and identify potential early targets for 
therapeutic intervention.  
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Chapter 2: General methods 
2.1. Transgenic mice 
Male and female mice were housed in individually ventilated cages (Optimice) on a 12h light 
/ dark cycle (07:00-19:00) with food and water available ad libitum.  All animal experiments 
were approved by the Animal Ethics Committee of the University of Tasmania (13741 and 
16151) and carried out in accordance with the Australian code of practice for the care and use 
of animals in science. Details of animal experiments are reported in accordance with the 
ARRIVE guidelines.  Rosa26-YFP Cre-sensitive reporter mice (Srinivas et al., 2001) were 
purchased from the Jackson Laboratory (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J, stock 
#006148) and backcrossed onto a C57BL/6 background in house for >10 generations.  PDGFb-
APPSw,Ind mice (referred to here as APP mice, but also known as J20 mice; Mucke et al., 2000) 
expressing a three point mutation (Swedish and Indiana) driven in neurons by the platelet 
derived growth factor-beta chain (PDGFb) were purchased from the Jackson Laboratory 
[B6.Cg-Zbtb20Tg(PDGFB-APPSwInd)20Lms/2Mmjax, stock #006293].  Prnp-MAPTP301S 
transgenic mice  (referred to here as MAPT mice, but also known as PS19 mice, Yoshiyama et 
al., 2007), that express a human variant of MAPT driven in neurons by the prion protein 
promoter, were purchased from the Jackson Laboratory (B6;C3-Tg(Prnp-
MAPT*P301S)PS19Vle/J, stock #008169) and backcrossed onto a C57BL/6 background for 
>20 generations.  Pdgfrα-CreERT2 transgenic mice (Rivers et al., 2008) were a kind gift from 
Prof. William D Richardson (University College London, UK).  Pdgfrα–H2BGFP mice 
(Hamilton et al., 2003) were purchased from the Jackson Laboratory (B6.129S4-
Pdgfratm11(EGFP)Sor/J, stock # 007669).  Mice were maintained on a C57BL/6 background 
and bred to generate experimental mice that were heterozygous for each transgene.   Mouse 
used for each aim in this study are listed below (Appendix 2. Table 1).   
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We performed cre-lox lineage tracing (Metzger et al., 1995; Leone et al., 2003) to fluorescently 
label adult OPCs and trace their generation of new oligodendrocytes over time.  When 
tamoxifen is delivered to Pdgfra-CreERT2 :: Rosa26-YFP transgenic mice, it binds to a form 
of cre-recombinase that is fused to the estrogen-receptor type II, only in OPCs, causing it to 
translocate to the nucleus.  In the nucleus, Cre recombinase recognises and recombines the 
loxp-sites that flank a stop codon in the Rosa26-YFP transgene, excising the stop codon and 
enabling expression of the yellow fluorescent protein (YFP) reporter.  YFP expression is 
permanently turned on in the OPCs and retained by their progeny (as per Rivers et al., 2008) 
In this system, Cre activation and OPC labelling has been shown to be strictly dependent on 
tamoxifen delivery (Rivers et al., 2008; Clarke et al., 2012; Young et al., 2013).  Mouse lines 
expressing an APP or MAPT mutation were selected due to reported cognitive decline prior to 
amyloid plaque (Palop et al., 2003; Wright et al., 2013) and neurofibrillary tangle (Yoshiyama 
et al., 2007; Takeuchi et al., 2011) formation allowing us to evaluate the effect of early stages 
AD-like pathology on the cells of the oligodendrocyte lineage.  
 
2.2. Genotyping transgenic mice tissue sample 
2.2.1. Genomic DNA extraction from ear clips 
To determine and confirm the genotype of each transgenic mouse, genomic deoxyribonucleic 
acid (DNA) was extracted from a small tissue biopsy.  Mice ear clips or tail samples were 
collected at ~ P30 and post-mortem.  Each sample was sealed in a DNAse free 1.5ml 
microcentrifuge tube and incubated with 250µl of DNA extraction buffer containing 6µl 
Proteinase K (stock solution 20mg/ml) at 55°C overnight on a heat block.  On the next day, 
they were briefly vortexed and centrifuged to avoid cross-contamination.  Subsequently, 6M 
Ammonium Acetate (100µl, Sigma) was added into samples using p200 Barrier Tip for cell 
lysis.  Samples were then vortexed, placed on ice for 15 min and centrifugated for 10 min at 
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13,200 rpm and 4°C to separate cellular debris from the DNA. The supernatant containing the 
DNA was poured into a fresh tube.  Isopropanol (250µL, Sigma) was added into the supernatant 
to precipitate the DNA.  Tubes were vortexed and spun at 13,200 rpm for 3 min at room 
temperature.  The supernatant was quickly poured off and the precipitated DNA was washed 
using 70% ethanol (125µL, Sigma).  Most of ethanol was removed after 3 min centrifugation.  
The DNA pellet was centrifuged for 1 min in the remaining solution, which was then removed.  
50µl of Milli-Q water were added and the DNA pellet resuspended at 55°C for 15 min or 
overnight at room temperature.  The DNA was quantified by spectrophotometry using a 
NanoDrop UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, USA). The DNA 
was then stored at -20°C or used to perform genotyping by polymerase chain reaction (PCR; 
see below). 
 
2.2.2. Amplification by Polymerase Chain Reaction of genomic DNA  
PCR was applied to genotype transgenic mice by a 25µl PCR reaction.  For most transgenes, 
0.5 to 2µl depending on concentration of extracted DNA was used as template in PCR 
reaction together with 12.5µl of GoTaq, 0.5µl of each primer, and 9.5 to 11µl of Milli-Q water 
to complete the 25µl required volume.  For the APP and MAPT transgenes, a Taq DNA 
polymerase with standard Taq (Mg-free) buffer (New England Biolabs) was used and included 
0.1µl of Taq, 2.5µl of standard buffer, 2.0µl of MgCl2, 0.5µl of deoxynucleotide solution mix 
(New England Biolabs), 0.2µl of each primers, and 17.5 to 19µl of Milli-Q water to complete 
the 25µl required volume. The DNA sequence was initially amplified at 94℃ for 4 min then 
for a various number of cycles; depending on the transgene of interest (Appendix 2. Table 2); 
at 94°C for 30 seconds, 57˚C or 62°C for 45 seconds and 72°C for 1 min, followed by 10 min 




2.2.3. Gel electrophoresis 
Following PCR, the DNA product was visualized by gel electrophoresis, which separates DNA 
based on its size.  1% and 2% (w/v) agarose gels were made by dissolving agarose powder 
(Biorad) in 1X Tris-Acetate EDTA (TAE) (LifeTechnologies).  The solution was heated in a 
microwave until the powder dissolved.  100mL of molten agarose were added to a gel cast 
containing 1μl of SybrSafe (Invitrogen) for DNA detection.  Once set the gel was transferred 
into a gel tank containing 1X TAE (Life Technologies).  The gel comb was removed, and 15μl 
of PCR product was loaded into each well.  5μl of Hyperladder I (Biorad) was loaded into one 
well as a reference to determine the size of the PCR product.  The gel was run at 100 volts for 
15 to 30 min depending on the gel concentration, 1 to 2 % respectively.  The gel was then 
removed from the gel tank and excited at 470nm using an Image Station Amershamä Imager 
600 (GE Healthcare Life Sciences) and bands were detected with an emission filter set at 
600nm. 
 
2.2.4. Genotyping by light to reveal fluorescence 
To confirm the Histone-GFP transgene expression in Pdgfrα–H2BGFP mice, pups were placed 
under a light after birth (P1-P2) to reveal brain fluorescence prior to skull skin thickening 
(Hamilton et al., 2003).   
 
2.3. Tamoxifen preparation and delivery 
Tamoxifen (Sigma) was dissolved in corn oil (40mg/ml) by sonication (Ultrasonic cleaner FXP 
8M, Unisonics Australia) at 21˚C for 2 hours and administered to adult mice (P60) to activate 
Cre-recombinase and induce expression of yellow fluorescent protein (YFP).  Control, MAPT 
and APP adult mice (P60) carrying the Pdgfrα-CreERT2 and Rosa26-YFP transgenes received 
300mg tamoxifen/kg body weight daily for four consecutive days by oral gavage as previously 
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described (O’Rourke et al., 2016).  Mice were analysed 7, 60, 90 or 120 days after their first 
dose of tamoxifen, and are referred to as P60+7, P60+60, P60+90 and P60+120, respectively.   
 
2.4. Western blot  
Mice were terminally anaesthetized with sodium pentobarbital (i.p.60mg/kg). Toe pinch-
response method was used to determine depth of anaesthesia.  Once mice were unresponsive, 
they were placed onto a shallow tray and a longitudinal incision was made to open the chest; 
the heart was exposed and carefully trimmed.  An incision was made to the mice’s right atrium 
with iris scissors, and mice were transcardially perfused with 0.01M phosphate buffer saline 
(PBS).  The brain was placed inside a coronal brain matrix (Agar Scientific, Essex, UK) and 
scalpel blades placed at Bregma -1.06 and -2.06.  The hippocampi were dissected from this 
brain slice and protein lysates produced in radioimmunoprecipitation assay (RIPA) cell lysis 
buffer (50mM Tris-HCL, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% Sodium 
dodecyl sulfate (SDS) and one phosphatase inhibitor tablet per 10mL in autoclaved MilliQ 
water).  Samples were centrifuged for 10 min at 13,200 rpm and 4˚C before the supernatant 
was collected and stored at -80°C.  Protein quantification by Bradford assay and western 
blotting was performed as previously described (Auderset et al., 2016).  The western gel was 
run for 1 hour at 21˚C and 90 V and 20 min at 165 V and the proteins transferred onto an 
ethanol-activated polyvinylidene fluoride (PVDF) membrane (Biorad) over a 60 min period at 
20 V and 4°C.  Each membrane was placed in blocking solution [5% (w/v) skim milk powder 
in 0.2% Tween-20 in Tris Buffered Saline (TBS-T)] and incubated on the orbital shaker for 1 
hour at 21°C, before being transferred into blocking solution containing primary antibodies 
(Appendix 3. Table 3) and incubated on a rotator overnight at 4°C. The membrane was then 
washed by agitation in TBS-T (3 x 10 min) at 21°C.  The relevant horseradish peroxidase 
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(HRP) conjugated secondary antibodies were diluted in 1% (w/v) skim milk powder in TBS-T 
and applied for 1 hour at 21°C. The membrane was again washed in TBS-T and exposed to 1:1 
Immobilon Western™ HRP Peroxidase Solution (Millipore) and Luminol Reagent (Millipore) 
for visualisation of the protein bands on an Image Station Amershamä Imager 600 (GE 
Healthcare Life Sciences).  
 
Membranes were washed with PBS, TBS-T and a blot stripping buffer (ThermoScientific) and 
incubated in blocking solution for 1 hour before exposure to mouse anti-b-actin (1:1000 in 
blocking solution) for 1 hour at 21˚C. The membrane was washed in TBS-T (3 x 10 min) before 
application of goat anti-mouse HRP (1:10000). The membrane was washed in TBS-T (2 x 8 
min) before band visualisation as describe above. Western blot band intensity was calculated 
by measuring integrated density and normalized to actin protein expression levels. 
 
2.5. Behavioural assessment 
Mice cognitive performance was assessed using a battery of behavioural tests, which involved 
the activation of our brain regions of interest that are highly involved in memory function and 
greatly affected in AD, the hippocampus and the entorhinal cortex.  Behavioural testing was 
carried out over 17 days (Figure 2.1a) for MAPT (Prnp-MAPTP301S) transgenic mice, APP 
(PDGFb- APPSw,Ind) transgenic mice and their wildtype (WT) littermates (C57BL/6 mice) in 
separate cohorts at 60, 90 and 180 days of age.  All behavioural testing was carried out during 
the dark phase of the light-dark cycle.  Mice were moved to the testing room 2 hours prior to 
the light cycle change, and habituated to the room for 3 hours.  All testing was carried out 
within the same 5-hour window of the dark phase.  Sodium lights were used in the room, and 
bright lights were used above the maze as needed.  All trials were video recorded and animal 
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movement tracked using automated tracking software (EthoVision XT 11, Noldus, 
Netherlands).  Males were tested prior to females but the order of testing was otherwise 
randomised between sessions.  All equipment was cleaned with 70% ethanol between trials to 
avoid olfactory cues.  To avoid any flaw due to fear or stress, mice were handled fifteen times 
prior to any behaviour assessment (5 min per day).   
 
2.5.1. Barnes Maze 
First, mice underwent a shortened version of the Barnes maze protocol, adapted from Attar et 
al. (2013) over seventeen days (Figure 2.1b).  On day 1, mice were placed in the brightly lit 
centre (120 lux) of an elevated (30cm above the ground), circular maze (100cm diameter) that 
contained 20 holes evenly spaced around the circumference.  After 1 min, the mice were gently 
directed to an escape box located underneath one of the holes in the circumference and left to 
habituate to the box for 5 min.  On days 2 and 3, the maze was raised to 70cm, and light 
intensity in the centre of the maze increased to 160 lux.  Distinct patterns were placed on each 
wall surrounding the maze, acting as spatial reference points that remained consistent 
throughout all trials. At the start of each trial, each mouse was placed at the centre of the maze 
under a covered start box for 15-30 sec before the box was removed, and the mouse left to 
explore until they found the escape box or 5 min elapsed.  If a mouse did not find the escape 
box prior to the end of trial, it was given direction to the box and allowed to enter it. After 
entering the escape box, each mouse was left for 1 min before being returned to the home cage 
to await the next trial. Mice were trained to learn the location of the escape box across three 
trials per day with an inter-trial interval of 30-45 min. During training, approaching any hole 
that did not lead to the escape box was considered a primary error, and the number of primary 
errors made during a trial was measured as an indicator of learning (reviewed by Gawel et al., 










Figure 2.1. Behavioural testing to evaluate spatial learning, recognition, short- and long-term memory 
a) Each experimental mouse was handled for 5 minutes per day for 15 consecutive days prior to starting behaviour 
testing and cognitive tests were performed in the order shown.  b) The Barnes maze was used to evaluate spatial 
learning, recognition, short-term and long-term memory.  c) The novel object recognition task was performed to 
examine recognition and short-term memory, and the first day of the novel object recognition task was used as an 




Short-term and long-term memory were assessed 1-day and 2-weeks after initial training, 
respectively. For each memory probe trial, mice were returned to the maze but with the escape 
box removed and left to explore the maze for 5 min.  The maze was divided into four quadrants 
within the tracking software (EthoVision XT 11) and the quadrant containing the hole that 
previously led to the escape hole was designated the target zone. The proportion of time spent 
within the target zone during the probe trial was measured as an indicator of intact memory for 
the location of the escape box.  
 
2.5.2. Open field and novel object recognition task 
The novel object recognition task was performed over 3 days (Figure 2.1c) to evaluate 
recognition memory and short-term memory.  On day 1, we carried out an open field 
assessment using a protocol adapted from Wang et al. (2013), to assess locomotor and anxiety-
like behaviour.  Each mouse was placed in an open square arena (30cm2, with walls of 20cm 
in height) lit (200 lux) to create a bright centre and dark perimeter, and the speed of movement 
and total distance moved was measured over a 10 min period.  On day 2, the arena was 
uniformly illuminated (50 lux) and contained two identical objects (multi-coloured green and 
blue Lego towers), equidistant from the box edges (7.5cm away from the box edges).  Each 
mouse was left to explore the arena and familiarise themselves with the identical objects for 10 
min.  On Day 3, one of the familiarised objects was replaced by a novel object (a multi-coloured 
green and blue Lego man) that was of similar size and colour, but a different shape and texture. 
Each mouse was returned to the arena and left to explore for 5 min.  The time spent exploring 
each object was recorded and the proportion of time exploring the novel object was calculated 




2.5.3. T Maze 
The final test used was the T maze, which was performed over a day (Figure 2.1d).  The T 
maze was used to evaluate mice working memory using a protocol adapted from Deacon and 
Rawlins (2006).  A mouse was placed in the start arm and once they chose to explore the left 
or right arm of the maze, retreat from that arm was blocked for 1 min.  The mouse was then 
returned to the start arm and allowed to make another choice.  This was repeated 10 times.  
Mice naturally exhibit exploratory behaviour and tend to choose the arm not visited in the 
previous trial, therefore, returning to the same arm in successive trials was recorded as an error.     
 
2.6. Tissue perfusion fixation and cryoprotection 
Mice were anaesthetized with sodium pentobarbital (i.p.60mg/kg) and depth of anaesthesia 
testing were performed as described above (see 2.4.).  4% (w/v) paraformaldehyde (PFA) in 
PBS was injected into left ventricle using a perfusion needle.  Once the blood was removed 
and the fixation was finished, the brain was taken out, sectioned coronally (1mm thick sections) 
using a brain matrix, immersion fixed into 4 % PFA at room temperature for 90 min and stored 
in 20% (w/v) sucrose in PBS overnight at 4°C.  The following day, brain sections were 
embedded with Thermofisher™ Cryomatrix™ medium and stored at -80°C until use. 
 
2.7. Immunohistochemistry and amyloid plaque detection 
30µm coronal brain cryosections containing the hippocampus, entorhinal cortex and fimbria 
(Bregma -1.34 to -2.54; Franklin & Paxinos, 2007) were collected and processed as floating 
sections.  Cryosections were incubated for 1 hour at 21°C in blocking solution [10% Fetal Calf 
Serum (FCS) / 0.1% triton x-100 in PBS] before being placed on an orbital shaker overnight at 
4˚C in blocking solution containing primary antibodies (Appendix 3. Table 4).  Sections were 
washed thrice in PBS before being placed on an orbital shaker at 4˚C overnight, in blocking 
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solution containing secondary antibodies, conjugated to Alexa Fluors (Appendix 3. Table 4).  
Cell nuclei were visualised by the inclusion of Hoechst 33342 (Appendix 3. Table 4).  To 
detect amyloid plaques, 40µm coronal brain cryosections were transferred into 0.1% (w/v) 
Thioflavin-S (Sigma) / 60% (v/v) ethanol / 40% (v/v) PBS, and agitated on a shaker for 3 min 
at 21°C.  Sections were de-stained by washing twice in 50% ethanol (v/v) in PBS and thrice in 
PBS.  Floating sections were mounted onto glass slides and the fluorescence preserved by the 
application of fluorescent mounting medium (Dako Australia Pty. Ltd., Campbellfield, 
Australia).   
 
2.8. EdU administration and detection 
EdU (Invitrogen) was administered to P175 mice via their drinking water (0.2 mg/ml, as per 
Young et al., 2013) for 5 consecutive days.  EdU-labelled cells were visualised using the 
AlexaFluor-647 Click-iT EdU kit (Invitrogen).  Briefly, 30µm floating cryosections were 
incubated for 15 min in 0.5% Triton X-100 (v/v) in PBS at room temperature before being 
transferred into the EdU developing cocktail and incubated for 45 min in the dark.  
Cryosections were washed twice in PBS before carrying out immunohistochemistry as 
described above.   
 
2.9. Confocal microscopy 
Confocal images (3µm spacing) were collected from the hippocampus, entorhinal cortex and 
fimbria, using a 20x air, 40x air or 100x oil objective and standard excitation and emission 
filters for 4',6-diamidino-2-phenylindole (DAPI), Fluorescein isothiocyanate (FITC; Alexa 
Fluor-488), Tetramethylrhodamine isothiocyanate (TRITC; Alexa Fluor-568) and Cyanine 5 
(CY5; Alexa Fluor-647).  A minimum of n=3 images were collected per area from each 
hemisphere, across n=3 brain sections and n=3 mice on an Andor Confocal microscope with 
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Nikon Software (Andor Technology Ltd., Belfast, Northern Ireland) or UltraView Spinning 
Disk Confocal microscope with Volocity Software (Perkin Elmer, Waltham, USA).  Brain 
regions of interests were delimited based on the Mouse Brain Atlas (Franklin and Paxinos, 
2007). Measurements to determine cell density, g-ratio and nodes length were performed 
manually using Fiji software (NIH, Washington DC, USA).  All measurements were made 
blind to the genotype and time-point being analysed. 
 
2.10. Electrophysiology 
Control, MAPT and APP mice carrying the Pdgfrα–H2BGFP transgene, in which OPCs 
express GFP, were used for the electrophysiological characterisation of OPCs.  Following 
cervical dislocation, P30 (P30-P35) and P100 (P100-P114) mice were decapitated and their 
brains transferred into ice cold slicing solution (124 mM NaCl, 26 mM NaHCO3, 1 mM 
NaH2PO4, 2.5 mM KCl, 2 mM MgCl2, 2.5 mM CaCl2, 10 mM glucose, and 1 mM Na-
kynurenate) saturated with 95% O2 / 5% CO2.  Horizontal brain slices (300 µm), prepared using 
a VT1200s vibratome (Leica), were incubated at 21°C in slicing solution that lacked Na-
kynurenate.  Whole cell patch clamp recordings were made at 21°C from GFP+ cells situated 
amongst the Schaffer collaterals in Cornu Ammonis field 1 (CA1) of the hippocampus.  
Recordings were made using an Axopatch200B or HEKA patchclamp EPC800 amplifier, 
collected using PClamp9.2 or PClamp10.5 software (Molecular Devices), sampled at a rate of 
50 kHz and filtered at 10 kHz.  The perfusion solution contained 144 mM NaCl, 2.5 mM KCl, 
2.5 mM CaCl2, 10 mM HEPES, 1 mM NaH2PO4 and 10 mM glucose set to pH 7.4 and saturated 
with O2.  Electrodes were prepared from glass capillaries with a resistance of 3-6 MΩ when 
filled with an internal solution containing 130 mM K-gluconate, 4 mM NaCl, 0.5 mM CaCl2, 
10 mM HEPES, 10 mM BAPTA, 4 mM MgATP, 0.5 mM Na2GTP set to pH of 7.2- 7.4, and 
an osmolarity of 290 ± 5 mOsm/kg.  
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Upon breakthrough, resting membrane potential (RMP), capacitance, membrane resistance, 
and the magnitude of the voltage-gated inward (sodium) current, elicited by a voltage step 
from -60 mV to 20 mV, were recorded as previously described (Clarke et al., 2012).  Cells with 
a voltage gated sodium channel current < 60 pA were classified as newly differentiated 
oligodendrocytes (Clarke et al., 2012) and were consequently removed from analysis.  Access 
resistance was measured before and after each recording and was between 12-25.0 MΩ (mean 
19.18 ± 0.42 MΩ).  Data were not included if the access resistance changed by ≥ 20% over the 
course of the recording or exceeded 25 MΩ.  To determine the effect of bath applied 100 µM 
kainate (KA; Abcam), cells were voltage clamped at -60 mV and currents elicited by 200 ms 
voltage steps from -100 to 20 mV (20 mV increments).  To measure the effect of bath-applied 
100 µM GABA (Sigma), cells were voltage clamped at 0 mV and currents elicited by 200 ms 
voltage steps from -80 to +80 mV (20 mV increments).  The average steady state current 
magnitude in the last 50 ms of the voltage step was measured using clampfit 10.5 (molecular 
devices) and the evoked current (current in the presence of drug minus baseline current) 
reported.  After recording the KA- or GABA-evoked current, 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX; a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/KA receptor 
antagonist, 10 µM, Sigma) or picrotoxin (PTX, GABAA receptor antagonist, 100 µM, Sigma) 
was bath applied for 2 minutes before reapplication of KA or GABA.   
 
2.11. Transmission electron microscopy 
2.11.1. Perfusion fixation and dehydration steps 
Mice were terminally anaesthetised using sodium pentobarbital (i.p. 60mg/kg) and 
transcardially perfused with Karnovsky’s fixative [0.8% (v/v) glutaraldehyde (GA) / 2% (w/v) 
PFA / 0.25mM CaCl2 / 0.5mM MgCl2 in 0.1M sodium-cacodylate buffer].  Brains were sliced 
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into 2mm thick coronal slices using a rodent brain matrix (Agar Scientific, Essex, UK) and 
immersion fixed at 21ºC for 2h, before being stored in 0.1M sodium-cacodylate buffer 
overnight at 4°C.  The stratum lacunosum moleculare of the CA1 of the hippocampus was 
dissected and immersed in 1% osmium tetroxide / 1.5% potassium ferricyanide in 0.065M 
sodium-cacodylate buffer, in the dark, for 2h at 4˚C.  Tissue was washed five times in Milli-Q 
water, before being dehydrated in: 70% ethanol (v/v) in Milli-Q water overnight at 21ºC; 80% 
ethanol (2 x 10 min); 85% ethanol (2 x 10 min); 90% ethanol (2 x 10 min); 95% ethanol (2 x 
10 min) and 100% ethanol (4 x 10 min).  Tissue was embedded by serial exposure to: 100% 
propylene oxide (2 x 5 min); 75% propylene oxide / 25% epon (4h); 67% propylene oxide / 
33% epon (4h); 50% propylene oxide / 50% epon (overnight); 33% propylene oxide / 67% 
epon (4h); 25% propylene oxide / 75% epon (4h), and 100% epon (overnight).  Tissue was 
transferred to fresh 100% epon for 4h before being polymerised at 60˚C for 72h.  Blocks 
containing the samples were stored at room temperature until use. 
 
2.11.2. Sectioning and grid staining 
Embedded sample size was reduced using an ultramicrotome (Ultracut, Leica) to hold the 
sample in position and razor blades to remove excess resin.  Glass-knifes were made using a 
knifemaker (7800 knifemaker, Leica).  Using an ultramicrotome (Reichert Ultracut S, Leica) 
and a glass knife, 1µm sections were cut to polish the samples.  Once the tissue was visible, a 
glass knife with a boat (fixed to the glass knife using nail polish and filled with water) was 
placed on the ultramicrotome to cut and collect floating sections with a perfect loop (Diatome).  
Sections were placed on a slide and stained with toluidine blue for 30s on a heat plate at 60˚C 
to locate the region of interest visualised with an optical microscope (Zeiss).  The glass knife 
was then replaced with a diamond knife (Diatome) and ultrathin floating sections (70nm thick) 
were cut and similarly collected with a perfect loop.  Ultrathin sections were placed on a gold 
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grid with formvar (ProSciTech).  The next day, sections were stained on the grid with 
Reynolds’ stain [Reynolds, 1963; lead citrate made from lead nitrate (Sigma) and trisodium 




Electron micrographs of the stratum lacunosum moleculare were collected using a HT7700 
(Hitachi) transmission electron microscope.  Axons were identified based on their microtubule 
organisation (reviewed by Stassart et al., 2018) and individual myelin lamella (wrap) by the 
presence of major dense lines (reviewed by Simons & Nave, 2016).  The g-ratio was measured 
for a minimum of 95 myelinated axons per mouse, and the number of myelin wraps for a 
minimum of 27 myelinated axons per mouse.  Quantification was performed by an 
experimenter blind to genotype for n=3-4 mice per group. 
 
2.12. Statistical analyses 
Statistical analyses were performed using GraphPad Prism 8.0 (La Jolla CA, USA).  The 
distribution of each data set was evaluated to determine whether the data were normally 
distributed using the D’Agostino & Pearson normality test or Shapiro-Wilk normality test 
where n ≥ 5.  Data that were normally distributed were analysed by a parametric test [one-way 
analysis of variance (ANOVA) or two-way ANOVA for groups comparison with a Bonferroni 
post-hoc test], and data that were not normally distributed were analysed using a non-
parametric text [Mann-Whitney U test or Kolmogorov-Smirnoff test].  For experiments where 
n=3, a normal distribution was assumed, and data were analysed using an unpaired two-tailed 
t-test.  Survival curve comparisons were performed using a Log-Rank (Mantel-Cox) test.  
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Statistical significance was established as p<0.05.  Statistical details are reported in 
corresponding figure legend and individual data points are presented on each graph.  
Behavioural and electrophysiological data are presented as mean ± standard error of the mean 
(SEM).  Western blot, immunohistochemical or TEM data are presented as mean ± standard 




Chapter 3: Grey and white matter oligodendrogenesis is increased 
prior to locomotor or memory impairment in an adult mouse 
model of tauopathy 
 
3.1. Introduction 
In physiological aging, white matter damage can be detected in brain regions that are critical 
for cognitive and emotional processing, including the hippocampus, neocortex and frontal 
white matter tracts, and the extent of white matter damage closely correlates with cognitive 
decline (Charlton et al., 2006; Hirsiger et al., 2017; Fan et al., 2019).  White matter 
degeneration is exacerbated in people diagnosed with a tauopathy.  For example, diffusion 
tensor imaging evaluations of people with frontotemporal dementia indicate that fractional 
anisotropy is reduced in frontal and temporal white matter regions including the anterior corpus 
callosum, anterior cingulum tracts and uncinate tracts, when compared with healthy controls 
(Zhang et al., 2009; Lu et al., 2014; Kassubek et al., 2018).  Similar studies show that people 
with AD have reduced fractional anisotropy in parietal, temporal and frontal regions including 
the corpus callosum, cingulum and uncinate tracts, compared to controls (Choi et al., 2005; 
Stricker et al., 2009; Zhang et al., 2009; O’Dwyer et al., 2011; Benitez et al., 2014; Brueggen 
et al., 2019).  In these tauopathies, the observed white matter degeneration likely reflects a 
combination of myelin breakdown and axon degeneration.   
 
Tauopathies are a group of diseases characterised by the aggregation of hyperphosphorylated 
tau in neurons and glial cells, including myelinating oligodendrocytes (reviewed by Ferrer, 
2018).  Tau aggregates in cells of the oligodendrocyte lineage are referred to as coiled bodies 
and threads, and have been identified in post-mortem tissue from people diagnosed with Pick’s 
55 
 
disease (Komori, 1999; Arai et al., 2001; Mimuro et al., 2010), progressive supranuclear palsy 
(Nishimura et al., 1995b; Arima et al., 1997; Komori, 1999; Arai et al., 2001; Jin et al., 2006), 
corticobasal degeneration (Wakabayashi et al., 1994; Feany and Dickson, 1995; Komori, 1999; 
Arai et al., 2001) frontotemporal lobar degeneration associated with variants in MAPT (Higuchi 
et al., 2005) and AD (Nishimura et al., 1995a).  In Frontotemporal dementia, myelin 
degenerates in the frontal white matter, and in AD white matter cholesterol and myelin proteins 
such as MBP, PLP and CNP (Roher et al., 2002) are progressively lost.  CNP expression is 
reduced in the frontal cortex in AD (Vlkolinský et al., 2001), and impaired myelin lipid 
synthesis occurs in the temporal grey matter, hippocampus and frontal grey matter in AD 
(Couttas et al., 2016).  Myelin degeneration is also detected post-mortem in the frontal and 
periventricular white matter regions of people with AD (Ihara et al., 2010; Zhan et al., 2014), 
and a recent proteomics study revealed that myelin sheath components are significantly 
reduced in the frontal cortex of people with sporadic AD (Zhang et al., 2018). 
 
Tauopathy-like oligodendrocyte pathology can be induced in mice by the injection of brain 
tissue homogenates from sporadic AD primary age-related tauopathy, aging-related tau 
astrogliopathy, globular glial tauopathy, progressive supranuclear palsy, Pick’s disease and 
frontotemporal lobar degeneration (linked to the MAPTP301L variant) into the corpus callosum.  
Phospho-tau deposits developed inside cells of the oligodendrocyte lineage and myelin 
disruption was evident within 6 months after injection (Ferrer et al., 2019).  However, a 
separate study found that tau-inclusions were rarely seen in mice inoculated with AD 
homogenates but were a common feature following inoculation with corticobasal degeneration 




Transgenic mice that express human tauopathy-associated variants in MAPT, primarily the 
MAPTP301L and MAPTP301S variants, also recapitulate many of the aspects of human tauopathy, 
including the development of gliosis, the formation of neurofibrillary tangles, neuron loss, and 
motor and cognitive impairment (Lewis et al., 2000; Lin et al., 2003b, 2003a; Ramsden et al., 
2005; Santacruz et al., 2005; Yoshiyama et al., 2007; Takeuchi et al., 2011; Ren et al., 2014).  
In the spinal cord of the Prnp-MAPTP301L transgenic mice, oligodendrocytes also undergo 
apoptosis (Zehr et al., 2004). Furthermore, when three human tauopathy MAPT variants are 
expressed under the control of the mouse α-tubulin promoter, in the absence of endogenous 
Mapt, coiled bodies form inside spinal cord oligodendrocytes, and oligodendrocyte number is 
reduced by 6 months of age - prior to neuron loss (Higuchi et al., 2002).  Consistent with these 
findings, the expression of MAPTP301L in CamKIIa+ neurons was associated with myelin 
thinning within perforant pathway axons that project from the entorhinal cortex to the 
hippocampus (Jackson et al., 2018), and when expression of this variant was restricted to 
oligodendrocytes (CNP promoter) myelin degeneration and axon loss from the spinal cord was 
detected prior to the development of tau aggregates in oligodendrocytes or oligodendrocyte 
loss (Higuchi et al., 2005).   
 
OPCs have the ability to proliferate and differentiate to produce new oligodendrocytes in 
response to oligodendrocyte loss and demyelination (Picard-Riera et al., 2002; Zawadzka et 
al., 2010; Assinck et al., 2017; Baxi et al., 2017), making it possible that oligodendrogenesis 
occurs alongside oligodendrocyte loss in tauopathy.  Following a focal, lysolecithin-induced 
demyelination of the spinal cord ventral funiculus in young adult Thy1.2-MAPTP301S mice, OPC 
density is maintained, but the density of oligodendrocytes and expression of MBP is elevated 
at the lesion site, compared with demyelinated WT mice (Ossola et al., 2016), suggesting that 
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in the presence of MAPTP301S, demyelination can be more effectively countered by 
oligodendrogenesis. 
 
In this study, we demonstrate that overexpression of the MAPTP301S variant, primarily in 
neurons, results in a large number of new oligodendrocytes accumulating in the hippocampus, 
entorhinal cortex and fimbria between 5 and 6 months of age.  This increase in oligodendrocyte 
addition occurred prior to axon loss or the development of overt cognitive deficits but did not 
increase the total number of oligodendrocytes detected in these regions, suggesting that new 
oligodendrocyte addition facilitates oligodendrocyte and myelin maintenance as early 
pathology develops in the CNS of MAPT transgenic mice.   
 
3.2. Results 
3.2.1. MAPT transgenic mice do not develop overt locomotor or memory impairment by 
P180 
Prior to examining the response of cells of the oligodendrocyte lineage to the earliest stages of 
tauopathy, we confirmed that human tau was expressed in brain tissue from MAPT mice 
(Figure 3.1).  Western blot analysis of the dorsal hippocampus indicated that human tau 
(Figure 3.1a, c) and phosphorylated human tau (phosphorylated at threonine 231; Figure 3.1b, 
d) was expressed by MAPT transgenic mice, but not their WT littermates, at P30, P60, P90 and 
P180.  By comparing the relative expression of human tau (upper band, Figure 3.2a) and 
endogenous mouse tau (lower band, Figure 3.2a), we determined that human tau expression 
was 2- to 5-fold more abundant than mouse tau in the hippocampus of MAPT mice (Figure 




Figure 3.1. MAPT mice do not develop overt locomotor or memory impairment by P180 
a-b) Western blots probing for tau (a; human ~55kDa; mouse ~51kDa) and phosphorylated tau (pTau) (b; human 
~55kDa, mouse ~51kDa) in hippocampal brain lysates from P30 wildtype (WT; open circles, black bars) and 
MAPT (black squares, open bars) mice. c) Human tau expression relative to β-actin in P30, P60, P90 and P180 
WT and MAPT mice [Two-way ANOVA, genotype: F (1, 16) = 110, p < 0.0001; age: F (3, 16) = 1.034, p = 
0.4040; interaction: F (3, 16) = 0.9767, p = 0.4282]. d) Human phosphorylated tau relative to β-actin in MAPT 
and WT mice at P30, P60, P90 and P180 [Two-way ANOVA, genotype: F (1, 16) = 148.4, p < 0.0001; age: F (3, 
16) = 2.078, p = 0.1434; interaction: F (3, 16) = 2.004, p = 0.1540]. e-f) Track visualisation (EthoVision XT) 
showing movement (white lines) of P180 WT (e) and MAPT (f) mice in the open field locomotor task. g) The total 
distance travelled by WT and MAPT mice in the open field task at P60, P90 and P180 [Two-way ANOVA, 
genotype: F (1, 94) = 3.536, p = 0.0631; age: F (2, 94) = 1.180, p = 0.3119; interaction: F (2, 94) = 0.767, p = 
0.4671]. h) Quantification of the average movement velocity of WT and MAPT mice during the open field task at 
P60, P90 and P180 [Two-way ANOVA, genotype: F (1, 94) = 3.466, p = 0.0658; age: F (2, 94) = 1.253, p = 
0.2904; interaction: F (2, 94) = 0.8427, p = 0.4338]. i) Schematic of the T-maze. j) Quantification of the 
proportion incorrect arm choices (errors) made by P60, P90 and P180 WT and MAPT mice during the T-maze 
alternation task [Two-way ANOVA, genotype: F (1, 96) = 4.317, p = 0.0404; age: F (2, 96) = 0.7271, p = 0.4859; 
interaction: F (2, 96) = 3.028, p = 0.0531]. k-l) Heatmaps (EthoVision XT) showing the relative proportion of 
time P180 WT (k) and MAPT (l) mice spent exploring the familiar and novel objects in the novel object recognition 
task. Warmer colours represent a greater proportion of time in that area. m) Quantification of the proportion of 
time P60, P90, and P180 WT or MAPT mice spent exploring the novel object relative to the total time spent 
exploring either object [Two-way ANOVA, genotype: F (1, 98) = 2.823, p = 0.0961; age: F (2, 98) = 2.506, p = 
0.0868; interaction: F (2, 98) = 0.006544, p = 0.9935]. n-o) Track visualisation images (EthoVision XT) showing 
movement (white lines) of P180 WT (n) and MAPT (o) mice during the Barnes maze long-term memory probe 
trial, carried out 2 weeks after mice learned the expected location of an escape box (red arrows). Yellow shading 
indicates the quadrant defined as the target zone. p) The proportion of time P60, P90, and P180 WT or MAPT 
mice spent within the target zone during the long-term memory probe trial [Two-way ANOVA, genotype: F (1, 
98) = 3.708, p = 0.0570; age: F (2, 98) = 0.5633, p = 0.5711; interaction: F (2, 98) = 2.623, p = 0.0777]. Western 
blot data are presented as mean ± SD, n = 3 mice per group.  Behaviour data are presented as mean ± SEM, n= 
9-24 mice per group. Asterisks denote significant differences identified by Bonferroni post hoc analysis, **p < 














Figure 3.2. Human tau protein expression is 2- to 5-fold higher than endogenous mouse tau in MAPT mice 
a) Representative images of western blots probing for human (~55kDa) and mouse (~51kDa) tau in hippocampal 
brain lysates from P60, P90 and P180 WT and MAPT mice (one western blot per time point). b) Representative 
images of western blots probing for human (~55kDa) and mouse (~51kDa) tau phosphorylated on Threonine 231 
site in hippocampal brain lysates from P60, P90 and P180 WT and MAPT mice (one western blot per time point). 
c) Fold change between human tau and mouse tau in MAPT mice at P30, P60, P90 and P180. d) Fold change 
between human phosphorylated tau and mouse phosphorylated tau in MAPT mice at P30, P60, P90 and P180. 
Results are presented as mean ± SD, n = 3 mice per genotype. e) 86% of MAPT mice (n = 39) survived to P200 


































10-fold more abundant than phosphorylated mouse tau (lower band, Figure 3.2b) in the 
hippocampus of MAPT mice (Figure 3.2d).  This transgenic overexpression of human MAPT 
was associated with the impaired survival of MAPT transgenic mice, relative to their WT 
littermates (Figure 3.2e), and reactive microgliosis by P180, that was primarily observed in 
the hippocampus and entorhinal cortex (Figure 3.3).  To determine whether the overexpression 
of human tau impacted gross locomotor or cognitive performance over this time period, MAPT 
and WT mice were subjected to a battery of behavioural tasks.  WT (Figure 3.1e) and MAPT 
(Figure 3.1f) mice were placed in an open field arena, and the distance that each mouse 
travelled (Figure 3.1g), and the velocity of that movement (Figure 3.1h), was mapped over a 
10 min period.  The overexpression of human tau did not alter the distance travelled (Figure 
3.1g) or the velocity of movement (Figure 3.1h) at P60, P90 or P180.  MAPT  and WT mice 
also spent a similar proportion of time in the central area of the open field [P60: WT 31.9 ± 2.0 
%, MAPT 38.2 ± 3.8 %; P90: WT 32.2 ± 2.0 %, MAPT 32.3 ± 3.5 %; P180: WT 35.8 ±1.9 %, 
MAPT 35.1 ± 3.3 %, mean ± SEM; Two-way ANOVA, genotype: F (1, 94) = 0.6999, p = 
0.4049; age: F (2, 94) = 0.8799, p = 0.4182; interaction: F (2, 94) = 0.9449, p = 0.3924].    
 
Working-memory was evaluated by assessing spontaneous alternation in the T-maze (Figure 
3.1i).  We found that the performance of WT and MAPT mice was equivalent for this task, with 
mice of each genotype making an equivalent number of errors at P60, P90 and P180 (Figure 
3.1j).  Short-term recognition memory was evaluated for WT (Figure 3.1k) and MAPT (Figure 
3.1l) mice using the novel object recognition task. Both WT and MAPT mice spent a larger 
proportion of their time exploring the novel object, compared to the familiar object, and we 
found that the overexpression of human tau did not affect the ability of mice to discriminate 





Figure 3.3. Reactive microglia are visible in MAPT mice at P180 
a-f) Representative confocal images of Iba1 (red) and Hoechst 33342 (blue) in the hippocampus (a-b), entorhinal 





as the short- and long-term memory performance of WT (Figure 3.1n) and MAPT (Figure 
3.1o) mice was assessed using a Barnes maze spatial learning task (Figure 3.4a).  We found 
that at P60, P90 and P180, WT and MAPT mice made fewer visits to incorrect holes (primary 
errors) on day 2 of training, compared with day 1, suggesting that mice of both genotypes 
learned the location of the escape box (Figure 3.4b-d).  One day after training, during the 
short-term memory probe phase, P180 WT and MAPT mice spent an equivalent amount of time 
in the target quadrant of the maze, and both groups spent more time in the target quadrant 
compared with all other quadrants (Figure 3.4e).  During the long-term memory probe phase, 
two weeks after initial training, WT mice spent more time in the target quadrant, relative to 
other maze quadrants, while MAPT mice spent an equivalent amount of time in all 4 quadrants 
(Figure 3.4f).  While these data may suggest that MAPT mice are beginning to experience 
long-term memory impairment, this was not a robust phenotype, as the time that MAPT mice 
spent in the target quadrant was equivalent to that of WT mice (Figure 3.1p).  Overall, these 
data indicate that human tau overexpression does not induce overt cognitive impairment in 
mice by P180.   
 
3.2.2. The number of new YFP+ cells produced by OPCs is elevated in P180 MAPT mice 
To determine whether the overexpression of human hyperphosphorylated tau in neurons could 
indirectly influence adult oligodendrogenesis, prior to the onset of a behavioural change, we 
performed cre-lox lineage tracing of PDGFRα+ OPCs in the hippocampus, entorhinal cortex 
and fimbria of control and MAPT mice.  The hippocampus and entorhinal cortex were selected, 
as they are among the first regions affected in human tauopathy associated with AD (Xu et al., 









Figure 3.4. Learning and memory performance in the Barnes maze 
a) Schematic diagram of the Barnes maze depicting the location of the escape box (red) relative to the spatial 
cues surrounding the maze and quadrant divisions. b) Quantification of the average number primary errors 
committed by P60 WT (open circles, black bars) and MAPT (black squares, open bars) mice during the first and 
second day of learning [Two-way ANOVA, genotype: F (1, 60) = 0.24, p = 0.6233; learning day: F (1, 60) = 
12.46, p = 0.0008; interaction: F (1, 60) = 0.39, p = 0.5307]. c) Quantification of the average number primary 
errors committed by P90 WT and MAPT mice during the first and second day of learning [Two-way ANOVA, 
genotype: F (1, 68) = 6.30, p = 0.0144; learning day: F (1, 68) = 13.37, p = 0.0005; interaction: F (1, 68) = 
0.25, p = 0.6166]. d) Quantification of the average number primary errors committed by P180 WT and MAPT 
mice during the first and second day of learning [Two-way ANOVA, genotype: F (1, 70) = 2.569, p = 0.1135; 
learning day: F (1, 70) = 13.91, p = 0.0004; interaction: F (1, 70) = 0.5959, p = 0.4428]. e) Quantification of 
the time spent by P180 WT and MAPT mice in each quadrant of the maze during the short-term memory probe 
phase [Two-way ANOVA, genotype: F (1, 140) = 6.558e-006, p = 0.9980; maze quadrant: F (3, 140) = 35.37, p 
< 0.0001; interaction: F (3, 140) = 1.959, p = 0.1230]. f) Quantification of the time spent by P180 WT and MAPT 
mice in each quadrant of the maze during the long-term memory probe phase [Two-way ANOVA, genotype: F (1, 
140) = 0.033, p = 0.8550; maze quadrant: F (3, 140) = 14.14, p < 0.0001; interaction: F (3, 140) = 6.737, p = 


















tract that connects the hippocampi of both hemispheres, and each hippocampus with other 
subcortical structures of the brain (Fimbria-fornix-commissural pathway; Wyss et al., 1980; 
reviewed by Kesner & Rolls, 2015).  Tamoxifen was administered to P60 control (Pdgfra-
CreERT2::Rosa26-YFP) and MAPT (Pdgfra-CreERT2::Rosa26-YFP::Prnp-MAPTP301S) mice, 
and brain tissue was collected at P60+7, 90 or 120 days (Figure 3.5).  Immunohistochemistry 
was performed on coronal cryosections, to allow detection of PDGFRα+ OPCs (red) and YFP 
(green) tracer in the hippocampus (Figure 3.5a-d), entorhinal cortex (Figure 3.5e-h) and 
fimbria (Figure 3.5i-l).  By quantifying the proportion of OPCs that expressed YFP, we 
determined that ~40% of OPCs had undergone recombination in all brain regions examined in 
control and MAPT mice (Figure 3.5m-o).  Furthermore, these YFP-labelled OPCs gave rise to 
YFP+ PDGFRα-negative presumptive oligodendrocytes over time (arrows, Figure 3.5a-l).  
However, between P60+90 and P60+120, the proportion of YFP+ cells that were PDGFRα-
negative significantly increased in the hippocampus (Figure 3.5p), entorhinal cortex (Figure 
3.5q) and fimbria (Figure 3.5r) of MAPT mice, despite being largely unchanged in controls.  
This equated to a doubling in the density of new YFP+ oligodendrocytes present in each region 
over a 1-month period, such that by P60+120 MAPT mice had significantly more new 
oligodendrocytes in the hippocampus (Figure 3.5s), entorhinal cortex (Figure 3.5t) and 
fimbria (Figure 3.5u), than control mice. 
 
3.2.3. Fimbria OPC proliferation is increased in P180 MAPT mice 
To determine whether human hyperphosphorylated tau influenced new oligodendrocyte 
number by modulating OPC proliferation, we next evaluated PDGFRα+ OPC density in the 
hippocampus (Figure 3.6a-c), entorhinal cortex (Figure 3.6d) and fimbria (Figure 3.6e) of 
control and MAPT mice, at P60+7, P60+90 and P60+120.  OPC density was equivalent in  
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Figure 3.5. New oligodendrocyte addition is increased in the hippocampus, entorhinal cortex and fimbria of 
MAPT mice at P180 
a-l) Representative confocal images showing PDGFRa (red), YFP (green), and Hoechst (blue) in the 
hippocampus (a-d), entorhinal cortex (e-h) and fimbria (i-l) of PDGFRα-CreERT2 :: Rosa26-YFP (control; a-b, 
e-f, i-j) and PDGFRα-CreERT2 :: Rosa26-YFP :: Prnp-MAPTP301S (MAPT; c-d, g-h, k-l) mice at 90 (P60+90) 
and 120 (P60+120) days post tamoxifen administration (P60).  m-o) Quantification of the proportion of 
recombined OPCs (YFP + PDGFRa +  / PDGFRa +) in the hippocampus [(m) : Two-way ANOVA, genotype: F 
(1, 23) = 1.272, p = 0.2710; age: F (2, 23) = 0.8038, p = 0.4598; interaction: F (2, 23) = 0.04821, p = 0.9530], 
the entorhinal cortex [(n) : Two-way ANOVA, genotype: F (1, 25) = 3.13, p = 0.0891; age: F (2, 25) = 0.982, p 
= 0.3885; interaction: F (2, 25) = 0.169, p = 0.8455] and the fimbria [(o) : Two-way ANOVA, genotype: F (1, 
23) = 3.469, p = 0.0753; age: F (2, 23) = 0.3587, p = 0.7024; interaction: F (2, 23) = 0.02172, p = 0.9785] of 
control (open circles, black bars) and MAPT (black squares, open bars) mice at 7, 90 and 120 days post tamoxifen 
administration (P60).  p-r) Quantification of the proportion of recombined OPCs that differentiated into new 
oligodendrocytes (PDGFRa negative YFP+ / YFP+) over 7, 90 and 120 days in the hippocampus [(p) : Two-way 
ANOVA, genotype: F (1, 23) = 18.33, p = 0.0003; age: F (2, 23) = 20.33, p < 0.0001; interaction: F (2, 23) = 
11.70, p = 0.0003], the entorhinal cortex [(q) : Two-way ANOVA, genotype: F (1, 25) = 9.489, p = 0.0050; age: 
F (2, 25) = 34.13, p < 0.0001; interaction: F (2, 25) = 15.42, p < 0.0001] and the fimbria [(r) : Two-way ANOVA, 
genotype: F (1, 23) = 10.18, p = 0.0041; age: F (2, 23) = 58.20, p < 0.0001; interaction: F (2, 23) = 10.49, p = 
0.0006] of control and MAPT mice.  s-u) Quantification of the density of new oligodendrocytes (PDGFRa-
negative YFP+ / mm2) added to the hippocampus [(s) : Two-way ANOVA, genotype: F (1, 23) = 23.09, p < 
0.0001; age: F (2, 23) = 20.88, p < 0.0001; interaction: F (2, 23) = 15.26, p < 0.0001], the entorhinal cortex [(t) 
: Two-way ANOVA, genotype: F (1, 25) = 14.94, p = 0.0007; age: F (2, 25) = 18.28, p < 0.0001; interaction: F 
(2, 25) = 14.37, p < 0.0001] and the fimbria [(u) : Two-way ANOVA, genotype: F (1, 23) = 26.15, p < 0.0001; 
age: F (2, 23) = 35.02, p < 0.0001; interaction: F (2, 23) = 21.65, p < 0.0001].  Data are presented as mean ± 
SD, n=4-6 mice per group. Asterisks indicate significant differences identified by Bonferroni post hoc analysis, 
****p < 0.0001. Scale bars represent 30 µm. Arrows indicate YFP+ PDGFRa+ recombined OPCs. Arrow heads 











Figure 3.6. OPC proliferation is increased in the fimbria of MAPT mice at P180  
a-b) Representative confocal image stacks showing PDGFRa labelling in the hippocampus of PDGFRα-CreERT2 
:: Rosa26-YFP (control; a) and PDGFRα-CreERT2 :: Rosa26-YFP :: Prnp-MAPTP301S (MAPT; b) mice at 120 
days post tamoxifen administration (P60). c-e) Quantification of OPC density (PDGFRa+ / mm2) in the 
hippocampus [(c): Two-way ANOVA, genotype: F (1, 23) = 1.938, p = 0.1772; age: F (2, 23) = 0.3121, p = 
0.7349; interaction: F (2, 23) = 2.015, p = 0.1562], the entorhinal cortex [(d): Two-way ANOVA, genotype: F 
(1, 25) = 1.188, p = 0.2861; age: F (2, 25) = 1.162, p = 0.3292; interaction: F (2, 25) = 3.189, p = 0.0584] and 
the fimbria [(e): Two-way ANOVA, genotype: F (1, 23) = 0.5396, p = 0.4700; age: F (2, 23) = 12.37, p = 0.0002; 
interaction: F (2, 23) = 0.2118, p = 0.8107] of control (open circles, black bars) and MAPT (black squares, open 
bars) mice. f-k) Representative confocal image stacks showing PDGFRa (red), EdU (green) and Hoechst 33342 
(blue) labelling in the hippocampus (f-g), entorhinal cortex (h-i) and fimbria (j-k) of P180 wildtype (WT; open 
circles, black bars) and MAPT (black squares, open bars) mice following 5 days of EdU administration. l) 
Quantification of the proportion of EdU+ OPCs  (EdU+ PDGFRa+ / PDGFRa+) in the hippocampus, entorhinal 
cortex and fimbria of WT and MAPT mice [(l): Two-way ANOVA, genotype: F (1, 20) = 11.98, p = 0.0025; brain 
region: F (2, 20) = 121.7, p < 0.0001; interaction: F (2, 20) = 5.997, p = 0.0091].   m-n) Representative confocal 
images showing cells expressing PDGFRa (red) and Ki67 (green) in the fimbria of P180 WT (m) and MAPT (n) 
mice. (o) Quantification of the proportion of Ki67+ OPCs (Ki67+ PDGFRa+ / PDGFRa+) at P180 within the 
fimbria (Two tailed, unpaired t-test, p = 0.798). Data are presented as mean ± SD for n=3-6 mice per group. 
Arrows indicate PDGFRa+ OPCs. Arrow heads indicate recently divided OPCs (EdU+ PDGFRa+).  Scale bars 












control and MAPT mice and did not change with age in any region (Figure 3.6c-e).  To 
determine whether OPC proliferation was affected by hyperphosphorylated tau, P175 WT and 
MAPT mice were given the thymidine-analogue EdU via their drinking water for 5 consecutive 
days, and coronal cryosections processed to detect PDGFRα (red) and EdU (green) (Figure 
3.6f-k).  The proportion of OPCs that proliferated to incorporate EdU (EdU+ PDGFRa+ / 
PDGFRα+ x 100) was equivalent in the hippocampus (Figure 3.6f, g, l) and entorhinal cortex 
(Figure 3.6h, i, l) of WT and MAPT mice.  By contrast, we detected a small but significant 
increase in OPC proliferation in the fimbria of MAPT mice, compared with WT mice (Figure 
3.6j-l), but this was not a large enough change in proliferation to overtly alter the proportion 
of OPCs that expressed the proliferative marker Ki67 at P180 (Figure 3.6m-n).  Consequently, 
this small increase in fimbria OPC proliferation appears unable to explain the large increase in 
new oligodendrocyte number noted across the hippocampus, entorhinal cortex and fimbria of 
MAPT mice at P60+120 (Figure 3.5).  
 
3.2.4. Oligodendrocyte density is normal in MAPT mice 
To determine whether the increase in new oligodendrocyte addition was accompanied by an 
overall increase in oligodendrocyte number in the hippocampus (Figure 3.7a-d), entorhinal 
cortex (Figure 3.7e-h) or fimbria (Figure 3.7i-l), we performed immunohistochemistry on 
coronal brain cryosections from P120 and P180 WT and MAPT mice, to detect the 
oligodendrocyte marker ASPA.  We found that the density of ASPA+ oligodendrocytes was 
unchanged between P120 and P180 in the hippocampus (Figure 3.7m), entorhinal cortex 
(Figure 3.7n) and fimbria (Figure 3.7o) of WT or MAPT mice, and that the overexpression of  
hyperphosphorylated tau did not influence total oligodendrocyte density in any region.  








Figure 3.7. Oligodendrocyte population is not altered in MAPT mice at P120 and P180  
a-l) Representative confocal images of ASPA (red) and Hoechst 33342 (blue) in the hippocampus (a-d), entorhinal 
cortex (EC; e-h) and fimbria (i-l) of WT and MAPT mice at P120 and P180. m-o) Quantification of total 
oligodendrocyte density  (ASPA+ / mm2) in the hippocampus [(m): Two-way ANOVA, genotype: F (1, 17) = 
0.417, p = 0.526; age: F (1, 17) = 0.849, p = 0.369; interaction: (1, 17) = 1.100, p = 0.308], the entorhinal cortex 
[(n): Two-way ANOVA, genotype: F (1, 18) = 0.004, p = 0.948; age: F (1, 18) = 0.0254, p = 0.875; interaction: 
F (1, 18) = 0.397, p = 0.536] and the fimbria [(o): Two-way ANOVA, genotype: F (1, 14) = 0.594, p = 0.453; 
age: F (1, 14) = 1.145, p = 0.302; interaction: F (1, 14) = 0.080, p = 0.781] of WT (open circles, black bars) and 
MAPT (black squares, open bars) mice at P120 and P180.  Data are presented as mean ± SD, n=3-5 mice per 



























hippocampus of P180 MAPT mice, and 95 ± 15 (mean ± SD) cells/mm2 are newborn 
oligodendrocytes, these data suggest that ~33% of oligodendrocytes present in the P180 MAPT 
hippocampus are newborn oligodendrocytes.  In the entorhinal cortex and fimbria, it equates 
to ~51 and 21%, respectively.  As the new oligodendrocytes comprise such a large proportion 
of all oligodendrocytes in the hippocampus, entorhinal cortex and fimbria of the P180 MAPT 
mice, but do not increase total oligodendrocyte density beyond that seen in WT mice, it is likely 
that oligodendrocyte addition is accompanied by oligodendrocyte loss in the MAPT mouse 
brain. 
To determine whether new oligodendrocytes added to the brains of P60+120 controls and 
MAPT mice are mature oligodendrocytes, we immunolabelled coronal cryosections, containing 
the hippocampus and fimbria, to detect PDGFRa+ (blue), YFP+ (green) and ASPA (red) 
(Figure 3.8a-h).  We found that the density of YFP+ ASPA+ mature oligodendrocytes was 
increased in the hippocampus (Figure 3.8.i) and fimbria (Figure 3.8.j) of MAPT mice relative 
to controls, while the density of YFP+ PDGFRa-negative ASPA-negative presumptive 
premyelinating oligodendrocytes was equivalent between MAPT mice and controls.  Therefore, 
new oligodendrocytes may be added to replace myelin. 
 
3.2.5. Myelination is not altered in MAPT mice 
To further explore the possibility of oligodendrocyte turnover, we next quantified myelination 
in the stratum lacunosum moleculare of the CA1 region of the hippocampus in P180 WT and 
MAPT mice by TEM (Figure 3.9).  We found that total axon density (Figure 3.9a-c) and 
myelinated axon density (Figure 3.9d) were equivalent between WT and MAPT mice.  
Looking more closely at the myelinated axons, we found that the g-ratio [axon diameter / 







Figure 3.8. MAPT mice add more ASPA+ mature oligodendrocytes to the hippocampus and fimbria than 
control mice between 5 and 6 months of age.  
a-h) Confocal images showing ASPA (red), PDGFRα (blue) and YFP (green) in the hippocampus of P60 + 120 
Pdgfrα-CreERT2:: Rosa26-YFP (control; a-d) and Pdgfrα-CreERT2:: Rosa26-YFP:: Prnp-MAPTP301S (MAPT; 
e-h) mice. i) Quantification of the density of all YFP+ cells that are PDGFRα-negative in the hippocampus of P60 
+ 120 control and MAPT mice, including those that are YFP+ PDGFRα-negative ASPA-negative premyelinating 
oligodendrocytes versus YFP+ PDGFRα-negative ASPA+ mature oligodendrocytes. [two-way ANOVA, genotype: 
F (1, 12) = 120.5, p < .0001; cell type: F (2, 12) = 79.72, p < .0001; interaction: F (2, 12) = 25.19, p < .0001]. 
j) Quantification of the density of all YFP+ cells that are PDGFRα-negative in the fimbria of P60 + 120 control 
and MAPT mice, including those that are YFP+ PDGFRα-negative ASPA-negative premyelinating 
oligodendrocytes versus YFP+ PDGFRα-negative ASPA+ mature oligodendrocytes. [two-way ANOVA, genotype: 
F (1, 12) = 40.81, p < .0001; cell type: F (2, 12) = 15.27, p = .0005; interaction: F (2, 12) = 5.46, p = .02]. 
Asterisks indicate significant differences identified by Bonferroni post hoc analysis, **p < .01, ***p < .001, ****p 






















Figure 3.9. Axon density, proportion of myelinated axons and myelin thickness are not altered in the 
hippocampus of MAPT mice at P180 
 a-b) Representative electron micrographs from the CA1 region of the hippocampus of WT (a) and MAPT (b) mice 
at P180. c) Quantification of axon density (axons/mm2) in WT (open circles) and MAPT (black squares) mice 
(Two-tailed, unpaired t-test: t=0.2567, df=5, p =0.8076).  d) Quantification of the proportion of myelinated axons 
in the CA1 of WT and MAPT mice at P180 (Two-tailed, unpaired t-test: t=0.1780, df=5, p = 0.8657). e) Graphical 
representation of the g-ratio distribution based on axon diameter (Kolmogorov-Smirnoff test, K-S D = 0.06307, 
p = 0.2825; n = 98-190 myelinated axons per mouse). f-i) Representative high magnification electron 
micrographs through a single myelinated axon within the CA1 region of the number of myelin wraps in WT (f-g) 
and MAPT mice (h-i) at P180. j) Quantification of average g-ratio per animal in WT and MAPT mice at P180 
(Two-tailed, unpaired t-test: t=0.5232, df=5, p = 0.6232). k) Quantification of average myelin wraps per animal 
in WT and MAPT mice at P180 (Two-tailed, unpaired t-test: t=1.112, df=5, p = 0.3167). Scale bars represent: 





























for axons in the hippocampus of WT and MAPT mice (Figure 3.9e-i) and that across individual 
mice, the average g-ratio (Figure 3.9j) and average number of myelin wraps per sheath (Figure 
3.9k) was also unaffected by genotype.  These data suggest that myelination is normal in the 
hippocampus of P180 MAPT mice, or that newborn oligodendrocytes act to maintain a normal 
level of myelination. 
 
3.3. Discussion 
Myelin and axon loss are associated with cognitive decline and is exacerbated in people 
diagnosed with tauopathy.  However, the behaviour of OPCs early in the disease process, and 
the potential for myelin repair remains unclear.  Herein, by tracing the fate of OPCs in MAPT  
transgenic mice we show that the number of adult-born oligodendrocytes increases in the 
hippocampus, entorhinal cortex and fimbria between 5 and 6 months of age, prior to the onset 
of overt cognitive symptoms.  This increase in new oligodendrocyte addition cannot be 
explained by an equivalent increase in OPC proliferation and was not associated with a change 
in total oligodendrocyte density, or myelination within the hippocampus.  
 
3.3.1. MAPT mice do not develop overt motor or cognitive deficits by 6 months of age.  
MAPT transgenic mice overexpress the T34 isoform of human MAPT (1N4R) with the P301S 
mutation under the regulation of the mouse prion promotor, leading to human tau being 
expressed in the brain at levels that are 5-times above that of the endogenous mouse protein 
(Yoshiyama et al., 2007).  To determine whether the relative expression of human tau within 
the hippocampus changed with age, we performed Western blot analysis of hippocampal 
lysates from P30, P60, P90 and P180 mice.  We found that human tau and hyperphosphorylated 
human tau were not detected in WT mice, but were abundantly expressed in MAPT mice, and 
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the level of expression remained stable over time (Figure 3.1).  MAPT mice, maintained on a 
B6C3H background, exhibit prominent microglial activation, prior to the formation of 
neurofibrillary tangles at 6 months of age (Yoshiyama et al., 2007).  We observed microglial 
activation at 6 months of age (Figure 3.3), and neurofibrillary tangles are reported to develop 
at 10 months of age when MAPT mice are backcrossed onto a C57BL/6 background (Dumont 
et al., 2011).  The more severe phenotype of MAPT mice on a B6C3H background is further 
supported by poorer survival outcomes with ~25% dying by 6 months of age (Yoshiyama et 
al., 2007) compared with only ~15% of mice dying within the first 6 months when they are 
crossed onto a C57BL/6 background (Merchán-Rubira et al., 2019; Figure 3.2).   
 
Tauopathies are associated with progressive motor degeneration and cognitive impairment 
(Lewis et al., 2000; Ramsden et al., 2005; Santacruz et al., 2005; Yoshiyama et al., 2007; 
Takeuchi et al., 2011; reviewed by Ferrer, 2018).  To determine whether MAPT mice had 
impaired locomotor or cognitive performance, they were subjected to a battery of behavioural 
tests at 2, 3 and 6 months of age.  We found that locomotion in an open field task was not 
affected by overexpression of MAPTP301S up to 6 months of age (Figure 3.1), suggesting there 
was no overt impairment in motor function.  There was also no effect of MAPTP301S 
overexpression on working memory performance in the T-maze, short term recognition 
memory in the novel object recognition task, or spatial learning and memory in the Barnes 
maze at any age (Figure 3.1), suggesting that these mice do not exhibit a decline in cognitive 
performance until after 6 months of age.  Overexpression of the P301L mutation of human 
MAPT under the mouse prion promotor results in a rapid decline in motor function from as 
early as 4.5 months of age in homozygous and 6.5 months in heterozygous mice (Lewis et al., 
2000).  However, motor decline is not observed in mice overexpressing the P301S mutation 
under the same promotor (Dumont et al., 2011; Takeuchi et al., 2011; Chalermpalanupap et 
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al., 2017; Figure 3.1).  Instead, transient increases in locomotor behaviour in an open field 
arena have been reported that are either only seen between 30 and 90 min of a 2-hour 
observation time (Takeuchi et al., 2011), or present at 7 months of age but not at 10 months 
(Dumont et al., 2011).  For MAPT mice raised on the B6CH3 background, spatial memory and 
contextual fear conditioning have been reported at 6 (Takeuchi et al., 2011) and 7.5 (Lasagna-
Reeves et al., 2016) months of age.  However, consistent with our data, when MAPT mice are 
backcrossed onto a C57BL/6 background the onset of memory impairment is delayed until 
after 10 months of age (Dumont et al., 2011; Chalermpalanupap et al., 2017), such that 
performance in a Barnes maze is equivalent to WT mice at 6 months of age (Takeuchi et al., 
2011).  These data indicated that cellular changes identified in MAPT mice ≤ 6 months of age 
occur prior to the onset of cognitive decline. 
 
3.3.2. The number of new oligodendrocytes added to the brain of MAPT mice increases 
between 5 and 6 months of age 
OPCs continue to generate new oligodendrocytes at different rates in the adult mouse brain 
grey and white matter (Dimou et al., 2008; Rivers et al., 2008; Hill et al., 2013; Young et al., 
2013; Fukushima et al., 2015).  While the rate of OPC proliferation and oligodendrocyte 
addition slows with aging in the mouse CNS (reviewed by Wang & Young, 2014), 
experimental interventions that produce demyelination have been shown to stimulate OPC 
proliferation and result in the rapid replacement of oligodendrocytes and remyelination 
(Tripathi et al., 2010; Zawadzka et al., 2010; Assinck et al., 2017; Baxi et al., 2017).  To 
determine whether the expression of the human MAPTP301S variant in neurons was associated 
with a change in OPC behaviour and new oligodendrocyte addition, we fluorescently labelled 
OPCs and followed their fate over time (Figure 3.5).  We found that a small number of 
newborn YFP-labelled oligodendrocytes accumulated in the hippocampus, entorhinal cortex 
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and fimbria of control and MAPT transgenic mice between P60 and P150, and that the rate of 
oligodendrocyte addition was not affected by MAPTP301S expression.  However, between P150 
and P180, when oligodendrocyte addition was negligible in control mice, the number of YFP-
labelled oligodendrocytes increased significantly in MAPT transgenic mice, in each of the brain 
regions examined.  Previous studies have not examined oligodendrogenesis in MAPT 
transgenic mice; however, there is some evidence that oligodendrogenesis is increased in P60 
adult Thy1.2-MAPTP301S transgenic mice following toxin-induced focal demyelination of the 
ventral funiculus in the spinal cord (Ossola et al., 2016).  14 days after demyelination, the 
density of APC+ OLIG2+ oligodendrocytes was increased in the lesion site of Thy1.2-
MAPTP301S transgenic mice compared to WT lesioned mice (Ossola et al., 2016), confirming 
the capacity for OPCs to efficiently remyelinate the injured CNS in the early stages of tau 
pathology.     
A large increase in oligodendrocyte generation is often accompanied by an increase in OPC 
proliferation, as OPC differentiation stimulates the proliferation of adjacent OPCs to sustain 
the OPC population (Hughes et al., 2013).  To determine whether expression of the human 
MAPTP301S variant, and the associated increase in new oligodendrocyte number, was associated 
with elevated OPC proliferation, dividing OPCs were EdU labelled in the brain of 6-month old 
control and MAPT transgenic mice (Figure 3.6).  While OPC proliferation was elevated in the 
fimbria of MAPT transgenic mice, when compared with WT littermates, it was not elevated in 
the hippocampus or entorhinal cortex.  These data could be explained by an increase in 
oligodendrogenesis occurring close to P150, such that OPC proliferation has returned to normal 
by P180.  We have previously shown that new oligodendrocyte number can be increased 
without increasing OPC proliferation, as this can be achieved by enhancing the survival of the 
newborn cells (Cullen et al., 2019).  It is therefore possible that oligodendrocyte loss or other 
stimuli could increase the number of new oligodendrocytes detected by enhancing newborn 
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oligodendrocyte survival in the MAPT transgenic mice.  Indeed, a combination of increased 
cell generation and improved survival would likely be needed to account for the substantial 
increase in new oligodendrocyte number observed over a one month-period in the MAPT 
transgenic mice.   
 
3.3.3. Is oligodendrocyte turnover increased in MAPT mice?    
To determine whether the large number of new oligodendrocytes added to the hippocampus, 
entorhinal cortex and fimbria of MAPT transgenic mice increased the total number of 
oligodendrocytes, or acted to replace oligodendrocytes lost to pathology, we quantified 
oligodendrocyte density in each region (Figure 3.7) and determined whether newborn 
oligodendrocytes added to the brains were mature oligodendrocytes (Figure 3.8).  
Oligodendrocyte density was significantly higher in the fimbria than in the hippocampus or 
entorhinal cortex but was equivalent between WT and MAPT transgenic mice in each region 
(Figure 3.7).  However, a larger proportion of new oligodendrocytes were added and matured 
between 5 and 6 months of age in MAPT mice compared to controls (Figure 3.8), suggesting 
that oligodendrocyte turnover had occurred.  To confirm that this phenotype was not associated 
with neuron loss, we quantified axon density and the proportion of axons that are myelinated 
(Figure 3.9) in the hippocampus at 6 months of age.  Axon density in the CA1 subfield of the 
hippocampus was normal in 6-month-old MAPT transgenic mice, and the proportion of axons 
that were myelinated, and their myelin thickness was also equivalent to that of WT mice.  As 
the newborn oligodendrocytes comprise a large proportion of all oligodendrocytes detected in 
the grey matter regions of MAPT transgenic mice, it would not be possible for their addition to 
result in no change in total oligodendrocyte addition or the proportion of axons that are 
myelinated without an increase in oligodendrocyte death and myelin loss.  Therefore, we 
suggest that oligodendrocyte addition between P150 and P180 is driven by the need for 
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oligodendrocyte replacement in the MAPT transgenic mice and propose that these 
oligodendrocytes act to maintain myelin at this early stage of tauopathy.   
Hyperphosphorylated tau can directly affect oligodendrocytes as they express tau proteins 
(Müller et al., 1997; Seiberlich et al., 2015), and can develop tau inclusions (Ikeda et al., 1998; 
Arai et al., 2001), which leads to oligodendrocyte degeneration in transgenic mice 
overexpressing human MAPTP301L variant throughout the CNS under the mouse a-tubulin 
promoter (Higuchi et al., 2002).  However, the human MAPTP301S variant is primarily expressed 
in neurons by the prion protein promoter (Bailly et al., 2004; Tremblay et al., 2007) in our 
study; therefore, the oligodendrocyte phenotype observed is likely to be a secondary outcome 
of neuronal tauopathy. 
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Chapter 4: Amyloidosis is associated with the formation of thicker 
myelin in development and increased adult oligodendrogenesis 
 
4.1. Introduction 
In the aging human brain, white matter degeneration occurs in regions critical for cognitive 
and emotional processing, including the hippocampus, neocortex and frontal white matter 
tracts, and the extent of white matter degeneration correlates with the degree of cognitive 
impairment and loss of information processing speed (Charlton et al., 2006; Hirsiger et al., 
2017; Chopra et al., 2018; Fan et al., 2019).  However, the degree of white matter degeneration 
is exacerbated in AD (Choi et al., 2005; Stricker et al., 2009; Zhang et al., 2009; O’Dwyer et 
al., 2011; Benitez et al., 2014; Brueggen et al., 2019).  AD is a progressive neurodegenerative 
disease characterized post-mortem by the presence of extracellular plaques of aggregated 
amyloid β (Miller et al., 1993; Roher et al., 1993; Burgold et al., 2011; reviewed by Selkoe and 
Hardy, 2016), and the detection of neurofibrillary tangles, form by the intracellular aggregation 
of cytoskeletal proteins, mainly hyperphosphorylated tau (Goedert et al., 1989; Schmidt et al., 
1990; Braak and Braak, 1996; Iseki et al., 2006).  Oligodendrocyte loss and demyelination has 
also been detected in post-mortem AD brain at the site of pathological inclusions throughout 
the brain (Mitew et al., 2010; Behrendt et al., 2013; Tse et al., 2018).  As diffusion tensor 
imaging studies, examining individuals in the preclinical stages of disease, have determined 
that the extent to which fractional anisotropy increases and mean diffusivity decreases for white 
matter regions including the fornix, cingulum and corpus callosum, correlates with amyloid 
β42 load (Gold et al., 2014; Racine et al., 2014; Shi et al., 2015), early white matter 
degeneration may be associated with amyloidosis.  This idea is further supported by the fact 
that in preclinical individuals carrying gene mutations associated with increased risk of AD, 
87 
 
lower cerebral spinal fluid concentration of amyloid β42 correlated with a greater severity of 
white matter hyperintensities identified by magnetic resonance imaging (Scott et al., 2015; Lee 
et al., 2016). Decreased concentration of amyloid β42 in cerebral spinal fluid are associated 
with increased amyloid plaque deposition in the brain of AD patients (Grimmer et al., 2009) 
and white matter hyperintensity volume increases after the reduction of cerebral spinal fluid 
amyloid β42 concentration, but prior to symptom onset in preclinical patients (Lee et al., 2016) 
indicating that amyloid induced changes in white matter integrity may be an early feature of 
AD pathophysiology.  
 
A number of studies have demonstrated that oligodendrocyte function is impaired by exposure 
to amyloid, with cultured rat oligodendrocytes exposed to amyloid β1-42 or amyloid β25-35, 
experiencing oxidative stress and undergoing cell death (Xu et al., 2001; Lee et al., 2004), and 
exposed to amyloid β1-42 showing impaired myelin sheath formation (Horiuchi et al., 2012).  
Additionally, exposure of a mouse oligodendrocyte progenitor cell line to amyloid β1-42 has 
been shown to induce cell death in the differentiated and undifferentiated cells (Desai et al., 
2010).  However, when the undifferentiated cells also carried pathological variant of human 
PSEN1M146V, exposure to amyloid β1-42 increased the number of CC1+ MBP-negative 
premyelinating oligodendrocytes, an effect that was not observed in cells carrying human 
PSEN1 (Desai et al., 2011), suggesting that pathological variants of PSEN1 can modulate the 
response of OPCs to amyloid pathology.   
 
A small number of studies have examined the influence of amyloid pathology on OPC and 
oligodendrocyte function in vivo, and these studies have largely examined the combined effect 
of human pathological variants in APP and PSEN1.  In APP/PS1 transgenic mice, amyloid 
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plaques form by 2 months of age (Radde et al., 2006), and are associated with focal 
demyelination at 6 months of age (Behrendt et al., 2013).  However, OPCs and 
oligodendrocytes appear to respond early to pathology, as expression of the OPC proteoglycan 
NG2 and the oligodendrocyte proteins CNP and MBP are already elevated in the hippocampus 
by 2 months of age (Wu et al., 2017).  Despite an increase in OPC density and proliferation 
and GSTpi+ oligodendrocyte number at 6 months of age, myelin aberrations can also be clearly 
detected, including double ensheathment, excess cytoplasm in the inner loop, myelin out-
folding, degenerating sheaths and myelin ballooning (Behrendt et al., 2013).  In 3xTg mice, 
that carry human pathological variants in APPSw, PSEN1M146V and MAPTP301L, amyloid β1-42 
is increased by  6 months of age (Desai et al., 2010); however, Schaffer collateral axons are 
already dystrophic and have granulated myelin by 2 months of age, and myelin protein 
expression is reduced in the CA1 region of the hippocampus (Desai et al., 2009), which 
manifests as fewer myelinated CA1 axons by 6 months of age (Desai et al., 2010).  As the viral 
delivery of intracellular targeted anti-Aβ antibodies to 3xTg mice at 2 months of age, to prevent 
Aβ aggregation, can restore myelination at 6 months of age (Desai et al., 2010), amyloid 
pathology appears to be the primary driver of oligodendrocyte damage in these mice.  
 
Herein, we show that mice carrying the Swedish and Indiana mutations in APP transgenic mice 
maintain a normal density of OPCs and oligodendrocytes in the hippocampus from P60 to 
P180; however, OPC behaviour is altered by amyloid pathology.  In young adulthood (P100), 
OPCs in the hippocampus of APP transgenic mice have an increased response to GABA, 
becoming more depolarised upon bath application of the neurotransmitter.  Oligodendrocyte 
maturation also appears to be affected in the hippocampus of these mice, as the nodes of 
Ranvier are shorter and the paranodes longer and this phenotype is associated with increased 
myelin thickness by P100.  The number of new oligodendrocytes produced by adult OPCs 
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appeared normal in early adulthood, but increased in the hippocampus, entorhinal cortex and 
fimbria of APP transgenic mice as pathology developed.  As total oligodendrocyte density was 
unchanged by P180, it is likely that the newborn oligodendrocytes replace oligodendrocytes 
lost to pathology. 
 
4.2. Results 
4.2.1. APP mice develop histopathological features of Alzheimer’s disease by P180 
To characterise the expression of human APP and the timeframe for the development of 
amyloid plaques in the brain of APP transgenic mice, we generated hippocampal brain lysates 
and coronal brain cryosections from WT, MAPT and APP mice at P30, P60, P90 and P180.  By 
performing a series of Western blots to detect immature and mature human APP (6E10 
antibody), we determined that human APP was already expressed by APP mice at P30, and 
expression was stable over time (Figure 4.1a, b).  Human APP (~100kDa) was not detected in 
hippocampal lysates from WT or MAPT transgenic mice (Figure 4.1b), which acted as an 
additional control for this experiment.  A smaller protein band (~55kDa) was detected in lysates 
from MAPT transgenic mice; however, this band does not correspond to human APP (Grant et 
al., 2019).  We next performed a histological study to determine whether human APP 
expression resulted in amyloid plaque formation in APP transgenic mice.  Coronal brain 
cryosections from P60, P90 and P180 WT and APP mice were stained with thioflavin S (Figure 
4.1c-i, green), which binds to β-sheet structures identifying amyloid β plaques (Sun et al., 2002; 
Bussière et al., 2004).  Sections were also co-labelled to detect the microglial marker Iba1 
(Figure 4.1c-i, red).  Plaques were absent from the hippocampus of WT and APP mice at P60 
(Figure 4.1c, d) and P90 (Figure 4.1e, f).  At P180, plaques had not formed in the hippocampus 







Figure 4.1. APP transgenic mice have impaired survival compared with their wildtype littermates 
a) A Western blot utilising the anti-human APP 6E10 antibody reveals a protein band of ~100kDa in hippocampal 
protein lysates generated from P30 APP mice, that is absent from lysates generated from WT littermates and 
Prnp-MAPTP301S (MAPT) transgenic mice.  A protein band corresponding to β-actin (~42kDa) was detected in 
all brain lysates.  b) Quantification of human APP expression, relative to β-actin expression, in brain lysates from 
P30, P60, P90 and P180 WT, MAPT and APP transgenic mice, indicated that human APP expression was 
significantly elevated in APP mice relative to WT and MAPT mice at all timepoints [Two-way ANOVA, genotype: 
F (2, 24) = 112.0, p < 0.0001; age: F (3, 24) = 2.35, p = 0.097; interaction: F (6, 24) = 2.31, p = 0.066].  P180 
APP transgenic mice expressed more human APP than P30, P60 or P90 mice of the same genotype [Bonferroni 
post-test: 30 vs 180, p = 0.040; 60 vs 180, p = 0.001; 90 vs 180, p = 0.030].  c-h) Coronal brain cryosections 
showing the hippocampus of P60, P90 and P180 WT and APP mice stained to detect the microglial marker Iba1 
(red) and amyloid plaques (thioflavin S; green).  White arrow heads indicate amyloid plaques.  i) A thioflavin S 
labelled amyloid plaque (green) surrounded by microglia (Iba1; red) in the hippocampus of a P180 APP 
transgenic mouse.  j) Quantification of the survival of WT and APP mice from birth until P241.  [Log Rank 
(Mantel-Cox) test: Chi square = 40.97, df = 1, p < 0.0001]. Asterisks denote significant differences identified by 




















While microglia were present in the hippocampus of WT and APP mice at all ages examined, 
Iba1 expression increased noticeably by P180 in the APP mice, which is indicative of reactive 
microgliosis, and microglia were also found to accumulate around amyloid plaques (Figure 
4.1i). 
 
While APP transgenic mice developed amyloid plaques by P180, their survival was impaired 
prior to adulthood.  By quantifying the survival of WT and APP transgenic mice from birth 
until P180, we determined that ~60% of APP transgenic mice die prior to P180, compared with 
only ~2% of WT mice [Log-rank (Mantel-Cox) test, p < 0.0001, Figure 4.1j].  As we next 
aimed to characterise the behavioural consequences of APPSw,Ind overexpression, it should be 
noted that the impaired survival of APP transgenic mice introduces an unavoidable bias into 
our analyses, skewing our characterisation towards the less affected mice that survive to the 
older ages. 
 
4.2.2. APP mice exhibit hyperactive behaviour by P60 but do not develop spatial 
learning deficits by P180 
To compare the cognitive performance of WT and APP transgenic mice prior to and during 
plaque formation, WT and APP mice were subjected to a battery of behavioural tasks at P60, 
P90 or P180.  WT (Figure 4.2a) and APP transgenic mice (Figure 4.2b) were placed into an 
open field arena for 10 minutes, over which time the total distance each mouse travelled 
(Figure 4.2c), and the average velocity of that movement (Figure 4.1d) was recorded.  At all 
ages tested, APP mice travelled further (Figure 4.2c) and faster (Figure 4.2d) than their WT 
littermates, suggesting that these mice are hyperactive.  Additionally, WT and APP mice spent 
a similar proportion of time in the brightly lit centre of the open field at P60 and P90; however,  
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Figure 4.2. APP transgenic mice are hyperactive but show no overt learning and memory deficit by 6 months 
of age 
a-b) Representative track visualisation images (EthoVision XT) showing movement (black lines) of P180 WT (a) 
and APP (b) mice during the open field task. c) Quantification of the total distance travelled by WT and APP mice 
in the open field task at P60, P90 and P180 [Two-way ANOVA, genotype: F (1, 53) = 48.59, p < 0.0001; age: F 
(2, 53) = 2.30, p = 0.109; interaction: F (2, 53) = 3.18, p = 0.049]. d) Quantification of the average movement 
velocity of WT and APP mice during the open field task at P60, P90 and P180 [Two-way ANOVA, genotype: F 
(1, 53) = 47.83, p < 0.0001; age: F (2, 53) = 2.27, p = 0.113; interaction: F (2, 53) = 3.21, p = 0.047]. e) 
Quantification of the proportion of time spent in the centre of the open field of WT and APP mice during the open 
field task at P60, P90 and P180 [Two-way ANOVA, genotype: F (1, 53) = 8.05, p = 0.006; age: F (2, 53) = 0.51, 
p = 0.59; interaction: F (2, 53) = 2.431, p =0.097]. f) Quantification of the proportion incorrect arm choices 
(errors) made by P60, P90 and P180 WT and APP mice during the T-maze alternation task [Two-way ANOVA, 
genotype: F (1, 50) = 18.89, p < 0.0001; age: F (2, 50) = 1.20, p = 0.204; interaction: F (2, 50) = 0.064, p = 
0.937]. g-h) Representative track visualisation images (EthoVision XT) showing movement (black lines) of P180 
WT (g) and APP (h) mice during the Barnes maze long-term memory probe trial, carried out 2 weeks after mice 
learned the expected location of an escape box (red arrows). Blue shading indicates the quadrant of the maze 
defined as the target zone. i) Quantification of the proportion of time P60, P90, and P180 WT or APP mice spent 
within the target zone during the long-term memory probe trial [Two-way ANOVA, genotype: F (1, 52) = 1.93, p 
= 0.170; age: F (2, 52) = 3.06, p = 0.055; interaction: F (2, 52) = 0.16, p = 0.844]. j) Quantification of the time 
spent by P180 WT and APP mice in each quadrant of the Barnes maze during the short-term memory probe phase 
[Two-way ANOVA, genotype: F (1, 80) = 0.006, p = 0.935; maze quadrant: F (3, 80) = 41.96, p < 0.0001; 
interaction: F (3, 80) = 1.212, p = 0.310]. k) Quantification of the time spent by P180 WT and APP mice in each 
quadrant of the Barnes maze during the long-term memory probe phase [Two-way ANOVA, genotype: F (1, 80) 
= 0.004, p = 0.946; maze quadrant: F (3, 80) = 42.55, p < 0.0001; interaction: F (3, 80) = 1.77, p = 0.159]. 
Data are presented as mean ± SEM, n= 8-11 mice per group. Asterisks denote significant differences identified 
by Bonferroni post hoc analysis, *p < 0.05, **p < 0.01, ****p < 0.0001. TA: target quadrant; OP: opposite 













by P180 APP mice spent less of their time in the centre region (Figure 4.2e), which is indicative 
of an increase in anxiety-like behaviour.   
 
Working-memory performance was subsequently evaluated by assessing spontaneous 
alternation in the T-maze.  We found that WT and APP mice performed similarly at P60, but 
that by P90 APP mice persistently made more repeat arm entries (errors) than their WT 
littermates (Figure 4.2f) suggesting that these mice have impaired working memory or 
attentional processing that is likely associated with their hyperactivity (Kim et al., 2017; 
Montarolo et al., 2019).  When evaluating short and long-term memory retention by WT 
(Figure 4.2g) and APP transgenic mice (Figure 4.2h) using the Barnes maze spatial navigation 
task, we found that regardless of age, APP mice and their WT littermates performed equally 
well in the short-term memory probe trial [P60: WT 35.11 ± 2.4, APP 34.02 ± 3.0; P90: WT 
40.35 ± 6.0, APP 44.90 ± 3.9; P180: WT 45.10 ± 3.8, APP 40.02 ± 3.5; mean ± SEM, time in 
target zone (%)] one day after learning the location of the escape box, and again two-weeks 
later during the long-term memory probe trial (Figure 4.2i).  This is highlighted by data 
showing that even at P180, WT and APP mice spend significantly more time in the target 
quadrant, compared to all other quadrants during the short-term (Figure 4.2j) and long-term 
(Figure 4.2k) memory trials, indicating that mice of both genotypes learned and remembered 
the location of the escape box.    
 
4.2.3. OPC density and membrane properties are unchanged, but the response to GABA 
is increased at P100 in APP mice 
To determine how OPC behaviour might be affected by amyloid pathology, we first quantified 
the density of PDGFRα+ OPCs in the hippocampus, entorhinal cortex and fimbria of WT and 
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APP mice (Figure 4.3a-i).  We found that OPC density was slightly reduced in the 
hippocampus of APP mice compared with control mice at P67; however, this difference was 
not maintained at later ages (Figure 4.3g).  In the entorhinal cortex (Figure 4.3h) and fimbria 
(Figure 4.3i), OPC density was not affected by genotype and remained stable over time.  To 
determine whether amyloid pathology affected the membrane properties of OPCs, we also 
performed whole cell patch clamp analysis of GFP+ OPCs in the hippocampus of brain slices 
collected from WT, MAPT or APP transgenic mice carrying the Pdgfrα–H2BGFP transgene.  
We report that neither the overexpression of human MAPTP301S or APPSw,Ind in neurons altered 
the OPC membrane capacitance (an approximate measure of cell size; Figure 4.3j), membrane 
resistance (Figure 4.3k) or RMP (Figure 4.3l), which were equivalent for WT, MAPT and 
APP transgenic mice at P30 and P100.  Furthermore, the magnitude of the inwards voltage-
gated sodium channel current recorded from P30 and P100 OPCs was equivalent for WT, 
MAPT and APP transgenic mice (Figure. 4.3m). 
 
As APP mice are hyperactive by P60, which may reflect altered neurotransmitter signalling or 
inhibitory-excitatory balance in the brain (Palop et al., 2007; Sanchez et al., 2012; Verret et al., 
2012; Snowden et al., 2019), we next used whole cell patch clamp electrophysiology to 
examine the ability of OPCs in the hippocampus of WT, MAPT and APP mice to respond to 
excitatory and inhibitory neurotransmitters.  GFP+ OPCs from WT mice were first held at -60 
mV and KA (100 μM) was bath applied to activate the ionotropic AMPA/KA subtype of 
glutamate receptors.  KA application evoked an inwards current that was sensitive to the 







Figure 4.3. OPC density and membrane properties are normal in APP transgenic mice 
a-f) Coronal brain sections (30µm) from P120 WT and APP mice were stained to detect PDGFRα+ OPCs in the 
hippocampus, entorhinal cortex and fimbria.  g) Quantification of OPC density in the hippocampus of P60, P120, 
150 and P180 WT and APP transgenic mice [Two-way ANOVA, genotype: F (1, 30) = 13.66, p = 0.0009; age: F 
(3, 30) = 0.14, p = 0.93; interaction: F (3, 30) = 0.91, p = 0.44].  h) Quantification of OPC density in the 
entorhinal cortex of P60, P120 and P180 WT and APP transgenic mice [Two-way ANOVA, genotype: F (1, 18) 
= 0.85, p = 0.36; age: F (2, 18) = 0.22, p = 0.80; interaction: F (2, 18) = 0.20, p = 0.81].  i) Quantification of 
OPC density in the fimbria of P60, P120, 150 and P180 WT and APP transgenic mice [Two-way ANOVA, 
genotype: F (1, 27) = 0.0009, p = 0.97; age: F (3, 27) = 4.49, p = 0.01; interaction: F (3, 27) = 1.23, p = 0.31].  
.31]. Data are presented as mean ± SD, n=3-6 mice per group (g-i).  j) The membrane capacitance of OPCs in 
the hippocampus of P30 and P100 WT, MAPT and APP mice [Two Two-way ANOVA, genotype: F (2, 77) = 
3.748, p = 0.03; age: F (1, 77) = 0.03 p = 0.87; interaction: F (2, 77) = 0.45, p = 0.64, Bonferroni’s post-test 
P30 or P100 WT vs APP or MAPT p>0.05].  k)  The membrane resistance of OPCs in the hippocampus of P30 
and P100 WT, MAPT and APP mice [Two-way ANOVA, genotype: F (2, 67) = 1.173, p = 0.31; age: F (1, 67) = 
0.24, p = 0.63; interaction: F (2, 67) = 0.49, p = 0.61].  l) The resting membrane potential of OPCs in the 
hippocampus of P30 and P100 WT, MAPT and APP mice [Two-way ANOVA, genotype: F (2, 77) = 1.7166, p = 
0.18; age: F (1, 77) = 1.35, p = 0.25; interaction: F (2, 77) = 0.75, p = 0.48].  m) The voltage-gated sodium 
channel current (INa) recorded from OPCs in the hippocampus of P30 and P100 WT, MAPT and APP mice [Two-
way ANOVA, genotype: F (2, 73) = 0.002, p = 0.998; age: F (1, 73) = 4.1, p = 0.047; interaction: F (2, 73) = 
0.019, p = 0.98, Bonferroni’s post-test P30 or P100 WT vs APP or MAPT p>0.05].  Data are presented as mean 
















Figure 4.4. OPCs from APP transgenic mice have a heightened response to GABA  
a) I-V relationship for the current evoked in hippocampal OPCs by the bath application of 100 µM KA (mean 
steady state baseline current was subtracted from the mean steady state current in the presence of KA) in P30 or 
P100 WT mice [Two-way ANOVA, genotype effect F (1,8) = 0.2372 p = 0.6393].  b) Quantification of KA (100 
µM) evoked currents when hippocampal OPCs are hyperpolarised to -100 mV in P30 or P100 WT mice in the 
presence or absence of CNQX (10 µM) [Two-way ANOVA, drug effect F (1,35) = 124.3 p < 0.0001, Bonferroni’s 
post-hoc test P30 or P100 KA vs KA+CNQX p <0.001].  c) Example traces show the baseline currents, currents 
in the presence of KA, or currents in the presence of KA + CNQX from OPCs of WT mice after a family of voltage 
steps from -100 to 20 mV (20 mV increments).  d) Quantification of KA-evoked currents measured after a 
hyperpolarising pulse (to -100 mV) for OPCs in the hippocampus of P30 or P100 WT, MAPT or APP transgenic 
mice [Two-way ANOVA, genotype effect F (2,54) = 0.1375 p = 0.2616].  e) Example traces showing KA-evoked 
currents (baseline current was subtracted from currents recorded in the presence of KA) after voltage steps form 
-100 mV to 20 mV (40 mV increments) in P30 or P100 WT, MAPT or APP mice.  f) I-V relationship for the current 
evoked in hippocampal OPCs by the bath application of 100 µM GABA (mean steady state baseline current 
subtracted from the mean steady state current in the presence of GABA) in P30 or P100 WT mice [Two-way 
ANOVA, genotype effect F (1,14) = 0.002744 p = 0.9590].  g)  Quantification of the GABA-evoked current 
measured after hyperpolarising hippocampal OPCs to -80 mV in the absence or presence of picrotoxin (50 µM) 
[Two-way ANOVA, drug effect F (1,14) = 46.75 p = 0.0001, Bonferroni’s post-hoc test P30 or P100 GABA vs 
GABA+PTX p <0.001].  h) Example traces showing the baseline currents, currents in the presence of GABA, or 
currents in the presence of GABA + picrotoxin from OPCs in hippocampal slices from WT mice after a family of 
voltage steps from -80 to 80 mV (20 mV increments).  i) Quantification of the GABA-evoked current measured 
after a hyperpolarising pulse to -80 mV in OPCs from P30 or P100 WT, MAPT or APP mice [Two-way ANOVA. 
genotype effect F (2,59) = 5.738 p = 0.0053, Bonferroni’s post-hoc test P100 WT vs APP p <0.001].  j) Example 
traces showing GABA-evoked currents (baseline current was subtracted from currents recorded in the presence 
of GABA) after voltage steps from -80 mV to 80 mV (40 mV increments) for hippocampal OPCs from P30 or P100 
WT, MAPT or APP mice. Values represent mean ± SEM, n=4-16 cells per group. *** = p <0.001 Two-way 













The KA-evoked current in OPCs at P30 and P100 was not linear and did not reverse (Figure 
4.4a), which is consistent with previous reports showing that in OPCs sodium entry through 
AMPA/KA receptors inhibits the voltage gated potassium channel current at depolarised 
potentials (Borges and Kettenmann, 1995).  We report that the amplitude of the KA-evoked 
current does not differ between P30 and P100, and is equivalent in WT, MAPT and APP 
transgenic mice (Figure 4.4d, e).  To assess the response of OPCs to the inhibitory 
neurotransmitter GABA (100 μM), OPCs were held at 0 mV while GABA was bath applied.  
At P30 and P100, GABA evoked an outwardly rectifying current that was completely abolished 
in the presence of PTX (100 μM; Figure 4.4f-h), indicating that the evoked currents resulted 
from the activation of ionotropic GABAA receptors.  There was no difference in the amplitude 
of current evoked by GABA in OPCs from P30 WT, MAPT and APP transgenic mice (Figure 
4.4i, j).  By contrast, OPCs in hippocampal slices generated from P100 APP transgenic mice 
responded more robustly to GABA at 80 mV than OPCs from P100 WT or MAPT mice (Figure 
4.4i, j).  These data suggest that early amyloid pathology is associated with a change in the 
subunit composition of GABAA receptors expressed by OPCs, or a change in the number of 
GABAA receptors expressed on the cell surface.   
  
4.2.4. Node of Ranvier length is decreased and paranode length increased in the 
hippocampus of P180 APP mice 
To determine whether myelin integrity was affected in young adult APP transgenic mice, we 
first examined the morphology of the nodes of Ranvier and their associated paranodes in P100 
WT and APP transgenic mice (Figure. 4.5).  Coronal brain cryosections containing the 
hippocampus (Figure 4.5a, b) and fimbria (Figure 4.5c, d) were immunolabelled to detect the 
nodal protein NaV1.6 (red) and the paranodal protein Caspr (green), and the length of each 





Figure 4.5. Nodes of Ranvier are shorter and paranodes longer in the hippocampus of APP transgenic mice 
a-d) Coronal brain sections (30µm) from P107 WT and APP mice were stained to detect Caspr (green; paranodal 
marker) and Nav1.6 (red; used to mark nodes of Ranvier) in the hippocampus and fimbria.  Magnified panels 
demonstrate measurement of nodes of Ranvier.  e) Quantification of node length in the hippocampus of WT (n = 
229 nodes) and APP (n = 142 nodes) mice (Mann Whitney test: U = 11990, p < 0.0001).  f) Cumulative 
distribution plot on node length in the hippocampus of WT (open circles) and APP mice (grey diamonds) 
(Kolmogorov-Smirnov test: D = 0.2033, p = 0.0014).  g) Quantification of mean hippocampal node length for 
each mouse in WT (n = 4) or APP (n = 3) mice (Two -tailed, unpaired t-test: t = 2.664, df = 5, p = 0.0447).  h) 
Quantification of paranode length in the hippocampus of WT (n = 135 paranodes) and APP (n = 113 paranodes) 
mice (Mann Whitney test: U = 5568, p = 0.0003).  i) Cumulative distribution plot on paranode length in the 
hippocampus of WT and APP mice (Kolmogorov-Smirnov test: D = 0.2507, p = 0.0009).  j) Quantification of 
mean hippocampal paranode length for each mouse in WT (n = 4) or APP (n = 3) mice (Two-tailed, unpaired t-
test: t = 2.799, df = 5, p = 0.038).  k) Quantification of node length in the fimbria of WT (n = 278 nodes) and 
APP (n = 163 nodes) mice (Mann-Whitney test: U = 20500, p = 0.0947).  l) Cumulative distribution plot of node 
length in the fimbria of WT and APP mice (Kolmogorov-Smirnov test: D = 0.1190, p = 0.1091).  m) Quantification 
of mean hippocampal node length for each mouse in WT (n = 4) or APP (n = 3) mice (Two-tailed, unpaired t-
test: t = 1.293, df = 5, p = 0.2526).  n) Quantification of paranode length in the hippocampus of WT (n = 193 
paranodes) and APP (n = 134 paranodes) mice (Mann-Whitney test: U = 12280, p = 0.4374).  o) Cumulative 
distribution plot on paranode length in the hippocampus of WT and APP mice (Kolmogorov-Smirnov test: D = 
0.08391, p = 0.6336).  p) Quantification of mean hippocampal paranode length for each mouse in WT (n = 4) or 
APP (n = 3) mice (Two-tailed, unpaired t-test: t = 0.5096, df = 5, p = 0.6338).  Results are presented as mean ± 



















shorter in the hippocampus of APP transgenic compared to WT mice (Figure 4.5e), with node 
length distribution being significantly shifted towards the formation of shorter nodes (Figure 
4.5f).  Furthermore, average node length per mouse was also reduced with APPSw,Ind expression 
(Figure 4.5g).  The observed change in node length was accompanied by a lengthening of the 
paranodes in the hippocampus of APP transgenic mice (Figure 4.5h), as paranode length 
distribution was shifted towards the generation of longer paranodes (Figure 4.5i).  Within the 
hippocampus of APP transgenic mice, average paranode length was also increased per mouse 
(Figure 4.5j).  By contrast, node of Ranvier length (Figure 4.5k-m) and paranode length 
(Figure 4.5n-p) was equivalent for WT and APP transgenic mice in the fimbria, suggesting 
that this phenotype is region specific.   
 
4.2.5. Myelin thickness is increased in the hippocampus of P100 APP transgenic mice 
As paranode lengthening can result from myelin decompaction (Howell et al., 2006; Stojic et 
al., 2018) or increasing myelin thickness following myelin sheath addition (Snaidero et al., 
2014), we next examined the ultrastructure of hippocampal myelin in P100 WT (Figure 4.6a) 
and APP mice (Figure 4.6b) by TEM.  We found that axon density (Figure 4.6c), myelinated 
axon density (Figure 4.6d), and the proportion of axons that are myelinated (Figure 4.6e) was 
equivalent between WT and APP mice, suggesting that developmental myelination was largely 
normal in these mice.  However, the g-ratio [axon diameter / (axon + myelin diameter)] 
measured for myelinated axons in the hippocampus of APP mice was reduced compared to 
those measured in WT mice (Figure 4.6f-g), suggesting that APP mice have thicker myelin in 
this region.  By further quantifying axon diameter and the number of myelin wraps per axon 
(Figure 4.6h-k), we confirmed that myelinated axon diameter was equivalent in the 
hippocampus of WT and APP transgenic mice (Figure 4.6l); however, the number of myelin 







Figure 4.6. Myelin thickness is increased in APP transgenic mice 
a-b) Representative electron micrographs from the CA1 region of the hippocampus of WT (a) and APP (b) mice 
at P90. c) Quantification of total axon density (axons / µm2) in WT (open circles) and APP (grey diamonds) mice 
(Two-tailed, unpaired t-test: t = 2.46, df = 4, p = 0.06).  d) Quantification of myelinated axon density (axons / 
µm2) in WT and APP mice (Two-tailed, unpaired t-test: t = 1.69, df = 4, p = 0.16). e)  Quantification of the 
proportion of myelinated axons in the CA1 of WT and APP mice at P90 (Two-tailed, unpaired t-test: t = 0.46, df 
= 4, p = 0.66). f) Graphical representation of the g-ratio distribution based on axon diameter (Kolmogorov-
Smirnoff test, K-S D = 0.2926 p < 0.0001). g) Quantification of average g-ratio for WT and APP mice (Two-
tailed, unpaired t-test: t = 4.18, df = 4, p = 0.013).  h-k) Representative high magnification electron micrographs 
through a single myelinated axon within the CA1 region of WT (h-i) and APP mice (j-k) at P90.  l) Quantification 
of average myelinated axon diameter within the CA1 region of WT and APP mice (Two-tailed, unpaired t-test: t 
= 2.27, df = 4, p = 0.085).  m) Quantification of average number of myelin wraps for axons within the CA1 region 
of WT and APP mice at P90 (Two-tailed, unpaired t-test: t = 4.12, df = 4, p = 0.014). Scale bars represent: 1µm 







indicate that early amyloid pathology influences the myelinating behaviour of 
oligodendrocytes in the hippocampus.  
 
4.2.6. New oligodendrocyte number is elevated in the hippocampus, entorhinal cortex 
and fimbria of adult APP transgenic mice 
To determine whether the ability of OPCs to generate new oligodendrocytes was affected by 
early amyloid pathology, we performed cre-lox lineage tracing of adult OPCs from P60, 
comparing oligodendrocyte generation in control (Pdgfra-CreERT2::Rosa26-YFP) and APP 
(Pdgfra-CreERT2::Rosa26-YFP::PDGFb-hAPPSw,Ind) mice (Figure 4.7).  Coronal brain 
cryosections from P60+7, P60+60, P60+90 and P60+120 control and APP transgenic mice, 
containing the hippocampus, entorhinal cortex and fimbria, were stained to detect YFP (green), 
PDGFRα (red) and Hoechst 33342 (blue) (Figure 4.7a-l).  While PDGFRα+ YFP+ OPCs gave 
rise to new PDGFRα-neg YFP+ cells over time, essentially all YFP-labelled cells expressed the 
transcription factor OLIG2, even at P60+120, confirming that they remained in the 
oligodendrocyte lineage.  For example, at P60+120, ~97 ± 1% of YFP+ cells in the 
hippocampus of control mice and ~96 ± 2% of YFP+ cells in the hippocampus of APP 
transgenic mice were OLIG2+ (mean ± SD).  While we found that OPCs differentiated to 
produce new oligodendrocytes in the hippocampus (Figure 4.7a-d), entorhinal cortex (Figure 
4.7e-h) and fimbria (Figure 4.7i-l) of adult control and APP mice, the proportion of YFP+ cells 
that became new oligodendrocytes was significantly increased in the hippocampus of APP 
transgenic mice compared to control mice by P60+90 (Figure 4.7m).  By P60+120, the 
proportion of YFP+ cells that were new oligodendrocytes was also significantly higher in the 
entorhinal cortex (Figure 4.7n) and fimbria (Figure 4.7o) of APP transgenic mice compared 





Figure 4.7. Adult oligodendrogenesis is elevated in the APP transgenic mouse brain 
a-d) Confocal images of the hippocampus in coronal brain cryosections from P60+60 and P60+120 control and 
APP transgenic mice stained to detect YFP (green), PDGFRα (red) and Hoechst 33342 (blue).  e-h) Confocal 
images of the entorhinal cortex in coronal brain cryosections from P60+60 and P60+120 control and APP 
transgenic mice stained to detect YFP (green), PDGFRα (red) and Hoechst 33342 (blue).  i-l) Confocal images 
of the fimbria in coronal brain cryosections from P60+60 and P60+120 control and APP transgenic mice stained 
to detect YFP (green), PDGFRα (red) and Hoechst 33342 (blue).  m) Quantification of the proportion of YFP+ 
cells in the hippocampus of control and APP mice that have differentiated into PDGFRα-negative YFP+ 
oligodendrocytes [Two-way ANOVA, genotype: F (1, 30) = 21.35, p < 0.0001; age: F (3, 30) = 13.12, p < 0.0001; 
interaction: F (3, 30) = 3.62, p = 0.024].  n) Quantification of the proportion of YFP+ cells in the entorhinal 
cortex of control and APP mice that have differentiated into PDGFRα-negative YFP+ oligodendrocytes [Two-
way ANOVA, genotype: F (1, 18) = 7.01, p = 0.016; age: F (2, 18) = 11.61, p = 0.0006; interaction: F (2, 18) = 
2.03, p = 0.16].  o) Quantification of the proportion of YFP+ cells in the fimbria that have differentiated of control 
and APP mice that have differentiated into PDGFRα-negative YFP+ oligodendrocytes [Two-way ANOVA, 
genotype: F (1, 27) = 14.29, p = 0.0008; age: F (3, 27) = 45.15, p < 0.0001; interaction: F (3, 27) = 3.11, p = 
0.042].  p) Quantification of the density of YFP+ PDGFRα-negative newborn oligodendrocytes in the 
hippocampus of control and APP transgenic mice (cells per mm2 as adjusted for x-y area only) [Two-way ANOVA, 
genotype: F (1, 30) = 16.92, p = 0.0003; age: F (3, 30) = 9.97, p = 0.0001; interaction: F (3, 30) = 3.41, p = 
0.029].  q) Quantification of the density of YFP+ PDGFRα-negative newborn oligodendrocytes in the entorhinal 
cortex of control and APP transgenic mice (oligodendrocytes per mm2 as adjusted for x-y area only) [Two-way 
ANOVA, genotype: F (1, 18) = 16.16, p = 0.0008; age: F (2, 18) = 18.50, p < 0.0001; interaction: F (2, 18) = 
4.41, p = 0.027].  r) Quantification of the density of YFP+ PDGFRα-negative newborn oligodendrocytes in the 
fimbria of control and APP transgenic mice (oligodendrocytes per mm2 as adjusted for x-y area only) [Two-way 
ANOVA, genotype: F (1, 27) = 24.73, p < 0.0001; age: F (3, 27) = 23.68, p < 0.0001; interaction: F (3, 27) = 
8.55, p = 0.0004].  White arrows indicate YFP+ PDGFRα-negative newborn oligodendrocytes.  Data are 















YFP+ oligodendrocytes detected in the hippocampus (Figure 4.7p), entorhinal cortex (Figure 
4.7q) and fimbria (Figure 4.7r) of APP mice relative to controls. 
 
Surprisingly, the addition of new oligodendrocytes did not alter the total density of 
oligodendrocytes detected in the hippocampus, entorhinal cortex or fimbria of control or APP 
mice (Figure 4.8).  By performing immunohistochemistry on coronal brain cryosections from 
P120 or P180 WT and APP transgenic mice to detect the oligodendrocyte marker ASPA 
(Figure 4.8 a-l), we determined that the density of ASPA+ oligodendrocytes was higher in the 
fimbria (Figure 4.8o) and hippocampus (Figure 4.8m) than the entorhinal cortex (Figure 
4.8n), but consistent across age and between WT and APP transgenic mice.  However, as there 
are only 213 ± 65 (mean ± SD) oligodendrocytes per mm2 of hippocampus in APP mice at 
P180 (Figure 4.8m) and 71 ± 7 (mean ± SD) cells per mm2 are newborn oligodendrocytes 
(Figure 4.7p), these data suggest that ~33% of oligodendrocytes present in the hippocampus 
of P180 APP mice are newborn. This equates to ~49% and ~23% in the entorhinal cortex 
(Figure 4.8n; Figure 4.7q) and fimbria (Figure 4.8o; Figure 4.7r), respectively, which is a 
significant contribution to the total population and strongly suggests that amyloid pathology is 
associated with oligodendrocyte turnover by P180.  To determine whether newborn 
oligodendrocytes are mature oligodendrocytes, we immunolabelled coronal sections 
containing the hippocampus and fimbria, to detect PDGFRα+ (blue), YFP+ (green) and ASPA+ 
(red) (Figure 4.9a-h).  We found that YFP+ ASPA+ mature oligodendrocyte addition was 
significantly increased at P60+120 in the hippocampus (Figure 4.9.i) and fimbria (Figure 









Figure 4.8. Oligodendrocyte number is normal in APP transgenic mice  
a-d) Confocal images of the hippocampus in coronal brain cryosections (30µm) from P120 and P180 WT and 
APP transgenic mice stained to detect the oligodendrocyte marker ASPA (red) and Hoechst 33342 (blue).  e-h) 
Confocal images of the entorhinal cortex in coronal brain cryosections from P120 and P180 WT and APP 
transgenic mice stained to detect the oligodendrocyte marker ASPA (red) and Hoechst 33342 (blue).  i-l) Confocal 
images of the fimbria in coronal brain cryosections from P120 and P180 WT and APP transgenic mice stained to 
detect the oligodendrocyte marker ASPA (red) and Hoechst 33342 (blue).  m) Quantification of the density of 
ASPA+ oligodendrocytes in the hippocampus of WT (black bars, open circles) and APP (grey bars, grey diamonds) 
transgenic mice (oligodendrocytes per mm2 as adjusted for x-y area only) [Two-way ANOVA, genotype: F (1, 16) 
= 2.11, p = 0.16; age: F (1, 16) = 1.48, p = 0.24; interaction: F (1, 16) = 1.27, p = 0.27].  n) Quantification of 
the density of ASPA+ oligodendrocytes in the entorhinal cortex of WT and APP transgenic mice (oligodendrocytes 
per mm2 as adjusted for x-y area only) [Two-way ANOVA, genotype: F (1, 18) = 2.08, p = 0.16; age: F (1, 18) = 
0.95, p = 0.34; interaction: F (2, 53) = 0.02, p = 0.87].  o) Quantification of the density of ASPA+ 
oligodendrocytes in the fimbria of WT and APP transgenic mice (oligodendrocytes per mm2 as adjusted for x-y 
area only) [Two-way ANOVA, genotype: F (1, 16) = 0.40, p = 0.53; age: F (1, 16) = 0.08, p = 0.77; interaction: 
F (1, 16) = 0.64, p = 0.43].  Results are presented as mean ± SD, n = 3-6 mice per group. Scale bars represent 
























Figure 4.9. APP mice add more ASPA+ mature oligodendrocytes to the hippocampus and fimbria than control 
mice by 6 months of age.  
a-h) Confocal images showing ASPA (red), PDGFRα (blue) and YFP (green) in the hippocampus of P60 + 120 
Pdgfrα-CreERT2:: Rosa26-YFP (control; a-d) and Pdgfrα-CreERT2:: Rosa26-YFP:: PDGFb-APPSw,Ind (APP; e-
h) mice. i) Quantification of the density of all YFP+ cells that are PDGFRα-negative in the hippocampus of P60 
+ 120 control and APP mice, including those that are YFP+ PDGFRα-negative ASPA-negative premyelinating 
oligodendrocytes versus YFP+ PDGFRα-negative ASPA+ mature oligodendrocytes. [two-way ANOVA, genotype: 
F (1, 15) = 49.33, p < 0.0001; cell type: F (2, 15) = 80.29, p < 0.0001; interaction: F (2, 15), p = 0.0029]. j) 
Quantification of the density of all YFP+ cells that are PDGFRα-negative in the fimbria of P60 + 120 control and 
APP mice, including those that are YFP+ PDGFRα-negative ASPA-negative premyelinating oligodendrocytes 
versus YFP+ PDGFRα-negative ASPA+ mature oligodendrocytes. [two-way ANOVA, genotype: F (1, 15) = 81.97, 
p < 0.0001; cell type: F (2,15) = 96.15, p < 0.0001; interaction: F (2, 15) = 21.21, p < 0.0001]. Asterisks indicate 
significant differences identified by Bonferroni post hoc analysis, **p < .01, ***p < .001, ****p < .0001. White 
arrow heads indicate OPCs in which YFP expression has been enabled; yellow arrow head indicate YFP+ cells 
that do not stain for either an OPC marker or a mature oligodendrocyte marker, suggesting that they are immature 
(premyelinating) oligodendrocytes. White arrows indicate YFP+ (newborn) oligodendrocytes (ASPA+ cells). Scale 





















Herein we show that APP transgenic mice have an increased level of human APP expression 
in the hippocampus at P180, which corresponds with their development of amyloid plaques 
(Figure 4.1).  Behaviourally these mice were hyperactive by 2 months of age, which impacted 
their performance in other behavioural assessments; however, they did not develop spatial 
memory deficit by 6 months of age (Figure 4.2).  OPCs within the hippocampus of APP 
transgenic mice are present at a normal density, but have an increased response to GABA by 
P100 (Figure 4.3 and Figure 4.4).  Additionally, developmental myelination was affected in 
APP transgenic mice, as the nodes of Ranvier along hippocampal axons were shorter and the 
paranodes longer in young adulthood, and this phenotype was associated with increased myelin 
thickness (Figure 4.5 and Figure 4.6).  OPCs in the hippocampus, entorhinal cortex and 
fimbria of young adult APP transgenic mice also produced a normal number of new 
oligodendrocytes; however, as pathology developed oligodendrogenesis increased (Figure 
4.7).  As this was not accompanied by a change in total oligodendrocyte number (Figure 4.8), 
but an increased addition of mature oligodendrocytes (Figure 4.9), we propose that APP 
transgenic mice have a higher level of oligodendrocyte turnover than their WT littermates by 
P180, which may be required to replace lost myelin. 
 
4.3.1. APP mice are hyperactive prior to amyloid plaque deposition 
APP or J20 mice express a human variant of APP containing the Swedish (K670N/M671L) 
and Indiana (V717F) familial AD-linked mutations, driven by the PDGFβ promoter (Mucke et 
al., 2000).  By performing a western blot analysis of hippocampal protein lysates from P30, 
P60, P90 and P180 WT, MAPT and APP mice,  detecting amino acids 1-16 of human APP 
using the 6E10 antibody, we found that human APP (~100kDa) was present in the hippocampus 
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of APP mice by P30 and was not present in WT mice (Mucke et al., 2000; Galvan et al., 2006).  
While a human APP band of ~100kDa was not present in the hippocampus of MAPT transgenic 
mice, the antibody bound to a protein of ~55kDa.  As peptide inhibitors designed to target a 
16-23 amino acid region of amyloid β to prevent its aggregation, can also prevent the 
aggregation of hyperphosphorylated tau, these two pathological proteins may share a common 
epitope (Griner et al., 2019).  Therefore, we propose that the protein band detected in MAPT 
mice using the 6E10 antibody corresponds to tau, usually detected at ~55kDa (Kalani et al., 
2017; Pu et al., 2018).  While human APP was present in APP mice by P30, APP expression 
increased significantly by P180, which coincided with the appearance of amyloid plaques.  
Wright et al. (2013) similarly found that APP mice express an increasing concentration of 
amyloid proteins over time, leading to amyloid plaque formation at 6 months of age, while 
others have reported the presence of amyloid plaques developing between 4-6 (Meilandt et al., 
2009) or 5-7 (Mucke et al., 2000) months of age, confirming that our APP mice follow the 
typical pattern of amyloid pathology reported for this strain.  Premature mortality has also been 
widely reported for APP mice, and is often attributed to a susceptibility to spontaneous seizures 
(Palop et al., 2007); however, the longevity described for these mice is highly varied, with 
survival rates ranging from 65-90% by 6 months of age (Cheng et al., 2007; Cissé et al., 2011; 
Murakami et al., 2011; Verret et al., 2012; Dubal et al., 2015).  We found that ~60% of APP 
mice died unexpectedly by 6 months of age, and it is reasonable to assume that the mice that 
died prematurely had developed greater pathology, such that the reduced survival of APP mice 
unavoidably biases our analyses, skewing our characterisation towards the less affected mice 
that survive to the older ages.  
 
By subjecting APP mice to a battery of behavioural tasks at 2, 3 or 6 months of age, we 
determined that APP mice were hyperactive, travelling further and faster than their WT 
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littermates in the open field task at all ages examined.  APP mice also developed episodic 
working memory deficits, observed in the T-maze spontaneous alternation task, by 3 months 
of age, and spent less time in the brightly lit centre of the open field by 6 months of age, which 
may suggest that these mice are developing anxiety-like behavioural traits.  However, these 
phenotypes may also be an artefact of the hyperactivity of these mice.  Hyperactivity is a 
consistent behavioural feature of APP mice (Cheng et al., 2007; Harris et al., 2010; Cissé et al., 
2011; Murakami et al., 2011; Sanchez et al., 2012; Verret et al., 2012; Wright et al., 2013; 
Dubal et al., 2015; Fujikawa et al., 2017; Flores et al., 2018); however, to our knowledge, we 
are the first to show a tendency towards increased anxiety-like behaviour in this strain.  Most 
studies report a decrease in anxiety-like behaviour, or a disinhibition of caution in APP mice 
demonstrated by an increase in open arm exploration time in the elevated plus maze as early 
as 2 months of age (Cheng et al., 2007; Harris et al., 2010; Cissé et al., 2011; Murakami et al., 
2011; Sanchez et al., 2012; Dubal et al., 2015).  However, others see no phenotype in the same 
test at 4, 6 or 11 months of age (Wright et al., 2013; Dekens et al., 2018) or no difference in 
performance in the light/dark emergence test at 5-8 months of age (Fujikawa et al., 2017).  It 
is interesting to note that mice expressing the Swedish (K670N/M671L), Iberian (I716F) and 
Artic (E693G) mutations in human APP (APPNL-G-F mice) have been shown to simultaneously 
exhibit anxiogenic behaviour in the open field (less time in the centre) and anxiolytic behaviour 
in the elevated plus maze (more time in the open arms) at 7-8 months of age (Pervolaraki et 
al., 2019) which the authors suggest is reflective of altered decision making processes, rather 
than a core deficit in emotional motivation.  
 
We report that APP mice were able to learn and remember the location of the escape box in 
the Barnes Maze task equally as well as their WT littermates for up to two weeks.  Our finding 
that APP mice have unimpaired spatial learning and memory function, even at 6 months of age, 
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is seemingly at odds with the field. Numerous studies have reported spatial learning and 
memory deficits in the Morris water maze task from as early as 3-4 months of age in this mouse 
strain, but most studies show the deficit develops between 5-8 months of age (Cheng et al., 
2007; Harris et al., 2010; Cissé et al., 2011; Sanchez et al., 2012; Mesquita et al., 2015). 
However, where other tests of spatial learning were used, the phenotype was less clear cut.  
Wright et al. (2013) reported that APP mice developed spatial learning deficits in the radial 
arm maze at 4 months of age, whereas Mably et al. (2015) did not see impairment in this task 
until 8 months of age. Similarly, Flores et al. (2018) reported that APP mice displayed spatial 
learning and memory impairment in the Barnes maze task from 5 months of age, while others 
reported no deficit in this task before 12 months of age (Nunes et al., 2015; Fujikawa et al., 
2017), suggesting that the Morris water maze has a greater sensitivity for identifying early 
spatial learning impairments in the APP mouse model.  Despite this, our data indicate that the 
cellular changes we observe in cells of the oligodendrocyte lineage before 6 months of age 
occur prior to the onset of overt amyloid pathology or cognitive decline.  
 
4.3.2. OPCs from P100 APP transgenic mice have a heightened response to GABA 
OPCs remained largely unchanged in APP transgenic mice, for example, their density, basic 
membrane properties and response to the AMPA/KA receptor agonist, KA, was unchanged; 
however, hippocampal OPCs from P100 APP mice responded more robustly to the bath 
application of the inhibitory neurotransmitter GABA.  APP is a synaptic protein and has been 
shown to modulate GABAergic signalling, predominantly modulating presynaptic 
metabotropic GABAB receptors or the reversal potential of chloride (reviewed by Tang, 2019).  
APP can bind to the GABAB1a subunit of presynaptic GABAB receptors, with secreted APP 
acting as a ligand at presynaptic GABAB receptors to modulate neurotransmission (Rice et al., 
2019); and the deletion of APP result in a deficit in GABAB mediated neurotransmitter release 
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(Dinamarca et al., 2019).  OPCs do express GABAB receptors (Luyt et al., 2003, 2007; Serrano-
Regal et al., 2019), but the currents evoked in OPCs by GABA application were completely 
antagonised by a selective GABAA receptor antagonist; however, it is possible that APP could 
modulate GABAB receptor activity on neurons to have a secondary effect on GABAA receptor 
expression or composition in OPCs, as the ability for GABAB to influence currents mediated 
by ion channels on OPCs has not been explored (Larson et al., 2016).   
 
APP has also been shown to affect the reversal potential for chloride in neurons via modulation 
of chloride transporters, particularly KCC2 (SLC12A5; Chen et al., 2017; Doshina et al., 2017), 
which, in turn, alters signalling through ionotropic GABAA receptors.  Within the CNS, 
NKCC1 (SlC12A2; Na+ K+ 2Cl- co-transporter 1) allows chloride to enter cells, while KCC2 
(K+-Cl- cotransporter 2) allows the efflux of chloride from cells (reviewed by Kaila et al., 
2014).  Together they maintain a gradient for chloride that determines the effect of GABAA 
receptor activation on cell membrane potential.  In E17 rat primary cortical neuron cultures, 
the overexpression of native human APP was found to decrease KCC2 expression by 
approximately 50%, but had no effect on NKCC1 (Doshina et al., 2017).  Consequently, GABA 
became more excitatory and the human APP-overexpressing neurons displayed a larger 
calcium increase in response to GABA application (Doshina et al., 2017).  KCC2 expression 
is also reduced in hippocampal CA1 neurons cultured from APP knockout mice, producing a 
depolarising shift in the chloride reversal potential relative to neurons from WT mice (Chen et 
al., 2017).  Relative to cortical neurons, OPCs have a high level of expression of NKCC1 and 
a low level of expression of KCC2 (Zhang et al., 2014), meaning that the chloride reversal 
potential in OPCs is depolarised compared with mature neurons, such that activation of 
GABAA receptors on OPCs is considered excitatory (Lin and Bergles, 2004); however, APP-
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induced changes in KCC2 may still have the capacity to influence GABAA receptor subunit 
expression to influence the GABA-mediated current recorded in these cells.   
 
GABAA receptors are pentameric ion channels made up from a number of different subunit 
combinations.  In APP knockout mouse hippocampal cultures have reduced KCC2 expression, 
but the amplitude of evoked unitary inhibitory post-synaptic currents recorded from 
glutamatergic neurons was reduced, as was the response of these neurons to the GABAA 
receptor agonist, isoguvacine (Chen et al., 2017).  This phenotype was associated with an ~50% 
reduction in expression of the α1 GABAA receptor subunit in the hippocampus of APP 
knockout mice that could be rescued by potentiating KCC2 function (Chen et al., 2017), 
suggesting that APP can modulate GABAA receptor subunit expression in a KCC2-dependent 
manner.  Miniature iPSCs recorded from hippocampal OPCs have slow decay kinetics 
compared to neurons and are insensitive to zolpidem, suggesting that OPCs have low 
expression of α1-containing GABAA receptors (Lin and Bergles, 2004), it is possible that the 
increased response to GABA detected in OPCs in the hippocampus of P100 APP mice could 
be the result of an APP mediated change in the expression of GABAA receptor subunits.  
 
A change in the OPC response to GABA may also be an indirect effect, as OPCs adapt to other 
changes in the APP transgenic mouse CNS.  Dysfunctional glutamatergic signalling has been 
demonstrated in AD (reviewed by Findley et al., 2019), and, while GABAA activation on OPCs 
is considered to be excitatory (Lin and Bergles, 2004), activation of GABAA receptors can still 
negatively modulate the response to glutamate by increasing membrane conductance 
(shunting) and/or altering intracellular chloride concentration.  Indeed, bath application of 5 
mM GABA significantly reduced the response to a 4 ms puff application of 200 µM KA in 
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hippocampal OPCs in acute brain slices prepared from P14 rat brains, an effect which persisted 
for several minutes after GABA had been washed off and the OPC membrane conductance had 
returned to baseline levels (Lin and Bergles, 2004), indicating that activation of GABAA 
receptors on OPCs could serve to dampen pathological glutamatergic signalling onto OPCs.  
 
It is currently unknown whether the altered response of adult OPCs in the hippocampus of APP 
transgenic mice to GABA could impact the behaviour of OPCs and the oligodendrocytes they 
produce.  Activating GABAA receptors by applying the agonist muscimol (20 µM) to rat OPC 
cultures has no effect on OPC differentiation or the expression of myelin proteins (MBP or 
MAG; Serrano-Regal et al., 2019); however, modulating GABAergic activity in vivo and in 
slice cultures, which preserve neuron and OPC interactions suggest that GABAergic signalling 
has a significant effect on the behaviour of cells of the oligodendrocyte lineage.  During 
development endogenous GABA acting at GABAA receptors can regulate oligodendrocyte 
lineage cell number. For example, when mice were injected with the GABAA receptor 
antagonist bicuculline (1mg/kg i.p., daily P5-P11), OPC number doubled, and this was 
accompanied by an ~40% decrease in the number of mature oligodendrocytes in the cerebellar 
white matter, while increasing the availability of endogenous GABA decreased OPC number 
and proliferation but increased the number of mature oligodendrocytes (Zonouzi et al., 2015), 
suggesting that GABAergic signalling in the cerebellum regulates OPC proliferation and 
differentiation.  The effect of GABAergic signalling on OPCs may differ between CNS region, 
as applying the GABAA receptor antagonist, GABAzine, to P8 mouse organotypic cortical slice 
cultures increased both the number of OPCs and the number of oligodendrocytes present at 6 
days in vitro (Hamilton et al., 2017).  Conversely, exposure of the slice cultures to the GABAA 
receptor agonist, muscimol, decreased the number of cells of the oligodendrocyte lineage 




The effect of endogenous GABA on cell number may be restricted to early development, as 
OPC density was equivalent in young adult WT and APP transgenic mice, despite altered 
GABAergic signalling in OPCs, and the application of GABAzine to slice cultures was unable 
to further increase cell number after 14 days in vitro (Hamilton et al., 2017).  The complex 
pathology that develops in APP mice also makes it difficult to specifically dissect the role of 
GABAergic signalling, as changes to neuronal signalling can also influence this signalling 
pathway in OPCs.  For example, the effect of GABAzine on oligodendrocyte lineage cell 
number was prevented by blocking neuronal action potentials with tetrodotoxin, suggesting 
that the effect of GABAzine was dependent on the release of an activity-dependent factor from 
neurons (Hamilton et al., 2017).  Interestingly, tetrodotoxin alone had no effect on 
oligodendrocyte lineage cell number, implying an interaction between a direct action at 
GABAA receptors on OPCs concomitant with release of an activity-dependent neuronal factor 
(Hamilton et al., 2017).  As neither GABAzine nor muscimol altered node of Ranvier length 
in mouse cortical organotypic cortical slice cultures (Hamilton et al., 2017), it is likely that the 
changes detected in node length were independent of the increased responsiveness of OPCs to 
GABA, and the impact the GABAergic signalling has on myelin thickness has not been 
explored. 
 
4.3.3. Amyloid accumulation changes myelin ultrastructure 
We have shown that paranodes are longer and nodes of Ranvier shorter for axons in the 
hippocampus of 3-month old APP transgenic mice, compared with WT controls.  Paranodes 
form at the end of each myelin internode, flanking the node of Ranvier, facilitated by contact-
mediated signalling between proteins in the myelin sheath and the axon to maintain the 
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clustered voltage gated sodium channels at the nodes of Ranvier; and tether the myelin 
internode to the axon (reviewed by Pepper et al., 2018).  As APP can be found at the nodes of 
Ranvier (Xu et al., 2014) and can increase NaV1.6-mediated sodium currents (Li et al., 2016), 
it is possible that pathological human APP could directly induce narrowing of nodes of Ranvier 
in the hippocampus.  In the 3xTg transgenic mouse line, a qualitative decrease was noted in 
NaV1.6 expression in the CA1 region of the hippocampus and the entorhinal cortex at 6 months 
of age (Desai et al., 2009); however, this could be the result of myelin degradation and an 
overall reduction in nodes of Ranvier number, rather than a change in nodal structure.  As axon 
diameter was consistent between WT and APP transgenic mice, this is unlikely to be a 
contributing factor to the node of Ranvier length.  The effect of amyloid pathology on the node 
of Ranvier length is also unlikely to result from changes in axon diameter, as we found no 
correlation between the node of Ranvier length and node width (a proxy for axon diameter) in 
WT or APP transgenic mice [linear regression node length v node width deviation of slope 
from 0: WT slope = 0.04, F(1, 227) = 2.2, p = 0.14; APP slope = 0.04, F (1, 140), p=0.22], 
which is consistent with a previous analysis of node of Ranvier length and width in the optic 
nerve and frontoparietal motor cortex of Sprague-Dawley rats (Arancibia-Cárcamo et al., 
2017).  
 
It is likely that the increased paranode length measured for hippocampal axons in the APP 
transgenic mice is the direct result of APP transgenic mice having thicker myelin.  On average, 
oligodendrocytes that myelinated axons in the hippocampus of APP mice produced an extra 
myelin lamella, relative to those in WT mice.  The extra layer of myelin must be anchored at 
the paranode, and could readily explain the increased paranode length, and perhaps, if the 
myelin encroaches on the node of Ranvier, the decrease in nodes of Ranvier length.  Increased 
myelin thickness has also been reported for hippocampal axons in 2-month old 
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APPSwe/PSEN1dE9 transgenic mice, and was attributed to an upregulation in neuregulin-1 
type III (Wu et al., 2017), a known regulator of myelination and myelin thickness (Taveggia et 
al., 2005, 2008; Velanac et al., 2012), cleaved by the enzyme BACE1 that also cleaves APP 
(Luo et al., 2011).   
 
While physiological APP was suggested to be a modulator of myelination and remyelination 
in mice (Truong et al., 2019), it is unclear whether APP regulates myelin thickness.  Myelin 
thickness was unchanged in the sciatic nerve, optic nerve and corpus callosum of APP 
knockout mice at P14 and P77 (Truong et al., 2019); however, pathological overexpression of 
human APP695Swe increased myelin thickness by 1.3% in the spinal cord of 3 months old 
Tg2576 mice (Xu et al., 2014), and we found that myelin thickness was increased by ~10% in 
the hippocampus of APP mice overexpressing APPSw,Ind relative to WT at the same age.  The 
marked increase in myelin thickness in our experiment compared to the change observed in 
Tg2576 mice could be attributed to higher level of soluble Ab produced in our model at this 
age (Hsiao et al., 1996; Mucke et al., 2000).  As soluble Ab induces neuronal hyperactivity in 
the hippocampus (Busche et al., 2012; Willem et al., 2015), and neuronal activity regulates 
myelination (Gibson et al., 2014), Ab could indirectly promote the addition of new myelin 
layers.   
 
4.3.4. Amyloid accumulation increases oligodendrocyte turnover 
OPCs continue to generate new oligodendrocytes in the grey and white matter of the adult 
mouse brain (Dimou et al., 2008; Rivers et al., 2008; Kang et al., 2010; Hill et al., 2013; Young 
et al., 2013; Fukushima et al., 2015).  While the rate of OPC proliferation and oligodendrocyte 
addition slows with aging (reviewed by Wang and Young, 2014), OPCs can rapidly proliferate 
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and differentiate in response to a demyelinating event, to facilitate the replacement of lost 
oligodendrocytes and enable remyelination (Tripathi et al., 2010; Zawadzka et al., 2010; 
Assinck et al., 2017; Baxi et al., 2017).  By performing Cre-lox lineage tracing using Pdgfrα-
CreERT2::Rosa26-YFP transgenic mice, we have shown the number of new oligodendrocytes 
that accumulate in the hippocampus, entorhinal cortex and fimbria of APP transgenic mice 
between P60 and P180 is significantly higher than the number added to these regions in the 
WT mouse brain.  In the hippocampus, oligodendrocyte addition started to deviate between 
WT and APP transgenic mice between 4 and 5 months of age.  However, the effect of amyloid 
pathology on oligodendrogenesis was delayed in the entorhinal cortex and fimbria, being seen 
between 4 and 6 months of age.  Despite the increased number of new oligodendrocytes added 
to the brain of APP transgenic mice, immunolabelling to detect the mature oligodendrocyte 
marker ASPA revealed that oligodendrocyte density in the hippocampus, entorhinal cortex and 
fimbria was equivalent between WT and APP transgenic mice.  However, mature 
oligodendrocyte addition was significantly increased in the hippocampus and fimbria of APP 
mice relative to controls suggesting that the large number of new cells may serve to replace 
oligodendrocytes and myelin that are lost.  Oligodendrocyte turnover is likely to be enhanced 
by Ab toxicity to oligodendrocytes (Xu et al., 2001; Lee et al., 2004), APP accumulation in 
oligodendrocytes (Bauer et al., 2002), or myelin aberrations (Behrendt et al., 2013); but 
whether APP or Ab drives oligodendrocyte replacement remains undefined. 
 
Myelin abnormalities have been reported for a number of animal models of amyloid pathology 
(Chu et al., 2017; Tse et al., 2018), including focal myelin loss associated with amyloid plaques 
(Mitew et al., 2010; Schmued et al., 2013).  We found that the proportion of hippocampal axons 
that were myelinated in 3-month old WT and APP transgenic mice was equivalent; however, 
the marked increase in oligodendrogenesis observed between 4 and 6 months of age in the APP 
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transgenic mice may suggest that oligodendrocyte loss and demyelination are a later feature of 
the pathogenesis.  This time line differs significantly from that of APPSw (R1.40) mice in which 
myelin loss was not reported until 18-months of age (Tse et al., 2018), but would be consistent 
with the marked reduction in myelinated axon number in the hippocampus of 6-month old 
3xTg mice, which occurred prior to plaque deposition (Desai et al., 2009), and the myelin 
aberrations detected in APP/PS1 mice at 6 months, coincident with plaque detection (Behrendt 




Chapter 5: General discussion and future directions 
 
5.1. Thesis findings summary 
The aim of this thesis was to evaluate the impact that overexpressing human pathological 
variants of MAPT or APP in neurons had on the behaviour of cells of the oligodendrocyte 
lineage.  Specifically, I aimed to determine whether cells of the oligodendrocyte lineage were 
affected early in disease, prior to the development of overt cognitive impairment or 
histopathological hallmarks of disease.  By performing cre-lox lineage tracing, 
immunohistochemistry, electrophysiology and TEM, I found that the cells of the 
oligodendrocyte lineage respond differently to each pathological protein, with amyloid but not 
tau pathology influencing the capacity of OPCs to respond to GABAergic signalling and the 
myelinating capacity of oligodendrocytes.  However, both amyloid and tau pathologies resulted 
in elevated adult oligodendrogenesis, without a coincident increase in total oligodendrocyte 
number but instead an increase in mature oligodendrocyte addition, perhaps suggesting that 
both pathologies drive oligodendrocyte and myelin turnover in the brain.   
 
5.2.  Does early tau or amyloid pathology drive oligodendrocyte turnover?  
By labelling OPCs with YFP in young adulthood, and following their fate over time, I was able 
to determine that the number of new YFP-labelled oligodendrocytes added to the hippocampus, 
entorhinal cortex and fimbria was increased in MAPT and APP transgenic mice when compared 
with their respective controls.  In the MAPT mice, this increase in oligodendrogenesis was 
absent at P60+90, but was first detected at P60+120, which indicates that a large number of 
new oligodendrocytes are added between 5 and 6 months of age; however, in APP mice, 
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oligodendrogenesis was stimulated earlier, with a significant increase in new oligodendrocyte 
number first being noted in the hippocampus as P60+90.  Nonetheless, by P60+120 the 
magnitude of the increase was equivalent in the hippocampus, entorhinal cortex and fimbria of 
MAPT mice compared to APP mice.  Together, this suggests that oligodendrocyte pathology 
is hastened in APP mice, but ultimately reaches similar levels in APP and MAPT mice by 6 
months of age. 
 
New oligodendrocytes produced in adulthood are likely to comprise a combination of 
premyelinating and myelinating cells.  The proportion of premyelinating and myelinating 
oligodendrocytes could be evaluated in one of two ways.  By delivering tamoxifen to Pdgfrα-
CreERT2::Tau-mGFP transgenic mice (Young et al., 2013; Cullen et al., 2019) that lack or 
carry the MAPT or APP transgenes, it would be possible to induce the expression of a 
membrane-targeted GFP in OPCs and oligodendrocytes produced, and visualise the full 
oligodendrocyte morphology, to classify them as being premyelinating or myelinating cells.  
Alternatively, tissue from the control, MAPT or APP transgenic mice utilised for lineage 
tracing in this study were stained to detect YFP and the mature oligodendrocyte marker ASPA.  
If the majority of new oligodendrocytes produced in response to tau or amyloid pathologies 
were premyelinating oligodendrocytes (YFP+ ASPA-negative), they would be unable to 
contribute myelin to axons.  However, I showed that mature oligodendrocytes were mainly 
added in the hippocampus and fimbria of MAPT and APP transgenic mice relative to their 
respective controls, while the total number of oligodendrocytes was equivalent for control mice 
and either MAPT or APP transgenic mice.  These data suggest that oligodendrocytes are being 
lost at the same time that new oligodendrocytes are being added.  If the replacement cells were 
not myelinating oligodendrocytes, the fraction of myelinated axons should go down over time.  
However, for MAPT mice, I noted that the fraction of myelinated axons was the same as that 
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of control mice at 6 months of age.  This was not specifically examined for APP mice at the 
time of increased oligodendrogenesis and yet should be examined to confirm the addition of 
myelinating cells over time.   
 
For the number of newborn oligodendrocytes to increase significantly, but the total number of 
oligodendrocytes in the hippocampus, entorhinal cortex and fimbria to remain the same, a 
significant number of pre-existing, developmentally-born oligodendrocytes must die in 
response to tau and amyloid pathology.  In the developing and mature CNS ~80% of all 
newborn premyelinating oligodendrocytes die (Barres et al., 1992; Trapp et al., 1997; Hughes 
et al., 2018), and there is some evidence that mature oligodendrocytes can also die over time 
(Tripathi et al., 2017).  Detecting and quantifying oligodendrocyte cell death is challenging as, 
once initiated, it occurs rapidly with cells being completely cleared within two days (Hughes 
et al., 2018).  However, it would be valuable to confirm that oligodendrocyte death increases 
in response to tau and amyloid pathologies produced in the MAPT and APP mice, respectively.  
Particularly as myelin protein levels including CNP, MAG, oligodendrocyte myelin 
glycoprotein and PLP are decreased in late AD suggesting a loss of myelin but also 
oligodendrocytes (Zhang et al., 2018); however, whether oligodendrocytes are lost in early AD 
is still unclear.  This could be done by evaluating cell death using a TUNEL assay to detect 
oligodendrocyte death in MAPT and APP mice at multiple ages between 2 and 6 months of 
age.  This experiment would be necessary to confirm that adult-born oligodendrocytes, 
generated in response to tau and amyloid pathologies, produce new myelinating cells that act 




As elevated concurrent oligodendrocyte loss and replacement resulting from tau and amyloid 
pathologies seems the most likely explanation for my data, they suggest that 
oligodendrogenesis is critical for sustaining myelin on axons in the hippocampus, entorhinal 
cortex and fimbria of MAPT and APP mice.  Consequently, I hypothesise that in the absence 
of continued adult oligodendrogenesis I would see a significant loss of oligodendrocytes and a 
loss of myelin in these regions.  It would be possible to determine the importance of adult 
oligodendrogenesis for myelin maintenance in the face of pathology, by preventing the addition 
of new oligodendrocytes in adulthood.  Pdgfra-CreERT2::MyRFflox/flox mice (Mckenzie et al., 
2014; Xiao et al., 2016) could be crossed with MAPT and APP mice, and the addition of 
tamoxifen would result in the loss of the transcription factor MyRF from OPCs and would 
ultimately prevent the maturation of OPCs into new oligodendrocytes.  I predict that this would 
result in a demyelination phenotype and ultimately precipitate or aggravate cognitive 
impairment in these mice.     
 
5.3. Does amyloid pathology alter the balance between inhibition and 
excitation in the brain?   
In APP but not MAPT transgenic mice, adult OPCs experienced enhanced depolarisation in 
response to the bath application of GABA; however, their depolarisation in response to the 
glutamate receptor agonist, KA, was normal.  Both GABA and KA exposure are known to 
depolarise OPCs, due to their low RMP (~-80mV) that results in chloride exiting the cell 
(Hoppe and Kettenmann, 1989; Lin and Bergles, 2004; Haberlandt et al., 2011; Hamilton et 
al., 2017), rather than entering the cell, which is the case for neurons.  However, these data 
suggest that between early development (P30) and early adulthood (P100) emerging amyloid 
pathology, driven by expression of the PDGFb-APPSw,Ind transgene, either results in a change 
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in the subunit composition of GABAA receptors, to allow more chloride efflux, or increases the 
number of GABAA receptors expressed on the surface of OPCs.   
 
A single-nucleus RNA sequencing study that compared gene expression in cells from healthy 
controls and people with AD, suggested that AD resulted in a reduction in GABA receptor 
subunit expression by OPCs and oligodendrocytes (Grubman et al., 2019).  This apparent 
discrepancy between our functional analysis of OPCs in transgenic APP mice and this gene 
expression analysis, is likely explained by changes that occur in receptor expression and 
activation susceptibility at different stages of disease.  My results could be explained by an 
increase in GABAA receptor expression on the surface of OPCs in APP transgenic mice. 
 
Under some circumstances, the cell surface expression of neurotransmitter receptors can be 
influenced by the level of the neurotransmitter expressed in the surrounding environment 
(Dulcis et al., 2013; Nair et al., 2013; Kwakowsky et al., 2018; Sanderson et al., 2018).  For 
example, a high level of neurotransmitter expression may be associated with the internalisation 
of receptors or downregulation of their expression by the target cells (Fuhrer et al., 2017; 
Kwakowsky et al., 2018; Sanderson et al., 2018).  Therefore, it may also be possible that a 
reduction in GABA expression in the brain could be associated with a change in GABAA 
receptor expression or composition by OPCs to allow them to respond more robustly to GABA 
within the environment.   Therefore, it would be interesting to determine and compare the level 
of GABA and glutamate expression within the brain of control, MAPT or APP transgenic mice 
by performing a Western blot analysis of glutamate decarboxylase (GAD67; to assess GABA 
production), glutamate dehydrogenase (GDH1; to measure glutamate production) and 
glutamine synthase (GLUL; to gauge homeostasis between glutamate and GABA production).  
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This is particularly interesting as previous reports have presented conflicting results on whether 
GABA and glutamate levels were increased (Madeira et al., 2018; Snowden et al., 2019) or 
decreased (Fayed et al., 2011; Gueli and Taibi, 2013; reviewed by Govindpani et al., 2017) in 
AD; which may result from differences in brain autopsy protocol, brain region variability and 
individual differences based on disease stage, age and gender (Roy et al., 2018). 
 
Altered GABAergic signalling can directly impact signalling by excitatory glutamatergic 
neurons in the CNS and there is some evidence that the level of inhibitory vs excitatory 
signalling is altered in mouse models of amyloidosis (Palop et al., 2007; Sun et al., 2009; Verret 
et al., 2012).  Interestingly, amyloid-induced neuronal overexcitation leads to an increase in 
aberrant GABAergic interneuron projections in the hippocampus of APP mice as a 
compensation attempt (Palop et al., 2007; Sun et al., 2009).  However, Nav1.1+ parvalbumin-
positive GABAergic interneurons are reduced in APP mice, which correlates with gamma 
oscillation deficits (Verret et al., 2012) and cognitive impairment in APP mice (Bender et al., 
2016).  Nonetheless, rescuing Nav1.1 levels in APP mice can restore cognitive function (Verret 
et al., 2012; Martinez-Losa et al., 2018); while transient enriched environment exposure, 
associated with cognitive improvement (Balthazar et al., 2018; Prado Lima et al., 2018), 
restores the number of parvalbumin-positive interneurons with a perineuronal net, which 
protects the cell integrity, in transgenic mice overexpressing APP (Tg2576) (Cattaud et al., 
2018).  As increased myelin thickness may result from neuronal hyperactivity in APP mice, it 
would be interesting to determine whether reducing glutamate signalling or enhancing GABA 




Both GABAergic and glutamatergic signalling have been shown to influence 
oligodendrogenesis and myelination (Gibson et al., 2014; Corell et al., 2015; Gautier et al., 
2015; Hamilton et al., 2017; Kougioumtzidou et al., 2017).  This is interesting as both 
inhibitory interneurons and excitatory projection neurons are known to become myelinated 
(Micheva et al., 2018) and a change in the balance of excitation and inhibition has the capacity 
to alter myelination in the CNS (Gibson et al., 2014; Gautier et al., 2015; Mitew et al., 2018).  
While we found no change in the proportion of axons that were myelinated in APP mice and 
their WT littermates at 4 months of age, or the proportion of axons that were myelinated in 
MAPT mice and their WT littermates at 6 months of age, I did note that myelin thickness was 
increased in the hippocampus of APP mice.  Ab-induced increase in neuronal activity (Beraldo 
et al., 2016; reviewed by Findley et al., 2019) may result in increased myelin thickness (Gibson 
et al., 2014).  Optogenetic stimulation of the mouse premotor cortex results in a rapid increase 
in new oligodendrocyte addition in this area and the underlying corpus callosum, which was 
followed by an increase in myelin thickness within 4 weeks post-optogenetic stimulation 
(Gibson et al., 2014).  Furthermore, node length was increased and myelin thickness was 
decreased during development in the spinal cord and sciatic nerve of APP knock-out transgenic 
mice (Truong et al., 2019), but myelin thickness was increased in the developmental spinal 
cord of transgenic mice overexpressing human APP695 (Xu et al., 2014).  It would be interesting 
to determine whether the decrease in node length and increase in myelin thickness observed in 
my thesis is partially regulated by APP clustering at the node, and whether this clustering is 
regulated by neuronal hyperactivity as APP regulate Nav1.6 sodium channel currents (Li et al., 




5.4. How does tau or amyloid pathology influence oligodendrogenesis? 
In APP and MAPT mice, adult oligodendrogenesis was increased by 5 and 6 months of age, 
respectively.  While tau is found to interact with MBP in vitro and is required for OPC 
differentiation and oligodendrocyte process outgrowth (Seiberlich et al., 2015), it is unlikely 
that MAPT overexpression would only promote an increase in adult oligodendrogenesis by 6 
months of age if it directly interacted with mature oligodendrocytes via exchange with neurons 
through the periaxonal space (Fünfschilling et al., 2012; Lee et al., 2012; reviewed by Stassart 
et al., 2018); or with OPC via synaptic and non-synaptic junctions with neurons (Bergles et al., 
2000; Lin and Bergles, 2004; Wake et al., 2015).  As a similar effect was observed in APP 
mice, it is possible that enhanced adult oligodendrogenesis occurs in response to the onset of 
neurodegeneration in both models, rather than an increase in neuronal activity.  Indeed, 
neuronal activity can regulate adult oligodendrogenesis (Gibson et al., 2014; Nagy et al., 2017; 
Cullen et al., 2019); however, as the increase in adult oligodendrogenesis was not observed at 
4 months of age in APP mice, it is likely that the increased neuronal activity previously reported 
in APP mice did not trigger new oligodendrocyte addition.  Instead, the increase in adult 
oligodendrogenesis was only observed from 5 months of age in the hippocampus, and only 
affected the entorhinal cortex and fimbria by 6 months of age coincident with amyloid plaque 
formation.  In close vicinity of amyloid plaques, oligodendrocytes and myelin are lost (Mitew 
et al., 2010), potentially playing a role in the increasing neuronal hypoactivity observed 
following amyloid plaque formation (Busche et al., 2012).  Interestingly, neuronal hypoactivity 
is prominent in tau pathology and dominates Ab-induced neuronal hyperactivity in intercrossed 
mice expressing both amyloid- and tau-pathology associated mutations (Busche et al., 2019).  
It was previously suggested that neuronal hypoactivity simply reflects excessive neuronal 
hyperactivity (reviewed by Zott et al., 2018), which may results in synaptic deficits and neuron 
loss of function.  This is particularly interesting as previous evidences in P301-htau mice 
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suggest that OPC differentiation is promoted following induced-spinal cord injury causing 
neuron loss (Ossola et al., 2016).  Furthermore, reactive microglia observed in APP and MAPT 
mice at 6 months of age may clear dysfunctional synapses in addition to amyloid plaques in 
APP mice (reviewed by Bar and Barak, 2019); and promote oligodendrogenesis and 
myelination (Miron et al., 2013; Shigemoto-Mogami et al., 2014; Naruse et al., 2018).  
Consequently, it would be interesting to determine whether new oligodendrocytes are added in 
APP and MAPT mice following synaptic deficits and whether reactive microglia promote adult 
oligodendrogenesis in APP and MAPT mice. 
 
5.5. Are OPCs potential targets for slowing dementia progression? 
In 2019, around 50 million people were diagnosed with dementia worldwide.  This figure is 
expected to reach 152 million by 2050 as reported by the world health organization.  AD is the 
main form of dementia and actually represents 60-70% of dementia cases making AD one of 
the main health care issues.  Most AD treatments include antipsychotic drugs (e.g. risperidone), 
antidepressants (e.g. sertraline, citalopram) and anticonvulsants (e.g. carbamazepine, 
valproate), anti-dementia drugs (e.g. memantine, donepezil and rivastigmine) and drugs to treat 
sleep disturbance.  While all treatments delay symptoms onset, they cannot be used as a long-
term solution.  Therapeutic development to slow down amyloid plaque formation in AD such 
as Solanezumab (Doody et al., 2014), marijuana (Ramírez et al., 2005) or immunotherapy 
(Oddo et al., 2004) have failed so far.  These multiple pharmaceutical failures show how 
complex neurodegenerative disease management is, particularly as we do not know what 
happens first, when and how it happens.  Consequently, some of these treatments may have 
some benefit if given at the right time; however, a proper early AD detection mechanism still 




There are currently two ways to define AD progression: the evaluation of protein levels of Ab1-
42, total tau and phosphorylated tau at phosphorylation site 181 in the cerebrospinal fluid as AD 
biomarkers (Bouwman et al., 2009; Mattsson et al., 2017; Hansson et al., 2018); or a change in 
brain structure detected using magnetic resonance imaging (deToledo-Morrell et al., 2004; 
Defrancesco et al., 2014; Kavroulakis et al., 2018).  A few compounds have been created to 
detect amyloid plaques by positron emission tomography or PET scan such as the Pittsburgh 
Compound B (Klunk et al., 2004; Cohen et al., 2012).  Although progress have been made 
towards better and earlier detection of brain changes in AD and other neurodegenerative 
diseases, we currently lack appropriate detection and therapy.  Consequently, new therapeutic 
targets should be considered, and it is worth examining the suitability of OPC and 
oligodendrocyte changes as a biomarker or potential therapeutic target. 
 
OPCs are able to generate large number of oligodendrocytes in the mouse healthy brain, which 
is increased following demyelination (Baxi et al., 2017) and in AD models (Desai et al., 2010; 
Behrendt et al., 2013; Ossola et al., 2016; and as shown in this thesis).  However, new 
oligodendrocyte generation does not occur to the same extent in humans as only 1 out of 300 
oligodendrocytes is replaced per year (Yeung et al., 2014).  While an increase in new 
oligodendrocyte addition was observed in some patients diagnosed with multiple sclerosis 
(Yeung et al., 2019), most of the remyelination in the human CNS seems to occur through 
surviving mature oligodendrocytes generating new myelin internodes following demyelination 




However, the expression of genes associated with newly generated and myelinating 
oligodendrocytes are upregulated in AD patients relative to age-matched controls, suggesting 
that some attempt is being made at repair (Itoh and Voskuhl, 2017), that could be 
therapeutically aided.  For example, increased Bridging-Integrator-1 (BIN1) mRNA (Chapuis 
et al., 2013; De Rossi et al., 2016) and altered expression of protein isoforms (Holler et al., 
2014) represent the second most prevalent risk factor for sporadic late-onset AD (Bertram et 
al., 2007), yet BIN1 function is still unknown.  However, BIN1 is highly expressed by mature 
oligodendrocytes (De Rossi et al., 2016) and upregulated in AD (Zhang et al., 2018).  
Interestingly, downregulation of neuronal BIN1 increases the flux of endosomes, in which tau 
aggregates, and endosomes are then damaged leaking tau aggregates into the cytoplasm for 
further seeding and tau pathology propagation (Calafate et al., 2016).  Furthermore, LINGO-1 
(Leucine rich repeat and Ig domain containing NOGO receptor interacting protein 1) is a 
negative regulator of neuronal survival, axonal integrity, oligodendrocyte differentiation and 
myelination, and LINGO-1 blockade was trialled as a remyelination therapy in multiple 
sclerosis (Biogen; Cadavid et al. 2019).  However, as LINGO-1 is significantly upregulated by 
excitatory neurons and oligodendrocytes in AD (Mathys et al., 2019), and anti-LINGO-1 
monoclonal antibodies reduce myelin impairment and improves spatial memory performance 
in the early phase of AD-like pathology in transgenic mice overexpressing human APP (Wu et 
al., 2018), anti-LINGO-1 may be a valid therapeutic to trial in AD.   
 
The development of novel AD treatment may benefit patients diagnosed with other forms of 
tauopathy, but clinical and pathological heterogeneity should be carefully considered.  
Tauopathies are defined by the presence of tau aggregates in neurons, astrocytes or 
oligodendrocytes (Ikeda et al., 1998; Arai et al., 2001; reviewed by Ferrer, 2018).  However, 
pathological tau strains extracted from post-mortem brains of corticobasal degeneration and 
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supranuclear palsy spread more rapidly throughout the non-transgenic mouse brain following 
injection, and targeted different cell populations than tau strains extracted from post-mortem 
AD brains (Narasimhan et al., 2017).  Oligodendrocytes developed tau coiled bodies and 
participated in tau seeding in a mouse injected with samples from corticobasal degeneration 
and supranuclear palsy post-mortem brains, while they did not when injected with samples 
from AD post-mortem brains (Narasimhan et al., 2017), therefore oligodendrocyte and OPC 
response may differ in other tauopathies.  OPC and oligodendrocyte behaviour should be 
assessed in additional tauopathy models to determine whether oligodendrocyte replacement 
could be a valid therapeutic target to delay the motor and cognitive deficit onset, if tau clearance 
is also ensured (Noack et al., 2014; Leyk et al., 2015; Noack and Richter-Landsberg, 2015) to 
avoid continuous spread of tau aggregates between oligodendrocytes (Ferrer et al., 2019). 
 
By demonstrating that MAPT and APP overexpression differently alter OPC response to 
neurotransmitters, oligodendrocyte myelinating capacity and adult oligodendrogenesis, this 
thesis improves our understanding of the early function of the cells of the oligodendrocyte 
lineage in AD pathology development.  This thesis suggests that OPCs and oligodendrocytes 
should be considered as potential therapeutic target in AD and other tauopathies.  Future studies 
should determine if enhancing adult oligodendrogenesis or myelination by mature 
oligodendrocytes and newly added oligodendrocytes can delay pathology onset; and whether 
changes in neuronal activity observed in AD affect OPCs and regulate adult 




Appendix 1: Solutions 
 
Common Laboratory Reagents 
0.01M Phosphate Buffered Saline (PBS) 
MilliQ water       850ml 
90.0g/L sodium chloride     100ml 
28.0g/L di-sodium hydrogen orthophosphate  40ml 
31.2g/L sodium di-hydrogen orthophosphate  10ml 
 
Blocking solution for Immunohistochemistry  
       Add    Final Conc. 
FCS        1ml   10% 
Triton-X100       10μl   1% 
PBS        top up to 10ml  - 
 
Solutions for DNA Extraction 
DNA Extraction Buffer 
1M Tris-HCL (pH 8.5)     12ml 
0.5M EDTA (pH 8.0)     1.2ml 
5M NaCl       4.8ml 
10% SDS       0.2% 







      Add   Final Conc. 
Thioflavin-S     0.1g   0.1% 
100% ethanol     60 mL   60% 
PBS      40 mL   40% 
 
Destain solution 
      Add   Final Conc. 
100% ethanol     50 mL   50% 
PBS      50 mL   50%  
 
Western blot solutions 
RIPA buffer (10ml) 
Add    Final Conc. 
MQ water      8190μl    - 
1M Tris-HCl (pH 7.4)    500μl    50mM 
5M NaCl      300μl    150mM 
10% NP-40      1mL    1% 
Sodium deoxycholate    100mg   1% 
10% SDS      10μl    0.1% 
Protease inhibitor tablets    1 per 10ml   - 





Tris-buffered saline – Tween 20 (TBS-T) 
      Add (per L)  Final Conc.  
NaCl      8g   150mM 
Tris-Base     3g   25mM 
Tween 20     2mL   0.2% 
 
Transfer buffer 
Add    Final Conc. 
20X Bolt MES transfer buffer   50ml    1x 
Methanol     100ml    10% 
Bolt Antioxidant     1ml    1% 
MQ water      top up to 1L   - 
 
TEM solutions 
0.8% GA 2% PFA in 0.1M sodium cacodylate (200mL) 
      Add   Final Conc. 
8% glutaraldehyde    20mL   0.8% 
16% paraformaldehyde    25mL   2% 
0.2M Sodium cacodylate   100mL   0.1% 
Calcium chloride    10mL   5mM 
Magnesium chloride    10mL   5mM 






Osmium tetroxide and potassium ferrycianide (10mL) 
      Add   Final Conc. 
0.1M Sodium cacodylate   6.5mL   0.065M 
4% OsO4     2.5mL   1% 
15% K3Fe(III)(CN)6 freshly made  1mL   1.5%  
Epon pure 
          Add 
Embed 812 resin        20 mL 
Dodecenyl Succinic Anhydride Specially Distilled (DDSA)   16 mL 
Methyl-5-Norbornene-2,3-Dicarboxylic Anhydride (NMA)   8 mL 





Table 1. Transgenic mice 
Strains Allow to/use as 
C57BL/6  Control, wild type mouse. 
PDGFb-APPSw,Ind Induce amyloid pathology (APP) or tau pathology 
(MAPT) in the brain. Mutations expressed in 
neurons. 
Prnp-MAPTP301S 
Pdgfrα-CreERT2::Rosa26-YFP Enable the fluorescent labelling of OPCs in 
adulthood, and the tracing of their progeny in vivo.  
Pdgfrα-CreERT2::Rosa26-YFP:: 
PDGFb-APPSw,Ind 
Enable the fluorescent labelling of OPCs in 
adulthood, and the tracing of their progeny in vivo 
in an AD-like environment of amyloid pathology 
(APP) or tau pathology (MAPT). 
Pdgfrα-CreERT2::Rosa26-YFP::Prnp-
MAPTP301S 
Pdgfrα–H2BGFP Induce fluorescent labelling of OPCs in vivo 
Pdgfrα–H2BGFP::PDGFb-APPSw,Ind Induce fluorescent labelling of OPCs in vivo, in an 
AD-like environment of amyloid pathology (APP) 






Table 2. PCR reaction for each transgene. 








Cre Cre 5’ CAG GTC TCA GGA GCT 
ATG TCC AAT TTA CTG 
ACC GTA 
34  
Cre 3’ GGT GTT ATA AGC AAT 
CCC CAG AA 
Rosa26 
WT 
Rosa26 WT 5’ AAA GTC GCT CTG AGT 
TGT TAT 
37  













hMAPT 5’ GGG GAC ACG TCT CCA 
CGG CAT CTC AGC AAT 
GTC TCC 
 35 
hMAPT 3’ TCC CCC AGC CTA GAC 
CAC GAG AAT 
hAPP hAPP 5’ GGT GAG TTT GTA AGT 
GAT GCC 
 35 







Table 3. Antibodies and concentrations used for Western blot analysis. 
Primary antibodies 
Antibody Concentration Supplier, Cat # 
Mouse anti-6E10 1:500 Covance, SIG-39320 
Rabbit anti-E178 (Tau) 1:1000 Abcam, AB32057 
Rabbit anti-THR 231 (pTau) 1:1000 Abcam, AB151559 
Mouse anti-b-actin 1:5000 Sigma-Aldrich, A1978 
Secondary antibodies 
Antibody Concentration Supplier, Cat # 
Goat anti-mouse HRP 1:10 000 Dako, P0447 
Goat anti-rabbit HRP 1:10 000 Dako, P0448 





Table 4. Antibodies and concentrations used for immunohistochemistry. 
Primary antibodies 
Antibody Concentration Supplier, Cat # 
Goat anti-PDGFRa 1:200 R&D Systems, AF1062 
Guinea pig anti-Iba1 1:500 Synaptic Systems, 234 004 
Rabbit anti-ASPA 1:200 Merck Millipore, ABN1698 
Rat anti-GFP 1:2000 Nacali Tesque, 0440484 
Rabbit anti-Ki67 1:200 Abcam, AB15580 
Rabbit anti-Nav1.6 1:200 Alomone labs, ASC-009 
Rabbit anti-OLIG2 1:400 Merck Millipore, AB9610 
Mouse anti-Caspr 1:200 Neuromab, MABN69 
Secondary antibodies 
Antibody Concentration Supplier, Cat # 
Donkey anti-Rat 488 1:500 Life Technologies, A21208 
Goat anti-Guinea pig 488 1:1000 Life Technologies, A-11073 
Donkey anti-Rabbit 488 1:1000 Life Technologies, A21206 
Donkey anti-Rabbit 568 1:1000 Life Technologies, A10042 
Donkey anti-Goat 488 1:1000 Life Technologies, A11055 
Donkey anti-Goat 568 1:1000 Life Technologies, A-11057 
Donkey anti-Goat 647 1:1000 Life Technologies, A21447 
Donkey anti-mouse 647 1:1000 Life Technologies, A31571 
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